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ABSTRACT 
The objective of this thesis work was to understand how the dynamic cross talk 
that occurs between vascular smooth muscle cells (SMCs) and macrophages (Mϕ) 
recruited to regions of arterial injury promotes the pathogenesis of neointimal 
hyperplasia. 
Macrophages were the predominant myeloid cell type recruited to wire-injured 
femoral arteries in mouse, as assessed by flow cytometry.  Recruited macrophages from 
injured vessels exhibited a distinct expression profile relative to circulating peripheral 
blood mononuclear cells. This phenotype was largely recapitulated in vitro by maturing 
rat bone marrow cells in the presence of macrophage-colony stimulating factor (M-CSF) 
and 20% conditioned media from cultured rat SMC (sMϕ), compared to maturation in M-
CSF alone (M0).  The physical parameters of the active factor present in SMC 
conditioned medium were consistent with the properties of TGF-β.  Recombinant TGF-
β1 recapitulated the effect of SMC conditioned medium on macrophage phenotypic 
modulation.  Macrophage maturation studies performed in the presence of a pan-TGF-β 
neutralizing antibody, a TGF-β receptor 1 inhibitor, or conditioned medium from TGF-β-
depleted SMCs confirmed that the SMC-derived factor responsible for macrophage 
activation was TGF-β.  Finally, we assessed the effect of SMC-mediated macrophage 
iv 
 
activation state on SMC biology.  SMCs cocultured with sMϕ exhibited increased rates of 
proliferation relative to SMCs cultured alone or with M0 macrophages. 
We assessed whether macrophage phenotype is differentially modulated in mice 
with targeted deletion of the protein and lipid phosphatase PTEN in SMC (PTEN iKO). 
At 15 days following injury there was an increase in the number of macrophages present 
in PTEN iKO lesions, and a larger percentage of macrophages were Ly6c
high
 by flow 
cytometry.  This suggests that, at this time point, monocyte recruitment in PTEN iKO 
lesions is enhanced relative to recruitment in wild type lesions. 
These data are significant since macrophages have been shown to play an 
important role in promotion of neointima formation following vascular injury, and these 
results begin to explain the mechanisms involved.  Our data show that TGF-β produced 
by SMCs is critical for promoting a macrophage phenotype representative of that 
observed in injured vessels.  These activated macrophages would be predicted to signal to 
the SMC in vivo, resulting in feed-forward promotion of neointima formation. 
 
The form and content of this abstract are approved.  I recommend its publication.  
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 INTRODUCTION: ETIOLOGY AND EPIDEMIOLOGY OF 
ATHEROSCLEROSIS AND RESTENOSIS 
 
Cardiovascular Disease 
Atherosclerosis-associated coronary artery disease and peripheral artery disease 
currently put the lives of approximately 17.6 and 8 million Americans at risk, 
respectively
1, 2
.  Approximately 30% of patients who undergo surgical intervention to 
treat these occlusive diseases develop restenosis
3
, or the subsequent re-occlusion of the 
artery lumen by the formation of a neointima composed of proliferating vascular smooth 
muscle cells (SMCs), inflammatory cells such as macrophages, and excessive deposition 
of extracellular matrix (ECM)
4
.  Vessel occlusion and inhibited blood flow, particularly 
in overweight and/or diabetic patients, results in significant morbidity, mortality, and 
strain on the healthcare system.  Considering that the incidence of diabetes is predicted to 
approximately double in the next 40 years
5
, and that obese and diabetic patients represent 
a large portion of the individuals undergoing these surgical procedures, the impact of 
morbidity and mortality due to neointimal hyperplasia is likely to increase in the near 
future.  In addition to restenosis following surgical treatment of atherosclerotic 
blockages, bypass grafts, organ transplants, and hemodialysis vein grafts all result in 
significant numbers of patients experiencing graft or transplant failure due to vessel 
occlusion from neointimal hyperplasia
6
.  Current therapies for preventing restenosis, such 
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as drug-eluting stents, have improved, but have not eliminated the occurrence of 
restenosis.  Furthermore, stent placement is not feasible for alleviating the restenotic 
response in bypass grafts, transplants, or hemodialysis grafts, and there have been reports 
of increased risk of late stent thrombosis following placement of drug-eluting stents
7
.  In 
order to develop better targeted therapies, with a decreased risk of stent-induced 
thrombosis, a better understanding of the pathogenesis of neointimal hyperplasia is 
required.  In this dissertation we sought to understand the molecular cross talk that occurs 
between two prominent cell types present in these lesions - SMCs and macrophages - in 
order to gain such an understanding.  
Structure of the Artery and Resident Cells  
Neointimal hyperplasia is largely a condition affecting the arteries.  Arteries 
consist of three layers, or tunicae, that serve separate roles in the tissue’s function 
(Figure 1A).  The structure and physiology of the artery, and it’s composite layers and 
cells, is reviewed in Kumar ed., 2010, and McPhee ed., 2010
8, 9
.  The most luminal layer 
is the tunica intima.  The intima is comprised of a single layer of endothelia cells joined 
by tight junctions that serve as a selectively permeable lining of the artery lumen in all 
vessels
10
.  In the context of normal vascular function, this endothelial layer is responsible 
for creating an interface between the blood and tissue that represses thrombosis, or 
clotting, unless required.  The endothelial layer is largely impermeable to serum proteins, 
but allows for the diffusion of oxygen and nutrients from the circulation into the more 
sub-luminal cell layers, or tissues in the case of capillaries. The endothelium also plays a 
role in blood vessel dilation and constriction, due to SMC relaxation and contraction, and 
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Figure 1: Schematic of the arterial tunicae and of neointima formation. 
A) Histological section of the mouse femoral artery with the intima, media, and 
adventitia indicated.  B)  Cartoon of the normal artery (left) and the artery with a 
neointimal lesion present (right). 
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is reviewed in VanHoutte, 2009
11
.  In response to a variety of stimuli, including 
mechanical forces (shear stress, stretch) and vasoactive substances, vasodilation in SMC 
is largely achieved by upregulation of endothelial nitric oxide synthase and subsequent 
release of nitric oxide that permeates to, and acts on, the underlying SMCs.  Conversely, 
endothelial cells can affect the contraction of SMCs, or induce vasoconstriction, by the 
release of factors such as endothelin-1 and, importantly, prostacyclin.  
The aforementioned SMCs are the primary constituent, along with interspersed 
and varying numbers of layers of elastic laminae, of the tunica media.  The smooth 
muscle cells of the media function to affect vasodilation/constriction and to regulate 
blood pressure. SMCs are a remarkable cell type in that they retain the ability to undergo 
profound changes in phenotype in response to a host of environmental and local stimuli.  
In this context, SMCs may lose their contractile phenotype and begin to exhibit a 
dedifferentiated, migratory/ proliferative /secretory phenotype.  It is this dedifferentiated 
phenotype that contributes to disease progression as it pertains to this dissertation.  The 
outer-most layer of the artery is the tunica adventitia.  Until recently, the adventitia was 
thought to be a rather loosely organized layer of fibroblasts and connective tissue.  
Recent studies (reviewed in Majesky el. al, 2011
12
) have demonstrated that the adventitia 
is a highly ordered tissue, consisting of leukocytes and resident progenitor populations 
that may contribute to vascular pathologies
13
.  In addition, the adventitial 
microvasculature (vaso vasorum), regulates circulating inflammatory cell trafficking 
between the blood and the tissue
12
.  Finally, a major function of this layer, in the healthy 






Vascular Smooth Muscle Cell Function and Phenotypic Modulation 
 The contractile and elastic characteristics of the arteries allow them to modulate 
changes in blood pressure due to the pulsatile blood flow delivered by the heart, and to 
dilate or constrict in order to regulate oxygen delivery to tissues depending on metabolic 
requirements (reviewed in Webb, 2003 and Pappano, 2013
15
). Vascular smooth muscle 
cells are the cellular constituent of arteries that physically mediates vascular tonus.  
SMCs are mononucleate cells that form several concentric layers in the mediae of larger 
arteries, down to single cell layers in mediae of arterioles.  Contraction and relaxation of 
vascular SMCs is elicited by either neural or humoral stimulation.  Contraction of 
vascular smooth muscle occurs through a different mechanism than it does in cardiac or 
skeletal muscle.  Rather than Ca
++
 binding to troponin-tropomyosin to allow myosin 
binding to actin, in vascular SMCs contraction occurs by Ca
++
-calmodulin 
phosphorylation of myosin light-chain kinase (MLCK).  MLCK then phosphorylates 
myosin light chain allowing for formation of myosin-actin cross bridges.  Contraction is 
antagonized by myosin light-chain phosphatase, the activity of which is negatively 
regulated by rho-kinase, PKC-dependent 17-kDa C-protein-potentiated inhibitor of 
protein phosphatase (CPI-17), and positively regulated by endothelial cell-derived nitric 
oxide (NO) through soluble guanylate cyclase-cGMP-PKG.  In vascular SMCs, 
intracellular Ca
++
 concentrations may be increased, to induce contraction, by influx from 
outside the cell through voltage-gated (also receptor-operated and store-operated) 
calcium channels that activate upon cellular depolarization, or from the sarcoplasmic 
reticulum by ryanodine or IP3 receptor channels (calcium-induced calcium release).  
Vasoactivity in SMCs may be induced by either excitation-contraction coupling (i.e. 
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action potentials) or pharmacomechanical (PM) coupling.  Both mechanisms can result in 
either contraction or relaxation.  Contraction-inducing PM agonists, such as 
norepinephrine, angiotensin-II, endothelin, and vasopressin, act through their respective 
GPCRs to activate Gαq/11 or Gα12/13 that engage downstream signaling pathways to 
activate MLCK and represses MLCP, respectively.  Relaxation-inducing PM agonists- 
such as atrial natriuretic factor- repress MLCK and increase potassium channel 
conductance via a similar intracellular signaling mechanism as NO
16
.   The majority of 
the vasculature is innervated by the sympathetic nervous system, and this innervation 
typically mediates vasoconstriction by norepinephrine release at varicosities, or axonal 
swellings on neurons from which norepinephrine is released, to act on nearby SMCs
17
.  
Conversely, the effect of epinephrine, produced by the adrenal medulla, is a long-range 
endocrine effect
15
.   
 In addition to smooth muscle α-actin and smooth muscle-myosin (the main 
mechanotransducers in the contractile SMC), several additional contractile apparatus 
proteins are expressed in the differentiated SMC such as SM-22α and calponin. (Aortic 
carboxypeptidase-like protein, desmin, caldesmon, vinculin, metavinculin, telokine, α- 
and β-tropomyosin, and smoothelin are additional smooth muscle-specific genes (SM-
genes) that have been used to assess SMC differentiation state
18, 19
 but their role in 
contraction or reliability as marker genes will not be discussed here.)  SM-22α and 
calponin associate with the cytoskeletal apparatus, and their expression is repressed in 
neointimal lesions
20, 21
. The precise function that SM-22α  serves in SMC contraction is 
not well understood
22
.  Calponin is an inhibitor of actino-myosin Mg
++
ATPase activity 
(which decreases the kinetics of cross-bridge formation), but also serves to decrease the 
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rate of dissociation of the actin-myosin complex and increase force generation
23
.  
Calponin is inactivated by phosphorylation in response to contractile stimuli by either 
PKC or CaMKII
24
.   
As progenitor cells give rise to mature SMCs, expression of SM-αActin (αActin, 
or SMA), SM-myosin heavy chain (SM-MHC), calponin, and SM-22α is induced, 
transcriptionally, by serum response factor (SRF)-myocardin complex binding to CArG 
boxes (CC(AT)6GG motifs; also known as serum response elements) in SM-gene 
promoters or intronic sequences
25
.  SRF is a ubiquitously expressed MADS box 
transcription factor that binds to GArG boxes as a homodimer
25
.  SRF is required for 
initiating transcription of both growth factor-induced genes, such as c-fos, as well as SM-
genes in response to differentiating stimuli such as arginine vasopressin
25, 26
.   In 2004 the 
Olson group explained how SRF can exhibit such dichotomous activities by showing that 
mitogenic signals induce association of the ETS-domain transcription factor Elk-1 with 
SRF, allowing it to associate with immediate early gene promoters; SRF-Elk-1 
association results in dissociation of the muscle-specific transcription factor myocardin 
from SRF, preventing transcriptional initiation at SM-gene promoters
27
.  Formation of 
multiple SRF-myocardin complexes on at least two of the three CArG boxes in SM-genes 
permits the TATA box-bound RNA polymerase II complex to initiate transcription
28
.  
SRF-myocardin-dependent transcription may also require cis-activators present at TGF-β 
control elements (TCE) and E-box elements
25
. The extrinsic signals (such as mechanical 
forces, contractile PM agonists, collagens I and IV, reactive oxygen species, TGF-β, and 
prostacyclin
25, 29
),  that induce SMC differentiation and SM-gene upregulation have 
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largely been characterized in vitro, and with the availability of conditional knockout 
technologies, are presently being validated in vivo.   
The dedifferentiated vascular smooth muscle cell is the primary cellular 
constituent of the restenotic neointimal lesion, and is thus typically considered diseased.  
However, it is useful for healthy SMCs to retain the ability to dedifferentiate in order to 
contribute to non-pathologic arteriogenesis.  Unfortunately, as with many normal cellular 
processes, control of SMC dedifferentiation may escape from normal negative feedback 
mechanisms, resulting in pathology.   
SMC dedifferentiation is characterized by repression of contractile proteins, 
aberrant proliferation, and expression of proteins characteristic of a pro-inflammatory 
phenotype such as cytokines, chemokines, matrix proteoglycans, and adhesion 
molecules
30
.  Following vascular injury, several factors, in addition to the injury itself, 
have been shown to induce SMC dedifferentiation and cytokine secretion from SMCs
31
, 
and remaining endothelial cells in the vessel wall
32
.  Damaged endothelial cells and 
activated platelets that bind to the exposed medial matrix secrete cytokines and 
chemokines such as PDGF-BB, angiotensin II (Ang II), and IL-1β
4
.   SM-gene repression 
has been suggested to be mediated by PDGF, in part, by association of the transcription 
factor KLF4 (Kruppel-like factor 4) from SM-gene promoters
33
.  SMC proliferation and 
migration have been suggested to be the result of engagement of several parallel, and 
potentially interacting, downstream pathways such as PI3K/AKT, PLC-γ, 
Ras/Raf/MAPK, and SRC/FAK
34
.  The functional redundancy of the many engaged 
pathways, and cross talk between pathways, has made identifying critical pathways or 
nodes elusive.  Similar to PDGF, Ang II has been shown to drive SMC proliferation, 
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migration, ECM deposition, hypertrophy, and inflammatory signaling.  Ang II has been 
shown to exert its activating effects on SMCs through angiotensin receptor 1 (AT1)
35
.  
AT1 antagonism by the peptide Ang(1-7) has been shown to reduce neointima formation 
following denudation injury in rat carotid arteries
36
, denudation and stent placement in rat 
abdominal aortas
37
, and denudation in rabbit aortas
38
. The chemotactic and mitogenic 
effect of Ang II on SMCs has been suggested to be mediated through EGFR 
transactivation and downstream AKT and ERK signaling
39
.  However, unlike PDGF, 
which induces repression of SM-genes, Ang II induces upregulation of SM-genes through 
upregulation of myocardin
40
.  The heterogeneous effects of PDGF and Ang II on SMC 
phenotype and function are illustrative of how multifactorial the regulation of SMC 
phenotype in the vessel wall can be.  
Atherosclerosis 
Primary atherosclerotic lesions (reviewed in Lusis, 2000 
41
 and Stocker, 2004
42
) 
tend to initiate in regions of arterial branching or curvature where blood flow is not 
laminar.  In these regions, the arterial endothelium exhibits non-uniform apical-
basolateral polarization and sub-optimal barrier function.  These regions of disturbed 
flow accumulate sub-pathologic fatty streaks within the first few decades of life. 
Endothelial heterogeneity is associated with increased deposition of lipid (low density 
lipoprotein: LDL) molecules that diffuse passively through disturbed endothelial cell 
junctions, or are deposited in the sub-endothelial space by transcytosis, and are retained 
due to interactions of LDL apolipoproteins with proteoglycans.  Sub-endothelially 
deposited LDL molecules are modified by lysosomal enzymes such as cathepsin D and 
10 
 
lysosomal acid lipase, resulting in the formation of LDL microaggregates.  These 
aggregates are readily taken up by SMCs and macrophages.  Retained LDL molecules in 
the sub-endothelial space undergo oxidation in response to exposure to oxidative species 
produced by resident vascular cells.  Virtually all cells in the vasculature generate 
superoxide radicals by reducing molecular oxygen with electrons derived from NADPH 
via NADH/NADPH oxidases.  Generation of reactive oxygen and nitrogen species can 
occur through the activity of several other enzymes in addition to NADH/NADPH 
oxidases, such as xanthine oxidase, nitric oxide synthase, myeloperoxidase, and 
lipoxygenase.  Released oxygen radicals, which are themselves primarily reductive, can 
then react with other species to generate strong oxidants that go on to oxidize fatty acids 
and cholesterol as well as proteins such as LDL apolipoproteins.  Oxidation products of 
fatty acids, such as linoleic, hydroxyoctadecaenoic acid, and hydroxyeicosatetraenoic 
acids, have been detected in atherosclerotic lesions, typically as cholesterol esters.  
Cholesterol oxidation products, or oxysterols, may be generated by non-enzymatic 
oxidation of cholesterol molecules or by the enzymatic modification of cholesterol by 
mitochondrial 27-hydroxylase.  Finally, protein oxidation can result in the production of 
hydroperoxides of the parent protein, as well as parent proteins with oxidant molecule 
adducts covalently attached to them.  Oxidation of LDL molecules allows for their LDL 
receptor-independent uptake into macrophages, leading to the development of foam cells.  
Foam cells are sub-endothelially localized, lipid-laden, macrophages.  Monocytes that 
give rise to foam cells transmigrate into the arterial media in response to upregulation of 
selectins on endothelial cells exposed to oxidized lipids.  In early atherosclerosis, 
accumulation of foam cells and sub-endothelial lipid results in increasing stable plaque 
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bulk.  Over time the complexity of the lesion increases.  Eventual death of foam cells and 
release of their lipid contents contributes to the formation of an unstable plaque with a 
necrotic core.  Cytokines, chemokines, and growth factors secreted by plaque-infiltrating 
macrophages, foam cells, as well as by other adaptive and innate immune cells, 
contribute to the activation of resident SMC.  SMC activation results in migration of 
SMCs from the medial layer of the vessel into the burgeoning plaque mass, as well as 
increased production of fibrotic extracellular matrix from SMCs.  This fibrous neointimal 
lesion, characterized by an SMC and ECM-rich fibrous cap containing an underlying 
necrotic core is predisposed to erosion at the luminal surface, as well as to hemorrhage of 
intra-plaque neo-vessels.  These events can trigger thrombosis and associated acute 
arterial occlusion resulting in infarction or stroke.    
Neointimal Hyperplasia 
  This dissertation is primarily concerned with the pathologic state termed 
neointimal hyperplasia (also termed stenosis, or restenosis if recurrence of stenosis 
follows surgical re-vascularization) that commonly occurs, in humans, following surgical 
treatment of atherosclerotic blockage.  (This will be discussed in further detail in the 
following section on epidemiology.) The neointima is a pathologic tissue comprised 
primarily of extensive ECM, activated medial smooth muscle cells, as well as leukocyte 
infiltrates (Figure 1B)
4
.  This pathologic tissue expands inward from the media toward 
the center of the artery lumen. (Further details on this process will be presented in the 
following section entitled Pathogenesis of Neointimal Hyperplasia.) 
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Stenosis of arteries due to development of a neointimal lesion results in 
significant mortality and morbidity in Western populations, and increasingly in non-
Western populations.  These lesions, either primary stenotic lesions or restenotic lesions, 
can be sufficiently occlusive so as to inhibit blood flow, resulting in angina pectoris, 
myocardial infarction, or significant ischemic peripheral artery disease.  Artery occlusion 
due to neointima formation is not exclusive to atherosclerosis or following angioplasty 
and stenting.  This pathologic state can also occur at the site of vessel grafts in organ 
transplant, in vascular grafts such as in coronary by-pass surgery, or in the setting of 
vascular access dysfunction in hemodialysis patients.  Vessel occlusion in these scenarios 
can result in transplant or graft failure, or systemic infection.   
Epidemiology 
Percutaneous revascularization procedures to alleviate primary atherosclerotic 
lesions include atherectomy or endarterectomy procedures, which mechanically remove 
the built up plaque, and angioplasty and stent deployment, which expand the vessel 
lumen outward to displace the plaque.  These procedures, while immediately effective at 





, and Pourdjabbar, 2011
45
).  The incidence of restenosis following balloon 
angioplasty was approximately 34% 
3
 prior to the introduction of intravascular stents.  
Stent placement at the site of intervention serves to prevent negative remodeling of the 
vessel due to stretch-induced vessel recoil.  The first stents available to interventionalists 
were bare-metal stents.  Incidence of restenosis in patients receiving bare-metal stents 
after angioplasty was reduced by approximately 10%
43
.  However, incidence of restenosis 
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was still reported to be somewhere in the range of 10-60% of surgical cases.  Since the 
mid-2000s drug-eluting stents have become more prolific.  These devices, typically 
eluting either rapamycin or paclitaxel analogues, have further reduced the incidence of 
restenosis by approximately 30% and 42%, respectively, as compared to bare-metal 
stents
44, 45
.  However, these anti-proliferative agents not only reduce SMC proliferation, 
but also inhibit endothelial cell proliferation, which results in delayed healing.  This delay 
in re-endothelialization of the vessel results in increased incidence of late stent 
thrombosis and associated mortality and/or morbidity
44
.  It is for this reason that a more 
complete understanding of the pathogenesis of neointimal hyperplasia is necessary; 
which will facilitate development of more targeted therapies to reduce neointimal 
hyperplasia while encouraging re-endothelialization of vessels denuded during re-
vascularization procedures.   
Pathogenesis of Neointimal Hyperplasia  
 As discussed above, the clinical methods for treating occlusion due to primary 
atherosclerotic lesions involve mechanical removal or displacement of the atherosclerotic 
plaque, which, in turn, denudes the arterial endothelium.  While these procedures are 
required to restore flow through occluded vessels, they also trigger a cascade of events 





, and Simon, 2012
46
).  Upon surgical interventions, denudation of the 
arterial endothelium, and the presence of stent struts, triggers platelet adhesion, even with 
the use of anti-platelet therapy.  Platelet deposition and de-granulation results in the 





.  These pro-inflammatory mediators influence both leukocyte recruitment as 
well as modulation of SMCs toward a dedifferentiated, synthetic, and proliferative  - or 
activated - phenotype.  In addition to increased secretion of pro-inflammatory ligands, 
SMC activation in response to mechanical injury as well as primary atherosclerotic 
plaque build-up, results in extracellular matrix deposition and remodeling.    
Aberrant ECM deposition is a significant aspect of the pathogenesis of neointimal 
hyperplasia because it contributes substantially to the bulk mass of the neointimal lesion.  
The lack of an endothelial lining allows for serum proteins such as fibrin and fibronectin 
to accumulate, encouraging adhesion of circulating monocytes.  Over time this 
provisional matrix is stabilized through deposition of collagen, hyaluronan, and 
proteoglycans such as versican, by SMCs.  Deposition of these proteins results in 
monocytes becoming trapped in the developing neointima, and reduces the anti-
thrombotic and elastic properties of the vessel.  This collagen-rich matrix also has been 
implicated in inducing apoptosis of SMCs in lesions, which has been suggested to 
correlate, perhaps counterintuitively, with worsened neointima formation
43
. 
  A major contributor to the pathogenesis of neointimal hyperplasia is sterile 
inflammation (i.e. inflammation in the absence of microbial infection) that can be defined 
as the recruitment of inflammatory cells, elaboration of pro-inflammatory factors and 
pro-inflammatory cross talk between resident cells and recruited leukocytes.  Many 
critical pro-inflammatory factors secreted in response to mechanical injury or primary 
atherosclerosis have been characterized.  Factors such as PDGF-BB, TGF-β
48
, Ang II, 
platelet factor 4 (CXCL4), SDF-1α (CXCL12), RANTES (CCL5), Mip-1α (CCL3), 
thromboxane A2, and many others
47, 49
, are secreted by adhered platelets within a short 
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period of time following injury.  These factors act to drive both smooth muscle cell 
activation as well as leukocyte recruitment.  As the lesion develops, activated SMCs and 
lesional leukocytes respond to platelet-derived factors, secrete many of the same pro-
inflammatory factors as well as additional factors, and engage in paracrine cross talk and 
autocrine signaling.  Indeed SMC activation and inflammation constitute two inputs into 
a feed-forward loop, and as such, identifying which of the two is the initiating event is 
extremely difficult.   
 As discussed above, a key aspect of sterile inflammation (in the absence of 
infection) is inflammatory cell recruitment to the site of injury.  Several leukocyte 
populations have been shown to be recruited to vascular lesions following mechanical 
denudation injury
50
.  While T-cells and B-cells have been shown to be present in vascular 
lesions, they have not been shown to significantly contribute to lesion pathogenesis
51-53
.  
Neutrophil recruitment to lesions has been shown to be an early and acute event 
following injury
54, 55
.  Interestingly, it has also been reported that systemic neutrophil 
depletion exacerbates neointimal lesion severity following denudation injury
56
, 
suggesting that acute neutrophil recruitment is an anti-stenotic event.  In contrast, several 
groups have published data that implicate macrophage recruitment to lesions as a pro-
stenotic factor.  For example, systemic neutralization of SDF-1α or MCP-1 has been 
shown to result in decreased monocyte-derived macrophage recruitment to lesions, as 
well as concomitant reduction in lesion size
11, 12
.  Further studies have shown that 
systemic bisphosphonate liposome or anti-leukocyte common antigen antibody-mediated 
macrophage depletion is sufficient to reduce neointima formation in response to 
mechanical injury in the mouse or rat, and rabbit, respectively
57-59
.  Additionally, studies 
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in humans have found that the presence of macrophages in atherectomy samples predicts, 
with high significance, future development of restenosis
60
.  Due to the overwhelming 
body of data implicating macrophages as pro-stenotic cells, we decided to focus on the 
role of macrophages, and their bi-directional cross talk with SMCs in driving the 
pathogenesis of neointimal hyperplasia.  As the term ‘bi-directional’ indicates, while we 
have described the process of SMCs becoming activated to recruit macrophages as a 
linear process, we hypothesized that this actually occurs as a feed-forward loop where 
SMCs modulate macrophages which then signal back to SMCs to exacerbate or maintain 
their activation to recruit more monocytes and modulate their phenotype, and so on.  We 
hypothesized that initial SMC activation contributes to monocyte recruitment to lesions, 
which mature into macrophages in the presence of SMC-derived factors.  We further 
hypothesized that these macrophages may be phenotypically modulated, as compared to 
resident vascular tissue macrophages or monocytic precursors, and then subsequently 
signal back to the resident SMCs to either maintain or exacerbate SMC activation. 
Macrophage Function and Phenotypic Modulation 
 In addition to the epithelial barrier, dendritic cells, eosinophils, neutrophils, 
natural killer cells, and certain plasma proteins, macrophages are a major component of 
the innate immune system (as reviewed in Abbas, 2014)
61
.  Macrophages play several 
important roles in host defense as well as in normal tissue homeostasis.  For example, 
they are responsible for phagocytizing antibody coated microbes, or opsonized or 
damaged cells via toll-like receptors (TLRs), NOD-like receptors (NLRs), or scavenger 
receptors.  They also present antigen to effector cells, and secrete cytokines that modulate 
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other adaptive and innate immune cells, and resident tissue cells.  Depending on the 
tissue they reside in, macrophages may exhibit different combinations of the above 
functions.  For example, in the spleen macrophages phagocytize old erythrocytes, while 
in the lung they phagocytize microorganisms and particulate matter
62
.   
The origin of macrophages in normal and diseased tissues is an area of much 
current research.  It is a commonly held belief among immunologists who focus on 
macrophages that being able to discriminate these cells by developmental origin will 
allow for a better understanding of their function. Mature tissue macrophages can derive 
from self-renewing yolk sac progenitors that arrive in the tissues early in development, or 
they may arise through the more well appreciated process of maturation from bone 
marrow-derived monocytes upon extravasation from the blood into the tissues
63
.  It is not 
currently known whether resident vascular macrophages originate from yolk sac-derived 
progenitors or from circulating monocytes.  However, while both of these mechanisms 
likely contribute to neointimal macrophages, it is known that upon vascular injury or 
atherosclerosis in murine models, at least some percentage of the cells that go on to 
become lesional macrophages are derived from bone marrow-derived monocytes
64, 65
.  
Maturation of monocytes to macrophages is mediated by M-CSF (CSF1) and/or IL-34 
(both ligands for CSFR1) via activation of the transcription factor PU.1
62, 66, 67
.  Upon 
vascular injury, or in primary atherosclerosis, it is known that bone marrow-derived 
Ly6c
high
 inflammatory monocytes, as well as Ly6c
low
 patrolling monocytes, are recruited 
to the lesion, and contribute to lesion progression
68, 69
.  It is possible that in addition to the 
heterogeneity in the neointimal macrophage population due to hematopoetic origin (bone 
marrow/medullary hematopoiesis versus extramedullary hematopoiesis of resident 
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vascular progenitors), additional heterogeneity may be the result of whether or not 
lesional macrophages mature from inflammatory or patrolling monocytes.  
A strong correlation between monocyte/macrophage infiltration to sites of 
vascular injury-induced neointima, and worsened neointimal hyperplasia, has been 
established by several laboratories
58, 60, 70, 71
.  For example, Moreno et. al. found that 
positive staining for macrophages in human atherectomy sections predicted, with high 
significance, whether or not patients would go on to develop restenosis.  Danenberg et. al. 
and Hong et. al. showed that bisphosphonate liposome depletion of macrophages in vivo 
decreased neointima formation in rat and mouse vascular injury models, respectively.  
Additionally, Furukawa et. al. showed that the neointima to media ratio was significantly 
smaller in rats treated systemically with macrophage chemoattractant protein-1 (MCP-1) 
neutralizing antibody, versus isotype control, in the balloon catheter carotid artery injury 
model.  MCP-1 has been repeatedly shown to be upregulated following vascular injury 
and to be involved in macrophage recruitment to vascular lesions (reviewed in Charo, 
2004
72
.  Although many studies have noted a correlation between inflammatory cell (e.g. 
macrophage) infiltration to sites of neointimal hyperplasia and severity of vessel 
occlusion, to date the specific mechanisms driving macrophage-induced exacerbation of 
neointima formation have remained largely undefined. 
Understanding macrophage phenotypic modulation upon maturation of 
monocytes to macrophages in vascular lesions may lead us to understand how these cells 
drive the pathogenesis of neointimal hyperplasia.  Tissue macrophages are exposed to a 
vast array of activating stimuli as they surveil normal tissue and phagocytize apoptotic 
cells, or as they are recruited to injured or infected tissue.  There exists a corresponding 
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vast continuum of macrophage activation states that are tailored to allow the macrophage 
to function appropriately depending on the stimulus.  It has become relatively accepted to 
assess macrophage phenotype, or polarization, by monitoring the extremes of the 
spectrum: M1 and M2 (characteristics of these two populations reviewed in Van 
Ginderachter, 2006
73
 and Mosser, 2008
74
).  These activation states were originally 
characterized in the setting of Leishmania major infection, where T lymphocytes from 
resistant mouse strains (C57BL/6, B10D2) were shown to express a T-helper 1(Th1) 
response (generation of interferon γ (IFN-γ) or tumor necrosis factor-α (TNF-α); resulting 
in Th1-modulated macrophages or M1 macrophages), while T cells from susceptible 
mouse strains (BALB/c, DBA/2) were shown to express a T-helper 2 (Th2) response 
(generation of IL-4; resulting in Th2-modulated macrophages or M2 macrophages)
75
.  
M1, also called classically activated macrophages, are described as pro-inflammatory, 
and are considered pro-stenotic but anti-tumorigenic.  The M1 phenotype is commonly 
modeled in vitro by stimulation with IFN-γ, and/or the pathogen-associated molecular 
pattern molecule lipopolysaccharide (LPS), a cell wall component of Gram-negative 
bacteria.  These M1 macrophages express markers/cytokines such as iNOS, IL-12, TNF-
α, and IL-1β.  Functionally, they produce cytotoxic compounds such as nitric oxide 
through the metabolism of L-arginine by iNOS, hydrogen peroxide, and superoxide.  
TNF-α and IL-1β are functionally important pro-inflammatory cytokines that add to the 
macrophage’s innate immune reactivity.  These reactive compounds and pro-
inflammatory cytokines are minimally harmful to host tissues in the short-term.  
However, chronic exposure to M1 products can have deleterious effects that lead to cell 
death and fibrosis.  Transcriptional regulation of many M1 products is thought to be 
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largely dependent on STAT1 and NF-κB transcriptional activity downstream of toll-like 
receptor and/or INF-γ receptor activation
76, 77
. 
In contrast to M1 macrophages, M2, or alternatively activated macrophages, are 
associated with injury resolution, and are considered to aid in stabilization of 
atherosclerotic plaque but to be pro-tumorigenic.  The M2 phenotype is commonly 
modeled in vitro by stimulation with IL-4 or IL-13.  These M2 macrophages express 
markers/cytokines such as arginase I (Arg I), IL-10, TGF-β, and MHC class II.  
Functionally, M2 macrophages are capable of antigen presentation, exhibit increased 
endo- and phagocytosis, reduce inflammatory signaling through production of IL-10 and 
TGF-β (TGF-β abrogates the pro-inflammatory effect of endotoxins, such as LPS
78
), and 
generate urea and L-ornithine through the metabolism of L-arginine by arginase I
73
. 
Transcriptional regulation of macrophage phenotype downstream of IL-4 has been 
reported to be largely dependent on STAT6 activity, while IL-13 has been reported to 
exert its transcriptional effects via STAT1/3/5A, and B as well as via STAT6
79
.  
In order to study the effector functions of macrophages of the aforementioned 
polarization states, several in vitro culture models have been used (described in Murray, 
2010
80
).  Mouse and rat macrophages have been isolated from the peritoneum by 
thioglycollate elicitation
81
, by alveolar lavage, or matured from precursors from PBMCs 
or bone marrow cultured in the presence of macrophage-colony stimulating factor (M-
CSF).  In order to study human macrophages in culture, they may be matured from 
precursor cells isolated from the peripheral blood in the presence of M-CSF.  As 
described above, M1 or M2 polarization is modeled by stimulating macrophages in vitro 
with LPS and IFN-γ, or IL-4, respectively. The control condition for these experiments is 
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a macrophage that is not exposed to either stimulus, but cultured in only M-CSF, often 
termed an M0 macrophage.  Because macrophage maturation in vivo probably does not 
occur only in the presence of M-CSF it is unclear how the in vitro matured M0 
macrophage relates to normal tissue macrophages in vivo.  It is for this reason that it is 
critical to validate data generated in vitro, using artificially M1/M2 polarized 
macrophages compared to un-polarized M0 macrophages, in an in vivo system.  
In human primary atherosclerosis, both M1 and M2 macrophages have been 
observed in lesions
82
.  To our knowledge, the phenotype of macrophages in human 
restenotic lesions has not been thoroughly assessed.  In animal models, macrophage 
phenotype has been studied in the murine apolipoprotein E (ApoE) and low-density 
lipoprotein receptor (LDLR) knockout models of atherosclerosis.  In both ApoE
-/-
 and the 
LDLR
-/-
 models, macrophages have been observed exhibiting hybrid or heterogeneous 
phenotypes, but with a prevalence of M1 macrophages and a correlation between lesion 
severity and proportion of M1-like cells
83, 84
.   Apolipoprotein E has been shown to 
repress a pro-inflammatory M1-like phenotype in macrophages by p38 MAP kinase-
mediated inhibition of STAT1 and NF-κB activity
85
.  In the context of mechanical 
vascular injury, Iwata et. al. attempted to characterize the molecular signature of 
neointimal lesion macrophages by comparing mRNA from macrophage-rich areas in 
neointimal lesions, as compared to macrophage-devoid areas.  This was accomplished by 
transplanting C57BL/6J mice with GFP bone marrow, performing wire-induced femoral 
artery injury, and then isolating GFP-rich neointimal tissue and GFP-devoid neointimal 
tissue by laser capture microdissection.  Real time PCR array of these microdissected 
samples revealed a hybrid/heterogeneous phenotype with upregulation of M1 markers 
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Characterization of macrophage phenotype in sterile inflammation based on the 
characteristics exhibited by macrophages in infectious disease may not be adequate.  
Logically it stands that while IFN-γ and IL-4 may well be expressed in sterile disease, 
and thus participate in macrophage phenotypic modulation, endotoxin is unlikely to be a 
major contributor to macrophage polarization in sterile inflammation.  Additionally, the 
bi-modal M1/M2 polarization model is clearly an over simplification.  The observation of 
a hybrid and/or heterogenous phenotype in human and animal models of atherosclerosis 
and restenosis suggest that there is more going on than simple M1 or M2 polarization.  
Indeed, several other factors present in vascular lesions have been shown to modulate 
macrophage phenotype.  Platelet factor 4 (PF4), a major factor released during platelet 
degranulation, has been shown to induce a pro-stenotic “M4” macrophage phenotype 
characterized by inability to upregulate heme oxygenase-1 (HO-1) in response to 
hemoglobin-haptoglobin complexes due to loss of CD163 (a scavenger receptor for 
hemoglobin-haptoglobin complex) expression.  This M4 macrophage also is 
characterized by increased expression, as compared to M-CSF matured control M0 
macrophage, by increased IL-6, TNF-α, TRAIL, CCL18 and 22, mannose receptor 
(CD206), CD86, MHC-II, MMP7 and 12
87
.  Another example of an atherosclerosis-
relevant but non-M1/M2 macrophage phenotype is the oxidized phospholipid-modulated 
macrophage, or Mox macrophage
83
. Mox macrophages are characterized by upregulation 
of HO-1, COX-2, VEGF, IL-1β, and several other genes, as compared to M0, M1, or M2 
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Macrophage phenotypic modulation, and cross talk with non-immune cell types, 
is an active area of research in several other disease areas
88
.  Characterization of 
macrophage phenotype in cancer models has illustrated that these cells exhibit 
polarization toward an M2-like or immunosuppressive phenotype which functionally 
allows tumors to escape cytotoxic killing and promotes angiogenesis
89
.  In a model of 
renal fibrosis, mesenchymal stem cells (MSCs) were found to induce an M2-like 
phenotype in macrophages which the authors suggest may be contributing to the 
reparative effect of MSCs on fibrosis
90
.  In contrast with renal fibrosis, but in 
concordance with cancer metastasis, M2 macrophage polarization has been reported to be 




Macrophage phenotypic maker regulation, as observed in rodent disease models, 
and in vitro assays, is often somewhat discordantly regulated as compared to in human 
samples (reviewed in Murray, 2011
80
).  Analysis of macrophage phenotypic modulation 
in murine models is difficult to translate to human disease due to discordance of human 
and mouse macrophages’ gene regulation in response to Th1 and Th2-type cytokines.  
Human monocyte-derived macrophages do not express iNOS in response to LPS/IFN-γ, 
nor do human macrophage cell lines.  However, tissue samples from tuberculosis infected 
individuals have been shown to express iNOS.  Additionally, in humans, arginase I seems 
to be expressed only by neutrophils and not macrophages whereas murine macrophages 
and neutrophils express this protein.  These discrepancies may be due to the origin of 
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cells isolated for analysis.  For example, studies on human in vitro matured macrophages 
are typically derived from peripheral blood while mouse-derived in vitro matured 
macrophages are usually isolated from bone marrow or elicited into the peritoneum by 
intraperitonial injection of thioglycollate
80
.  Alternatively, it is possible that macrophage 
effector functions are specialized differently in human as compared to mouse, and/or rat, 
and that differential protein expression in these cells reflects that difference in 
specialization. Several other markers typically used to differentiate M1 from M2 
macrophages in the mouse do not have homologues in the human such as Fizz1, and 
Ym1
92
.  Significant work is currently underway in order to characterize molecular 
markers that are concordantly regulated in human and mouse macrophages in response to 
M1and M2 stimuli.  Recent proteomic analysis of human and mouse-derived 
macrophages suggests that mannose receptor 1(CD206) may be reliable discriminator for 
identification of M2-polarized macrophages
93
.  M1-polarized macrophages from both 
species have not been directly compared in an un-biased manner.  However, two recent 
studies comparing human-derived M0, M1, and M2 macrophages suggest that increased 
expression (at both the transcriptional and translational levels) of CCR7, CXCL10 
(interferon-inducible protein 10) , CXCL11 (interferon-inducible protein 9), and CCL5 
may be characteristic of human M1 macrophages
92, 94
.  In contrast to the mouse, where 
low IL-10 and high IL-12 expression is well characterized
73
, these studies in human 
samples suggest that IL-10 and Il-12 are not markedly regulated transcriptionally, but that 






SMC-Macrophage Interactions in Atherosclerosis and Restenosis 
 Observational studies of phenotypic modulation of macrophages in various 
disease states is informative for hypothesis generation, but we are particularly interested 
in how macrophages functionally modulate other cell types in the vessel wall with which 
they interact.  In clinical samples, the presence of macrophages in human atherectomy 
samples has been shown to predict future incidence of restenosis with high significance
60
.  
However, existing clinical data are of limited utility in understanding how SMCs and 
macrophages interact and how that interaction exacerbates disease, as these data can 
establish correlation but not causation.  Pre-clinical disease models and in vitro studies 
have provided more insight into these interactions. 
 Several studies performed in rodents have established a causative link between 
monocyte/macrophage recruitment to vascular lesions and progression of neointimal 
hyperplasia, as discussed above.  In vitro studies dating back to the late 1980’s showed 
evidence that vascular SMCs and macrophages interact in a pro-stenotic fashion;  
Rennick et. al. showed that coculture of macrophages and SMCs resulted in enhanced 
proliferation of SMCs relative to SMCs cultured alone
95
.  More recent, mechanistic 
studies have provided some insight into how macrophages and SMCs cross talk with 
respect to macrophage recruitment to lesions (adhesion and migration), macrophage 
phenotypic modulation, apoptotic signaling, and SMC activation.  For example, in the 




 monocytes to 




, allowing for CX3CR1-dependent adhesion to 
SMCs
96
.  The Natarajan group has performed studies that specifically address 
macrophage SMC interactions such as would be expected to occur in the early stages of 
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restenosis triggered by endothelial denudation (i.e in the context of SMC exposed to the 
circulation)
97, 98
.  This group observed that angiotensin II and PDGF-BB, two molecules 
known to promote pathologic vascular remodeling
39, 99
, and diabetic stimuli (elevated 
glucose or pharmacologic activation of the receptor for advanced glycation end products) 
increased monocyte adhesion to SMCs.  Further, they showed that interaction of 
monocytes to SMCs in direct coculture resulted in increased surface expression of CD36 
by macrophages, which might be predicted to participate in TGF-β activation and 
subsequent paracrine effects on both macrophages and SMCs (see the section TGF-β’s 
Role in Atherosclerosis and Restenosis)
97, 98
. 
Correlative studies have assessed expression of molecules by SMCs that would be 
predicted to modulate macrophage phenotype upon monocyte recruitment.  Plenz et. al. 
showed that SMCs in the non-diseased vessel express GM-CSF (granulocyte-macrophage 
colony-stimulating factor), which is increased in SMCs from lesions as well as in 
activated SMCs in vitro
100
.  This cytokine acts as a maturation factor for dendritic cells 
and as a chemoattractant and activation/proliferation factor for macrophages
101
.   
Several groups have also characterized the effect of cross talk between SMCs and 
macrophages with respect to modulation of apoptosis in either cell type.  In addition to 
their findings related to the effect of SMCs on macrophage CD36 expression, the 
Natarajan lab has also published that physical interaction of macrophages with SMCs, via 
VCAM-1, can reduce the macrophage apoptotic response to serum deprivation by 
increasing AKT pathway activation and downstream Bcl-2 expression
102
.  From the other 
perspective, activated lesional macrophage-derived NO induces surface expression of Fas 
and TNF-α receptor 1 by SMCs, making them more susceptible to pro-apoptotic signals.  
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The same lesional macrophages are known to express surface Fas ligand and TNF-α
103
.  
Further, it has been shown in vitro that macrophages are capable of inducing Fas-
mediated apoptosis of SMCs
104, 105
, and SMCs undergo apoptosis when plated on Mϕ-
modified collagen I, versus unmodified collagen I
106
.   
 While it is appreciated that apoptosis of SMCs and macrophages is involved in 
the pathogenesis of neointimal hyperplasia, SMC activation is considered the more 
prominent contributor.  The Natarajan group published informative studies in the early 
2000s assessing the interactions of SMCs and monocytes in vitro.  They are one of the 
few groups that have tried to assess the interactions of these two cells not in the context 
of super-physiologic stimulation of macrophages with LPS.  Several studies in the 
vascular disease literature have used LPS-polarized macrophages in order to model the 
M1-like phenotype that has been observed to be a prevalent population in atherosclerotic 
lesions
107-109
.  For example, Chen et. al. showed that LPS-stimulation of human 
monocytes resulted in synergistic upregulation of pro-inflammatory cytokines from both 
macrophages and cocultured saphenous vein SMCs (which agrees with our data 
presented in Appendix A)
110
.   
Investigators performing such studies in the vascular literature have looked to the 
infectious disease literature, where the effects of LPS on macrophage phenotype is more 
relevant, to understand how other growth factors influence the phenotype of 
macrophages.  The difficulty in extrapolating from the infection literature to the setting of 
sterile-inflammation (such as cardiovascular disease or cancer) is that activation of 
macrophages does not occur by the same mechanisms, and the modulatory effects of 
other growth factors may not be the same in the presence and absence of LPS stimulation.  
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For example, several studies by Carl Nathan’s lab have established that TGF-β - 
specifically in the presence of LPS - inhibits activation of macrophages (see section TGF-
β’s Role in Atherosclerosis and Restenosis).  TGF-β has thereafter been accepted to be a 
macrophage de-activating factor, particularly in the field of vascular biology.  However, 
we will present data in this dissertation showing that TGF-β, in the absence of LPS, 
promotes an activated macrophage phenotype, and is ultimately pro-stenotic.  
TGF-β’s Role in Atherosclerosis and Restenosis 
 TGF-β is a multifunctional 24 kiloDalton (kDa) dimeric peptide growth factor 




, and Annes, 2003
113
) that is part of a 
family of cytokines that includes bone morphogenic proteins, growth differentiation 
factors, activins, nodals, and anti-mullerian hormone
111
.  There are three isoforms of 
TGF-β (TGF-β 1, 2 and 3) which are encoded by different genes (TGFB1, TGFB2, and 
TGFB3, respectively), and are expressed differentially across cell or tissue types.  TGF-
β1 is known to be expressed in epithelial cells, smooth muscle cells, hematopoietic cells, 
and by fibroblasts.  TGF-β2 is preferentially expressed by epithelial cells as well as 
neurons, and TGF-β3 is primarily expressed by mesenchymal cells. While data exists that 
all TGF-β isoforms are upregulated in vascular injury, studies from many groups suggest 
that the TGF-β1 isoform is the isoform that influences neointimal hyperplasia to the 
greatest extent. The TGF-β gene product is expressed as a 75kDa dimeric pro-protein that 
is cleaved in the Golgi by furin-type enzymes into the truncated mature 24kDa dimer plus 
a pro-domain latency-associated protein, or LAP, dimer.  This inactive form of the 
cytokine is referred to as the small latent complex, or SLC.  The SLC is further stabilized 
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and inactivated by the association with one of several isoforms of a latent TGF-β binding 
protein (LTBP) via di-sulfide linkages.  This greater than 200kDa form of TGF-β, of the 
large latent complex (LLC), is secreted and can form covalent cross-linkages with 
extracellular matrix molecules by transglutaminases.  When bound by LAP or LAP-
LTBP dimers, TGF-β is sterically unable to bind to its receptors to engage signaling 
cascades.  The evolutionary reason for why TGF-β may be constitutively produced and 
held in an inactive form in the ECM is not well understood.  However, it is due to this 
primed but inactive state that assessing TGF-β activation state is essential for 
understanding its biology.  There are several biologic and physical mechanisms for the 
activation of latent TGF-β.  TGF-β can be activated enzymatically by liberation of the 
mature dimer from LAP-LTBP, such as by MMPs, plasmin, or by furins or other 
convertases
112
.  Active TGF-β can also be liberated from the LLC by a conformational 
change induced by LAP-binding receptors, such as the thrombospondin 1/CD36 
complex
114
, mannose 6-phosphate receptor, and several αV-containing integrins
112
.  It is 
unclear whether this latter mechanism of TGF-β activation requires both conformational 
change as well as protease activity, or if conformational change in the LLC is sufficient 
to liberate fully active mature TGF-β dimer.  In addition to these protein-mediated 
mechanisms of TGF-β activation, the mature active form can also be released from latent 
complexes due to exposure to low pH, reactive oxygen species, as well as by freeze-
thawing
113
.   
 Active TGF-β engages signaling cascades by binding to tetrameric receptor 
complexes consisting of two type I receptors (TBRI) and two type II (TBRII) receptors.  
TGF-β receptors (TBRs) are transmembrane serine-threonine kinases.  Ligand binding to 
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the TBRII dimer results in association of the TBRI dimer to form the tetrameric receptor 
complex.  TBRII then phosphorylates TBRI, initiating canonical and non-canonical 
signaling pathways.  In canonical signaling, ligand binding initiates association of a 
receptor Smad (R-Smad; Smad2 or 3) and Smad anchor for receptor for activation 
(SARA) with the activated receptor.  The R-Smad is phosphorylated, allowing for co-
Smad (Smad-4) association and nuclear translocation.  This R-Smad/co-Smad complex is 
then able to bind to Smad-binding elements, TGF-β control elements, or CarG boxes in 
promoter regions of genes to modulate gene expression
115
.  An inhibitory aspect of 
canonical TGF-β signaling is the repression of R-Smad/Co-Smad nuclear localization by 
inhibitory Smads.  These proteins may act as part of a negative feedback loop that serves 
to limit TBRI/II signaling by acting as a dominant negative to prevent R-Smad activation, 
or by inciting receptor degradation.   In contrast to canonical TGF-β signaling, non-
canonical signaling is not mediated through Smad proteins.  In a cell type-dependent 
manner JNK/p38, ERK, Rho- GTPase, and AKT signaling pathways may be engaged to 
modulate, positively or negatively, Smad-dependent effects.  These modulatory effects 
may also vary in a cell type-dependent manner in terms of whether they exert their effects 
by parallel signaling or by direct physical interaction with Smad signaling molecules
111
.   
 Upregulation of TGF-β
116, 117
, and TGF-β signaling has been observed in human 
primary atherosclerotic
118
 as well as restenotic
119
 lesions.  Retrospective cohort studies in 
humans have linked altered TGF-β production or mutations in TGF-β signaling 
components to cardiovascular disease
120, 121
.  Further, McCaffrey et. al.
122
 published that 
TBRI/II expression ratios were found to be altered in SMCs in atherosclerotic human 
arteries; in vitro data by Grainger et. al.
123
, suggests that a high TBRII:TBRI ratio results 
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in a differentiating response to TGF-β stimulation, but that a low TBRII:TBRI ratio 
results in a pro-synthetic response.  However, the inability to perform genetic 
manipulations in the human have made it difficult determine the net contribution of TGF-
β signaling to atherosclerotic plaque development or restenotic neointimal hyperplasia, 
and even more so to determine the contribution of cell type-specific TGF-β signaling on 
these disease processes.   
Pre-clinical models of vascular disease have offered some insight into the role 
TGF-β may be playing in the pathogenesis of atherosclerosis and restenosis. As early as 
the late 1980’s animal studies demonstrated that TGF-β was upregulated transcriptionally 
following mechanical vascular injury
124, 125
.  It has more recently been shown that latent 
TGF-β is activated by mechanical arterial injury, and that systemic inhibition of TGF-β 
signaling with a TBRI kinase inhibitor (SB-505124) is sufficient to inhibit NIH
126
. 
Additional studies in rat and/or mouse injury models have also shown reduced NIH with 
systemic administration of anti-TGF-β neutralizing antibody, soluble receptor, or 
ribozyme oligonucleotide.  Correspondingly, several groups have found overexpression 
or infusion of TGF-β sufficient to induce exacerbated NIH
111
.  The role of TGF-β 
signaling in murine atherosclerotic models suggests a similar effect on cellular behavior, 
but a different result with respect to disease progression due to mechanistic differences 
between atherosclerosis and restenosis.  At least two groups have published that 
neutralization of TGF-β in ApoE null mice was sufficient to reduce ECM production in 
the lesion leading to decreased fibrosis and more unstable plaques
127, 128
.  When 
extrapolated to restenosis, where ECM production is a major contributor to pathogenesis, 
these data suggest that TGF-β neutralization would be anti-stenotic. 
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 In order to further interrogate TGF-β’s role on cell biology, many laboratories 
have studied the effect of this cytokine on cells in vitro. Studies in primary cultured 
vascular smooth muscle cells have shown consistently that TGF-β acts as an anti-
proliferative/ pro-differentiation factor for SMCs.  TGF-β has also been shown to be a 
critical differentiation signal responsible for driving embryonic stem cell differentiation 
to an SMC lineage
115, 129
.  Additionally, while TGF-β has been reported to induce ECM 
production by SMCs, suggesting promotion of a synthetic phenotype, it also induces 
upregulation of smooth muscle contractile apparatus proteins and repressed migration, 
suggesting net promotion of a contractile phenotype
123
.  Mechanistically, TGF-β has been 
shown to regulate SM-gene transcription (reviewed in Guo, 2012
115
) by inducing 
expression of miR143 and 145, which repress expression of the transcription factor 
KLF4.  KLF4 has been shown to repress SM-gene transcription by binding to TGF-β 
control elements, whereas KLF5 exerts the opposite effect on SM-genes via TCE 
binding.  TGF-β is also known to induce nuclear translocation of, and nuclear complex 
formation at Smad binding elements (SBEs) by Smad3 and 4 along with CArG element-
bound myocardin.  This effect is specific to Smad3 and is not seen with Smad2.  TGF-β’s 
effect on SM-gene regulation is also mediated through RhoA/ROCK-dependent 
regulation of serum response factor (SRF) expression, and nuclear translocation and 
binding to CArG boxes. RhoA has also been reported to be required for TGF-β-
dependent Smad phosphorylation and promoter activation.   
 In contrast with TGF-β’s effect on SM-gene expression and SMC differentiation 
state, TGF-β’s role in macrophage phenotypic modulation has been studied in less detail.   
By the late 1980s, TGF-β had been shown to induce tissue granulation involving collagen 
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production, fibroblast proliferation, angiogenesis, and leukocyte recruitment
130
.  
Subsequent in vitro studies showed that TGF-β is potent as a chemoattractant for 
monocytic cells at femto- to low picomolar concentrations, and that TGF-β induced 
cytokine (IL-1, FGF, and TNF) production by monocytes
131
.   TGF-β (and not colony 
stimulating factors, interleukins, interferon γ, or endotoxin) has also been shown to 
induce FcRII, or CD16, on cultured monocytes, which allows them to bind IgG 
multimers to effect immunophagocytosis and oxidative burst.  In seeming contrast to 
these pro-inflammatory effects of TGF-β on cultured monocytes, it was also reported 
around the same time, by the Nathan lab, that TGF-β is a macrophage de-activating 
factor
78, 132, 133
.  This concept has persisted across many research areas where the 
contribution of macrophages to disease progression in the setting of primarily sterile 
inflammation (cancer, cardiovascular disease) is studied.  However, these studies that 
presented TGF-β as a de-activating factor for macrophages were focused on the effect of 
TGF-β on macrophage phenotype in the presence of microbial (or helminth) infection in 
vivo, or endotoxin in vitro.  From these data it is clear that TGF-β is capable of repressing 
the effects of endotoxin on macrophage activation, however our data, along with data 
from Wahl et. al.
131
 and Pang et. al
134
, suggest that the role of TGF-β on macrophage 
phenotype in the setting of sterile inflammation is pro-inflammatory.   
Overview of this Dissertation 
 The objective of this project was to define the role of SMCs in modulating the 
phenotype of macrophages, the role of macrophages in the dedifferentiation of SMCs, 
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and the cross talk between SMCs and macrophages using both in vitro and in vivo 
approaches. 
 The results of these studies are presented in Chapters 2-4.  In Chapter II we 
investigate how macrophage phenotype was modulated in vivo in response to the wire-
induced femoral artery injury model of angioplasty.  In Chapter III we use an in vitro 
culture-based system to investigate how SMC-derived factors modulate macrophage 
phenotype, and to determine what factor is responsible for modulation of macrophage 
phenotype.  Lastly, in Chapter IV we begin to examine how monocyte recruitment to 
neointimal lesions is influenced by the expression level of PTEN in SMCs.  Chapter V of 
this dissertation summarizes the results of these studies and presents follow-up studies 
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Neointimal hyperplasia is known to occur in the context of atherosclerosis, or 
following percutaneous interventions, bypass grafting, or transplant.  Despite the 
implementation of drug-eluting stents, luminal narrowing due to restenosis remains a 
significant clinical problem
44
.  A more complete understanding of the pathogenesis of 
neointimal hyperplasia is required to develop more precisely targeted therapies that will 
allow for complete re-endothelialization of re-vascularized or grafted vessels and vessel 
repair in order to improve outcomes.   
Neointimal lesions have been shown to be largely composed of activated or 
dedifferentiated vascular smooth muscle cells that migrate from the tunica media to the 
developing neointima
86, 135
.  Activation of resident SMCs is a complex, multi-faceted 
process that promotes a transition to a highly proliferative, inflammatory phenotype 
characterized by down-regulation of SM contractile genes and increased production of 
multiple growth factors, cytokines, and chemokines
4, 43, 46, 136
 .  Many of these factors 
___________________________ 
1
 Published with permission from Wolters Kluwer Health, Lippincott Williams & 
Wilkins. Ostriker A, Horita HN, Poczobutt J, Weiser-Evans MC, Nemenoff RA. 
Arterioscler Thromb Vasc Biol. 2014;34:877-886. 
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participate in neointima formation through direct effects on SMCs combined with 
recruitment of inflammatory cells that sustain lesion progression.  As SMCs are critical in 
initiating and promoting neointima formation, targeting SMCs is a logical strategy to 
inhibit progression of vascular disease.  However, simply focusing on blocking SMC 
proliferation is likely an ineffective means to prevent disease as these therapies inhibit 
proliferation of other cells (i.e. endothelial cells) that are required for vessel recovery. 
Preventing vascular inflammation is an equally important approach to limit restenosis 
since it also plays a central role in intimal growth. Several studies have demonstrated a 
critical role for recruited macrophages in the progression of neointimal hyperplasia
58, 64, 
71, 137-140
.  For example, clodronate depletion of macrophages has been shown to reduce 




.  However, the 
mechanisms underlying how macrophages specifically cross talk with SMC, and vice 
versa, to induce and/or perpetuate SMC activation and neointimal hyperplasia are not 
well understood.  
Macrophages are highly plastic cells which undergo phenotypic modulation in 
response to signals from the microenvironment.  Macrophage phenotypic modulation, or 
polarization, is typically described as either LPS+interferon-γ-mediated classical M1 
activation or IL-4/IL-10-mediated alternative M2 activation
73, 75
.  Modulation of 
macrophage phenotype in the vasculature has largely been studied in the context of 
atherosclerosis, where these cells have been found to exhibit a spectrum of phenotypes
68, 
84, 141, 142
.  As macrophages have been identified as the predominant inflammatory cell 
infiltrating injured vessels, we sought to characterize the phenotype of macrophages 
recruited to neointimal lesions in vivo.  In Chapter III of this dissertation, we will 
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describe studies defining how signals from SMCs contribute to this macrophage 
phenotype, and studies assessing if macrophages modulated by SMCs gain the ability to 
signal back to SMCs to promote or maintain SMC activation.  
Materials and Methods 
Reagents: Antibodies: CD68-FITC (Biolegend), SM-α-actin-Cy3 and unconjugated 
(Sigma), F4/80 (Cl:A3-1, Abcam), anti-rat-Alexa 488 (Life Technologies). Flow 
cytometry antibodies:  biotinylated-F4/80 (Cl:A3-1, AbD Serotec), streptavidin-RPE, 
CD11b-FITC, Ly6g-PE-Cy7, SiglecF-PE, CD11c-APC-Cy7 (all BD Biosciences), MHC-
II-PerCP eFluor 710 (eBiosciences).   
 
Femoral Artery Injury: All animal procedures were approved by, and performed in 
accordance with the guidelines of the University of Colorado IACUC. Guide-wire 
denudation femoral artery injury was performed, as shown by us previously
137
, on right 
femoral arteries of male 20-28g C57BL/6 mice (Figure 2A).  Mice were anesthetized 
with 50μg/g sodium pentobarbital (diluted to 5mg/ml in sterile saline) administered 
intraperitoneally (IP).  Anesthetized animals’ right inguinal regions were depilated.  
Approximately 100μl of lidocaine solution was delivered subcutaneously (SQ) at the 
incision site.  After allowing local anesthesia to take effect for about a minute, a ~one 
centimeter incision was made to expose the superficial vasculature from the knee 
proximally to the abdominal wall (for illustrations of the murine vasculature see The 
Anatomy of the Laboratory Mouse website
143
).  The femoral artery, and the attached vein, 
were isolated from the surrounding tissue and femoral nerve by blunt dissection.  Silk 6-0 
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suture was used to ligate the proximal end of the femoral artery where a branch enters in 
between the rectus femoris and the vastus medialis muscles. Another suture was used to 
stabilize the proximal end of the femoral artery (separated from the femoral vein) where a 
branch moves superficially toward the subcutaneous fat. An arteriotomy was created in 
the femoral artery between these two ligatures.  A 0.38mm guide wire (Cook, C-SF-15-
15) was then inserted into the femoral artery at least until the bifurcation of the 
abdominal aorta – where the aorta becomes the common iliac arteries and the caudal 
artery. The guide wire was inserted fully, and pulled back ~50% of the way, and inserted 
fully again three times to mechanically denude the arterial endothelium.  The wire was 
then left in place for one minute to induce a stretch-induced injury.  Upon removing the 
wire the two ligatures were tied tight.  Blood flow was restored to the portion of the 
artery proximal to the artery branches just proximal to the upper ligature. The incision 
was then closed using 5-0 silk suture with curved cutting blade (Covidien).  In order to 
ascertain if femoral arteries were being sufficiently denuded retro-orbital injection of 
100μl of filtered Evans Blue dye was injected, in non-experimental animals, immediately 
following terminal anesthesia with isofluorane overdose (Figure 2B).  Evans blue dye 
stains vessels with disrupted endothelial cell monolayers
144
. Injured femoral arteries, 
contra-lateral control femoral arteries, aortas, and carotids were harvested on day 15 post-
injury following euthanasia and flushing of the vasculature with heparinized PBS 
(80kU/L).  
 
Flow Cytometry: Isolated injured, and contralateral control vessels, were digested to 
single cells by digestion at 37°C for 2hr in collagenase buffer (3.2mg/ml collagenase II, 
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Figure 2: Anatomy of the medial aspect of the mouse hind-limb and Evans 
Blue staining of guide wire-denuded femoral artery.   
A) The vasculature of the mouse was perfused with trypan blue.  The artery is 
stained blue.  The vein is perfused with blood and appears red.  Locations of 
ligatures and arteriotomy used in the femoral artery injury model are indicated.  B) 
Immediately following injury, Evans blue dye was injected retro-orbitally.  
Regions of disrupted endothelial integrity, due to wire-injury, are stained blue.  
Shown is an isolated femoral artery from the distal ligature to the iliac bifurcation 




0.7mg/ml elastase (Worthington), 0.2mg/ml soybean trypsin inhibitor (Sigma) in Hank’s 
buffered saline solution (HBSS), pH7.5). Red blood cells were lysed for 2-5 min in RBC 
lysis buffer (0.15 M NH4Cl, 10 mM KHCO3, 0.1 mM Na2EDTA (pH 7.2)). Single cell 
suspensions were stained for CD11b, F4/80, Ly6g, MHC-II, Siglec-F, CD11c, and DAPI 
to stain for dead cells. Flow cytometry was performed on a Galios cytometer (Becton 
Dickenson) as demonstrated by our group previously
145
.   Gating strategy for flow 
cytometry is shown in Figure 3A. Briefly, after gating out dead cells and debris, live cells 
were plotted for CD11b versus Ly6g.  Neutrophils appear as a distinct double positive 
population
146
, and were gated out.  Remaining traces were then plotted for CD11b versus 
F4/80.  The remaining double positive population contains macrophages, eosinophils, and 
dendritric cells.  The eosinophil population was gated out by plotting the CD11b+/F4/80+ 
population for forward scatter versus side scatter. This high forward scatter, low side 
scatter side population was verified to be CD11b+/SiglecF+ eosinophils 
145
 (red traces,  
Figure 3A, upper right). Dendritic cells were enumerated and gated out by plotting 
CD11c high cells for MHC-II expression versus forward scatter, and selecting the MHC-
II+ low forward scatter population.  
 
CD11b Magnetic Bead Positive Selection of Cell Suspensions:  Peripheral blood 
mononuclear cells (PBMCs) were isolated from heparinized whole blood spun over a 
Histopaque 1.077g/ml (Sigma) gradient at 500xg for 30min as shown by us previously
147
.  
Buffy coat layers were then washed with sterile PBS and spun at 300xg for 10min to 
separate mononuclear cells from platelets. Single cell suspensions were prepared from 
injured, or contralateral control, vessels as described under Flow Cytometry.  Anti-
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CD11b antibody-conjugated magnetic beads (Miltenyi) were used to separate CD11b 
positive and negative populations from PBMC and vessel suspensions as per the 
manufacturer's specifications.  Single cell suspensions from PBMC and injured vessel 
CD11b positive selections were analyzed by flow cytometry for purity of macrophages as 
described under Flow cytometry.  Total RNA was prepared from CD11b positive cell 
isolates using RNEasy Plus Micro columns (Qiagen).   
 
Real Time qPCR: cDNA was prepared from total RNA isolates (equal total μg/reaction 
based on maximum allowable in the lowest concentration sample) using the iScript 
cDNA Synthesis kit from Bio-Rad.   Real time qPCR then performed using the Power 
Sybr Green supermix from Applied Biosystems as shown previously
147-149
.  Reactions 
were carried out on an iCycler (Bio-Rad).  Cycling parameters were: 5min at 95˚C; 15sec 
at 95˚C, 30sec at the annealing temperature optimized for each primer pair, and 30sec at 
72˚C for 50 cycles (60 cycles for CD11b pulldown samples).  GAPDH was used as a 
reference gene.  
 
qPCR Primers: See Table 1.  
 
Statistics: Data are expressed as means ± standard error. Student’s T-tests were used to 
compare data sets with two samples.  Data sets with more than two samples were 
analyzed by ANOVA followed by Tukey multiple comparisons post-tests.  
42 
 
Table 1: Chapter II qPCR primers 
Mouse and rat glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) 
Forward: cgt gga gtc tac tgg cgt ctt cac 
Reverse: cgg aga tga tga ccc ttt tgg c 
Mouse and Rat TNF-α Forward: ctc ttc tgt cta ctg aac ttc ggg 
Reverse: gagaagatgatctgagtgtgaggg 
Mouse CCL5 Forward: ctg ccc tca cca tca tcc tc 
Reverse: aga ggt agg caa agc agc ag 
Mouse IL-6 Forward: gat gct acc aaa ctg gat ata atc 
Reverse: ggt cct tag cca ctc ctt ctg tg 
Mouse Il-10 Forward: gcg ctg tca tcg att tct cc 
Reverse: ggc ctt gta gac acc ttg gtc 
Mouse Il-12a Forward: gtc tta gcc agt ccc gaa ac 
Reverse: ggt ccc gtg tga tgt ctt c 
Mouse Il-12b Forward: ccg gac ggt tca cgt gct ca   
Reverse: cac tgc ccg aga gtc agg gga   
Mouse CCR3 Forward: tga tgt tta cta cct gac tgg tg 
Reverse: tgc cat tct act tgt ctc tgg t 
Mouse CCR7 Forward: gtg gtg gct ctc ctt gtc att 
Reverse: ctt gaa gca cac cga ctc gta 
Mouse MMP9 Forward: tag atc att cca gcg tgc cg 
Reverse: gcc ttg ggt cag gct tag ag 
Mouse iNOS 
 
Forward: cct cag ttc tgc gcc ttt gc 
Reverse: aaa ggt ctc aca ggc tgc cc 
Mouse arginase 1 Forward: ctc caa gcc aaa gtc ctt aga 
Reverse: agg agc tgt cat tag gga cat 
 





Macrophages Recruited to Injured Vessels are Phenotypically Distinct from Peripheral 




, have shown 
increased recruitment of bone marrow-derived macrophages to the arterial wall following 
endothelial denudation-mediated arterial injury in stained tissues.  Flow cytometry was 
used to quantitatively verify enhanced presence of macrophages in the setting of vascular 
injury (gating strategy: Figure 3A) at 15 days post-injury, when macrophage 
accumulation was previously observed to be maximal
12
, and when neutrophil recruitment 
is expected to have abated
54
.  We found that in injured femoral arteries, relative to contra-
lateral control femoral arteries or aortas from injured animals and femoral arteries or 
aortas from naïve animals, macrophages made up a significantly larger percentage of 
total cells than did neutrophils, eosinophils, or dendritic cells (Figure 3B-F).  Eosinophil 
and neutrophil recruitment was not increased at this time point following injury. We 
sought to determine if these recruited macrophages are phenotypically distinct from 
PBMC precursor monocytes.  In order to compare neointima-associated macrophages 
versus resident tissue macrophages, or circulating monocyte controls, CD11b+ cells were 
isolated from injured femoral arteries, uninjured arteries, or Histopaque-separated buffy 
coats by positive selection using anti-CD11b antibody-conjugated magnetic beads. 
Positively selected cells stained for F4/80, indicating that they were largely 
monocytes/macrophages, whereas non-selected cells stained positive only for smooth 
muscle α-actin (SM-αActin), indicating SMCs, or were negative for both F4/80 and SM-
αActin, indicating other cell types (Figure 4A).  CD11b positive selection resulted in 
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Figure 3: Analysis of myeloid populations in injured arteries by flow 
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Figure 3: Analysis of myeloid populations in injured arteries by flow 
cytometry.   
Single cell suspensions were isolated from femoral arteries following 2-wks wire-
induced injury (iRFA), from contralateral control femoral arteries (LFA) and 
aortas from injured mice, and from aorta and femoral arteries of naïve mice. Cells 
were stained for CD11b, Ly6g, F4/80, SiglecF+, CD11c, MHC-II, and DAPI and 
analyzed by flow cytometry. A) Live cells were plotted for CD11c vs Forward 
Scatter (FS), CD11c
hi 







 dendritic cells. Live cells, excluding dendritic 










population, based on higher forward scatter and low side scatter or Siglec-F 
positivity. A, Upper right) Scatter plot showing that the FS/SS eosinophil gating 
strategy distinguishes CD11b+/Ly6g-/SiglecF+ eosinophils (red) from the 
CD11b+/Ly6g-/F4/80+ macrophages (green).  B) Representative CD11b vs F4/80 
scatter plots from injured versus uninjured arteries at day 15 after wire-induced 
injury. C) Neutrophils, D) eosinophils, E) dendritic cells and F) macrophages were 
quantified by flow cytometry 15 days after injury using the gating strategy 
described above.  Each point represents a pool of arteries from 3-5 animals. n=2 to 
4 independent experiments. Red gates indicate populations gated out prior to 
subsequent analysis step; black gates indicate populations gated on for subsequent 





Figure 4:  Immunofluorescent and flow cytometry characterization of in vivo cell 
populations. 
A) Single cell suspensions were isolated from femoral arteries 2-wks after wire-
induced injury. CD11b positive (CD11b+) and negative (CD11b-) cell fractions from 
peripheral blood mononuclear cells (PBMCs), uninjured arteries, and injured femoral 
arteries (iRFA) were assessed for SM-αActin (red) and F4/80 (green) expression.  
DAPI was used to visualize nuclei. Representative images shown.  B) CD11b positive 
cell fractions from PBMCs and iRFA were assessed for contaminating cell 
populations by flow cytometry using the gating strategy described in Figure 3. 




80% monocyte/macrophages from either PMBCs or injured femoral arteries, as 
determined by flow cytometry analysis of CD11b positively selected cells.  Flow 
cytometry analysis of uninjured vessels for quantity of macrophages was not performed.  
Injured artery isolations contained similar percentages of eosinophils and neutrophils, and 
slightly more dendritic cells then did PBMC isolations (Figure 4B).  Since contaminating 
cell populations were similar in PBMC and injured vessel isolations, comparing mRNA 
levels in these cell isolations was valid.  Expression of a panel of genes was assessed in 
CD11b positive cell isolates by real time quantitative polymerase chain reaction (qPCR) 
(Figure 5). We focused on genes that have been shown to be upregulated in bone marrow 
cell derived-rich regions of neointimae
86
, as well as on genes that have been suggested to 
be upregulated in inflammatory mouse, rat, and human macrophages
150
.  Several genes 
(IL-6, CCR3, CCR7, IL-10, IL-12b, and TNF-α) were upregulated in CD11b+ cells from 
injured vessels relative to CD11b+ PBMCs.  In contrast, expression of IL-12a and MMP9 
was repressed in CD11b+ cells from injured vessels relative to PBMC controls. In 
addition to this 9-gene panel, we assessed expression of inducible nitric oxide synthase 
(iNOS) and arginase 1 (Arg I), markers of M1 and alternatively activated M2 
macrophages, respectively. INOS and Arg I expression was higher in CD11b+ cells from 
injured arteries relative to controls. Several of these genes were modulated similarly, 
compared to PBMC precursors, in both macrophages from uninjured vessels as well as in 
macrophages from injured vessels.  The genes that fell into this category were: IL-10, IL-
12a, and perhaps Arg I, although Arg I data from uninjured vessels had a very large error.  
In contrast, several genes were modulated differentially in macrophages from injured 




was decreased in macrophages from injured vessels as compared to macrophages from 
uninjured vessels.  There was a similar trend exhibited by IL-12b.  Lastly, when 
compared to both monocytic precursors and macrophages from uninjured vessels, 
macrophages from injured vessels expressed markedly higher iNOS, and there was a 
trend toward higher CCR3 and CCR7.  
  
CD11b+ cells were isolated from circulating peripheral blood mononuclear cells 
(PBMCs), and from digested uninjured femoral arteries (Uninjured) and femoral 
arteries following 2-wks wire-induced injury (iRFA).  Total RNA was isolated 
and qPCR conducted for the indicated mRNAs. Shown are mRNA copy number 




























































 Progression of vascular remodeling in response to vascular injury involves 
complex interactions between vascular cells and recruited inflammatory cells.  
Inflammatory cells, including circulating monocytes, are recruited to the site of injury 
where they undergo differentiation into macrophages.  In human atherectomy samples, 
presence of macrophages predicts development of restenosis with high significance
60
.  
Macrophages have been shown to contribute to pathogenesis of restenosis through 
secretion of growth factors, cytokines, and chemokines which induce SMC and 
endothelial cell proliferation, as well as contribute to SMC activation.  Neointimal lesion 
macrophages additionally contribute to the developing neointima by secreting matrix-
remodeling enzymes (eg. MMPs) that facilitate development of fibrosis
4
.  Macrophages 
exhibit remarkable phenotypic plasticity in response to signals from the local tissue 
microenvironment. The phenotype of macrophages in an injured vessel will depend on 
both the lineage commitment and environmental signals generated through interactions 
with other cell types in the lesion, including smooth muscle cells
68
.  The goal of this 
study was to define characteristics of macrophages in the developing neointima that are 
distinct from other immature/circulating monocytes and to define the role SMCs play in 
influencing this macrophage phenotype.  Understanding the signals critical for 
macrophage phenotypic modulation may shed light on novel therapeutic strategies to 
limit SMC proliferation and ECM deposition while allowing for re-endothelialization and 




Conclusions: Using flow cytometry, we were able to quantitatively show increased 
recruitment/retention of monocyte/macrophages to injured vessels.  We were then able to 
define an expression signature that distinguishes lesional macrophages from resident 
tissue macrophages or precursor monocytes.  These macrophages manifest several 
features of classically activated M1-like macrophages 
88
, although there were some noted 
dissimilarities (e.g. decreased TNF-, and increased arginase I expression), possibly 
suggesting a complex activation state, or heterogeneous population.  Gene regulation in 
these samples could be clustered into three categories: genes that were expressed at 
similar levels in macrophages from injured and uninjured vessels but at different levels in 
PBMCs (IL-10, IL-12a, arginase I), genes that were expressed at similar levels in PBMCs 
and macrophages from uninjured vessels but differentially in macrophages from injured 
vessels (CCR3, and possibly CCL5), and genes that were expressed differentially in all 
three populations (IL-6, Il12b, CCR7, TNF-α, MMP9, iNOS).  These different categories 
of gene modulation patterns may reflect that regulation of some genes in both 
macrophage populations, relative to precursor monocytes, may be regulated by 
monocyte-to-macrophage maturation while other genes may be regulated by injury-
associated factors, or finally a combination of maturation and injury associated factors. 
Together, these data suggest that, in addition to increased recruitment upon vascular 
injury, monocytes recruited to vascular lesions receive injury-specific molecular signals 
that result in promotion of an altered activation state that is distinct from precursor 
monocytes and macrophages present in uninjured vessels, and exhibits characteristics of 
both M1 and M2 phenotypes.  
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Based on these data, and numerous studies presented in the atherosclerosis 
literature supporting the occurrence of phenotypic modulation in plaque macrophages
68
, 
we hypothesized that factors produced by SMC were critical in promoting this injury-
associated phenotype.  Chapter III of this dissertation discusses in vitro studies performed 
to ascertain if SMC-derived factors have the ability to modulate the phenotype of 
macrophages as they mature from immature precursors. 
 
Limitations and Future Directions:  Interpretation of the study presented in this chapter 
is complicated by several technical limitations.  First, we decided to assess the phenotype 
of both the macrophages present in the uninjured vessels and the monocytes present in 
the peripheral blood as control populations because it has not been determined in the 
vascular biology field whether the cells that give rise to macrophages in restenotic lesions 
derive predominantly from resident mature macrophages present in normal vessels, from 
myeloid progenitor populations present in the arterial adventitia, or from circulating 
monocytes.  It is most likely that more than of these scenarios occur concomitantly.  
Therefore the control population that would most accurately represent a control 
population with which to compare the macrophages present in the injured vessel might be 
a combination of macrophages (and/or progenitors) present in the uninjured vessel and 
precursor monocytes.  However, determining exactly how to isolate a control population 
of monocyte/macrophages that represents the population present in an injured vessel, but 
just prior to exposure to the factors elaborated at the site of injury, is far from being 
elucidated.    
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 An additional technical limitation of these studies is the fact that the cell 
populations that we were able to isolate by CD11b positive selection are not 
homogenous, as shown by flow cytometry in Figure 4B.  Indeed we do not know if the 
macrophage population present in these isolations would be proven to be homogenous, 
with respect to phenotypic polarization or growth factor production, even if they 
appeared to be purely macrophages by flow cytometry analysis.  It is possible that if we 
were to develop FACS methodologies to isolate pure populations of 
monocyte/macrophages from injured and uninjured vessels, and from peripheral blood, 
with respect to surface marker expression that these populations would still be 
heterogeneous with respect to function.  We may be able to assess this heterogeneity in 
future studies by identifying more reliable cell surface markers to isolate subpopulations 
of macrophages by FACS.  For example, if we were to find, using immunofluorescent 
staining, that a large percentage of macrophages in the injured vessel co-expressed iNOS 
and arginase I, but do not express CD206 (see Figure 12B), we could potentially isolate 
iNOS/ArgI positive macrophages, versus CD206 positive macrophages by laser capture 
micro-dissection and subsequent RNA-seq to truly characterize the transcriptome of, at 
least, these two populations.  Transcriptome analysis might then yield cell surface 
markers that could be used to isolate macrophages of different polarization states from 
injured and uninjured vessels for use in ex vivo SMC cross talk studies to understand how 
these different subpopulations may influence SMC biology. 
A final complicating factor is that, in these studies, we have only assessed 
macrophage phenotype at a single time point.  It is possible that some of the similarity we 
observed between macrophages in the injured vessel compared to macrophages in the 
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uninjured vessel (as well as the discordance we observe between these data and the in 
vitro data presented in Chapter III), may be due to temporal effects on macrophage 
phenotype.  Perhaps if we were to assess the phenotype of macrophages at earlier time 
points we may observe a phenotype in macrophages from injured vessels that is markedly 
distinct from macrophages in uninjured vessels with respect to more of the genes in our 
panel.   
The studies performed in this chapter assessed macrophage phenotype in the 
setting of endothelial denudation injury in non-atherogenic mice.  A future direction of 
this project would be to expand these studies to understand how monocyte recruitment 
and phenotypic modulation in vascular injury is influenced by hyperlipidemia (ApoE or 
LDLR knockout plus high fat diet).  Additionally, it would be informative to assess how 
macrophages isolated from hyperlipidemic lesions may differ in terms of cross talk with 





RECAPITULATION OF NEOINTIMAL LESION-LIKE PHENOTYPE IN 





In Chapter II we showed that macrophages present in injured vessels express a 
distinct phenotype as compared to precursor monocytes.  We hypothesized that this 
phenotype was the result of monocytes maturing into macrophages in the presence of 
SMC-derived factors in vivo.  In this chapter we assess this hypothesis using an in vitro 
model of macrophage maturation from immature precursors in the presence or absence of 
SMC-derived factors.   
 As discussed above (see Chapter I: Macrophage Function and Phenotypic 
Modulation), macrophages are phenotypically plastic cells that exhibit altered phenotype 
and function in response to environmental cues.  It is clear that while in vivo studies are 
critical for assaying the effect of disease on tissues and cells, and ultimately for validating 
strategies for intervening in disease pathogenesis in a pre-clinical setting, it is often 
essential to turn to in vitro model systems in order to identify mechanisms of 
pathogenesis. Several groups have assayed the effects of other cell types on macrophages 
in vitro in order to characterize the effects of cross talk on, and identify factors 
___________________________ 
2
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responsible for, macrophage phenotypic modulation.   For example, studies from our lab 
showed that in-direct Boyden chamber coculture of murine lung adenocarcinoma cells 
with bone marrow-derived macrophages was capable of inducing arginase I expression in 
macrophages, indicative of induction of an M2-like phenotype
151
.  Cai et. al. cultured 
macrophages in direct contact with human vascular SMCs and observed that both 
VCAM-1 and MCP-1-mediated upregulation of CD36, indicative of a pro-atherogenic 
phenotype, as well as enhanced resistance to death in response to serum deprivation
102
.  
Whether in direct or in in-direct coculture, the aforementioned methods assay the net 
result of bi-directional cross talk.  Performing such studies with macrophages and SMCs 
is complicated by the fact that these two cell types are very plastic.  Macrophages are 
capable of dramatic phenotypic modulation in response to paracrine or autocrine factors, 
and SMCs are capable of converting from a differentiated, contractile, phenotype to a 
dedifferentiated, non-contractile, motile, and synthetic phenotype.  Because cell types 
will undergo phenotypic changes in coculture, these approaches may be of limited utility 
in assessing the effect of one cell on the other.   
  In contrast with coculture studies, conditioned medium studies allow for 
dissection of uni-directional aspects of intercellular cross talk.  For example, a study 
originating from the Karin lab showed, using conditioned medium isolated from Lewis 
lung carcinoma cells, that a soluble form of the matrix proteoglycan, versican, was 
capable of inducing an activated (increased production of TNF-α, IL-6, and IL-1β) 
phenotype in in vitro matured bone marrow-derived macrophages
152
.  We decided to 
employ a similar strategy to assay uni-directional effects of SMC-derived factors on 
macrophages.  In addition to focusing on the uni-directional effects of SMCs on Mϕ, we 
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also wanted to study those effects in the context of monocyte-to-macrophage maturation.  
We hypothesized that we could more closely recapitulate the in vivo scenario of a 
recruited monocyte maturing to a lesional macrophage by stimulating immature bone 
marrow-derived monocyte/macrophages with SMC-derived factors prior to them 
attaining a mature macrophage fate; as opposed to stimulating fully mature macrophages 
with SMC-derived factors.  Using this approach we have identified TGF-β as a factor 
produced by SMCs which produces an activated macrophage phenotype. 
We performed our in vitro studies using rat SMCs because we have found that 
mouse-derived aortic SMC isolations in culture are highly heterogeneous.  Rat-derived 
SMCs are a well-characterized system, and isolations of SMC from rat aortas are reliably 
homogenous.  In order to perform cross talk studies using cells from one species, we 
studied the effects of rat SMC CM on rat BMC maturation to macrophages.  Rat 
macrophage maturation from whole bone marrow has been characterized previously
153
; in 
these studies, mouse L929 cell conditioned medium was used as a source of M-CSF to 
induce maturation of rat BMC to mature macrophages.  We have found the concentration 
of M-CSF to be variable in L929 cell conditioned medium.  We therefore purchased 
recombinant mouse M-CSF to mature BMCs to macrophages in a way that has been 
previously characterized and with an invariant concentration of M-CSF.  
Materials and Methods 
Reagents: Antibodies: CD68-FITC (Biolegend), SM-α-actin-Cy3 and unconjugated 
(Sigma), phospho-SMAD2 (Cell Signaling), β-actin (Sigma), SM-22α (Abcam), SM-
MHC (Biomedical Technologies), Calponin and β-tubulin (Santa Cruz Biotechnologies), 
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BrdU (BD Biosciences), F4/80 (Cl:A3-1, Abcam), anti-rabbit-AP and anti-mouse-HRP 
(Santa Cruz), anti-rat-Alexa 488 (Life Technologies), Universal Elite HRP Kit (Vector 
Labs), IRDye 800CW Donkey anti-mouse IgG and IRDye 680RD donkey anti-rabbit IgG 
(Li-Cor). Flow cytometry antibodies:  biotinylated-F4/80 (Cl:A3-1, AbD Serotec), 
streptavidin-PE, streptavidin-PerCP-Cy5.5, CD11b-FITC, Ly6g-PE-Cy7, SiglecF-PE, 
CD11c-APC-Cy7, and CCR3-Alexa Fluor 647 (all BD Biosciences), CCR7-PE 
(eBioscience).  Recombinant proteins: human TGF-β1 (R&D Systems), mouse M-CSF 
(eBiosciences). Small molecule agonists/antagonists: SB203580, BAY 11-7082, LY-
294002, sulindac sulfide, and PD-98059 (Calbiochem), SB431542 and pioglitazone 
(Cayman).   
 
Cell Culture and Isolation of Conditioned Medium: Primary aortic SMCs were isolated 
from Sprague-Dawley rats as previously described
149
.  SMCs were used for experiments 
between passages 8 and 15.  Rat SMCs were plated at 7*10
6
 cells/150 mm dish in MEM 
medium supplemented with 10% fetal bovine serum (FBS) and 1x penicillin/ 
streptomycin (20 IU/ml penicillin, 20ug/ml streptomycin).  Twenty four hours after 
plating, cells were serum restricted in 0.1% serum medium (reduced serum medium; 
SRM) for 24 hours, then new SRM was refreshed and allowed to condition for a further 
24 hours.  This conditioned medium was cleared by centrifugation at 500xg for 10min, 
and stored at -80˚C until use. Primary bone marrow-derived Mϕ were isolated from 
Sprague-Dawley rats, or C57BL6/j mice, as previously described
137
.  Whole bone 
marrow was frozen as described
154
, and thawed for each experiment without passaging in 
the presence of 20ng/ml M-CSF (eBioscience). 
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Macrophage Maturation In Vitro: Bone marrow cells (BMC) were thawed and plated at 
a density of 2*10
6
/35mm dish in DMEM supplemented with FBS (10% for rat BMC, 
20% for mouse BMC), 1x penicillin/streptomycin, and 20ng/ml M-CSF.  Two days after 
plating, control medium (M0), 20% SMC conditioned medium (sMϕ), or 500pg/ml TGF-
β (tMϕ) was added to BMCs (final concentration: FBS, 10%; M-CSF 20ng/ml).  At day 
five of maturation, media was replaced with fresh media containing the same 
concentrations of SMC CM, TGF-β, FBS, and M-CSF as at day 2.  Total RNA was 
isolated from 7-day matured macrophages for qPCR.  To analyze cytokine protein levels, 
macrophage media was changed to SRM, collected after 48 hours, and concentrated using 
3kDa cut-off Amicon Ultra centrifugal filters. To study interactions with SMCs in 
coculture, macrophages were trypsinized, re-plated in 6.5mm diameter transwells (0.4 
μm; Corning) and added to SMC cultures.  
 
Immunofluorescent Staining:  Bone marrow derived macrophages were matured on 
glass chamber slides in the absence or presence of SMC CM, respectively, for 7 days. 
Cells isolated from vessels or PBMCs by positive selection by CD11b magnetic beads 
were plated onto glass chamber slides in 0.1% serum culture media for 48hrs. Cells were 
fixed in 4% PFA, permeabilized with MeOH, and incubated with anti-ED1-FITC, or anti-
F4/80 and anti-smooth muscle α-actin-Cy3 primary antibodies overnight at 4˚C. F4/80 
antigen:antibody complexes were visualized using Alexa Fluor-488 conjugated secondary 
antibodies (Life Technologies). Coverslips were mounted with VectaShield medium 
(Vector Laboratories) containing DAPI to detect all cell nuclei and cells imaged using an 
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Real Time qPCR: cDNA was prepared from total RNA isolates (1ug/rxn) using the 
iScript cDNA Synthesis kit from Bio-Rad.   Real time qPCR then performed using the 
Power Sybr Green supermix from Applied Biosystems as shown previously
147-149
.  
Reactions were carried out on an iCycler (Bio-Rad).  Cycling parameters were: 5min at 
95˚C; 15sec at 95˚C, 30sec at the annealing temperature optimized for each primer pair, 




: See Table 2. 
 
Table 2: Chapter III qPCR primers 
Mouse and rat glyceraldehyde-3-
phosphate dehydrogenase 
(GAPDH) 
Forward: cgt gga gtc tac tgg cgt ctt cac 
Reverse: cgg aga tga tga ccc ttt tgg c 
Mouse and Rat TNF-α Forward: ctc ttc tgt cta ctg aac ttc ggg 
Reverse: gagaagatgatctgagtgtgaggg 
Rat CCL5 Forward: gtc gtc ttt gtc act cga ag 
Reverse: agg atc aga atg gag aga cc 
Rat IL-6
1
 Forward: aac tcc atc tgc cct tca gga aca 
Reverse: aag gca gtg gct gtc aac aac atc 
Rat IL-10 Forward: gca gga ctt taa ggg tta ctt ggg 
Reverse: ctt gat ttc tgg gcc atg gtt ctc 
Rat Il-12a Forward: ggt gat gaa cta tct gag ctc ctc c 





Table 2 continued. 
Rat Il-12b Forward: cct gtg aca gtc ctg aag aag atg 
Reverse: gcc agc atc tag aaa ctc tct gac 
Rat CCR3 Forward: ctg ctc ttt ctc ttc act gtc cca 
Reverse: ctc gct gta caa ggc cag gta ata 
Rat CCR7 Forward: agc agc tca aca ttg cct atg acg 
Reverse: gaa ctt gac gcc gat gaa ggc ata 
Rat MMP9 Forward: ttc gac gct gac aag aag tg 
Reverse: agg gga gtc ctc gtg gta gt 
Rat iNOS Forward: tgt gac aca cag cgc tac aac atc 
Reverse: aca gcc cgg tct ttc cag a 
Rat arginase 1 Forward: gga tgc tca cac tga cat caa cac 
Reverse: gag aat cct ggt aca tct ggg aac 
Rat MCP-1 (CCL2) Forward: tgc tgt ctc agc cag atg cag tta 
Reverse: tac agc ttc ttt ggg aca cct gct 
Rat KC (Cxcl1) Forward: cta aaa ggt gtc ccc aag taa c 
Reverse: att gta tag tgt tgt cag aag cc 
Rat SDF1 (CCL12) Forward: ttt gag agc cat gtc gcc ag 
Reverse: tgt tgt tgc ttt tca gcc ttg c 
Mouse CCL5 Forward: ctg ccc tca cca tca tcc tc 
Reverse: aga ggt agg caa agc agc ag 
Mouse IL-6 Forward: gat gct acc aaa ctg gat ata atc 
Reverse: ggt cct tag cca ctc ctt ctg tg 
Mouse Il-10 Forward: gcg ctg tca tcg att tct cc 
Reverse: ggc ctt gta gac acc ttg gtc 
Mouse Il-12a Forward: gtc tta gcc agt ccc gaa ac 
Reverse: ggt ccc gtg tga tgt ctt c 
Mouse Il-12b Forward: ccg gac ggt tca cgt gct ca   




Table 2 continued. 
Mouse CCR3 Forward: tga tgt tta cta cct gac tgg tg 
Reverse: tgc cat tct act tgt ctc tgg t 
Mouse CCR7 Forward: gtg gtg gct ctc ctt gtc att 
Reverse: ctt gaa gca cac cga ctc gta 
Mouse MMP9 Forward: tag atc att cca gcg tgc cg 
Reverse: gcc ttg ggt cag gct tag ag 
Mouse iNOS 
 
Forward: cct cag ttc tgc gcc ttt gc 
Reverse: aaa ggt ctc aca ggc tgc cc 
Mouse arginase 1 Forward: ctc caa gcc aaa gtc ctt aga 
Reverse: agg agc tgt cat tag gga cat 
 
Western Blotting: Whole cell lysates were prepared using protein lysis buffer (50mM β-
glycerophosphate [pH 7.2], 100μM sodium vanadate, 2mM magnesium chloride, 1mM 
EGTA, 0.5% Triton X-100, 1mM DTT, and protease inhibitor cocktail [1:100 Sigma, 
P8340]) and cleared by centrifugation.  Samples were normalized by protein 
concentration and SDS-PAGE was performed as described previously
155
. 
Electrophoresed proteins were transferred to polyvinylidene difluoride membranes, and 
blocked with 5% bovine serum albumin or non-fat dry milk in tris-buffered saline. 
Membranes were probed with primary antibodies, and subsequently with horseradish 
peroxidase or alkaline phosphatase-conjugated secondary antibodies.  Antibody binding 
was visualized with either enhanced chemiluminescence substrate (Perkin Elmer) or 




Enzyme-Linked Immunosorbent Assay:  ELISA for TGF-β was performed on SMC 
conditioned media, as per the manufacturer’s instructions (R&D Systems, DY240).  Total 
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TGF-β was determined by acidification of samples as recommended in the 
manufacturer’s instructions.   
 
Multiplex Luminex Assay: 48 hour macrophage SRM conditioned media samples, 
prepared as described above, were concentrated ~20x with 3kDa Amicon Ultra spin 
filters (Millipore) and then assayed for IL-6, CCL5, TNF-α, IL-10, and IL-12p70 using 
Milliplex Map beads (Millipore).  Samples were quantified using a MagPix instrument 
(Luminex).  Analyte concentrations obtained from Luminex assay were normalized to 
total protein or RNA per sample. 
 
Gelatin Zymography: Whole cell lysate, or 10x concentrated low serum conditioned 
medium, was electrophoresed under non-reducing, non-denaturing conditions on 10% 
gelatin zymography gels (Novex/Invitrogen).  Renaturation, development, and staining 
with Simply Blue Safe Stain (Invitrogen) were performed as per the manufacturer’s 
specifications. 
 
SMC Proliferation Assay:  SMC proliferation was assessed as previously described
137, 
147
.  Briefly, SMCs were plated in 24-well plates at a density of 3*10
4
 cells/well, allowed 
to attach and spread overnight, and media replaced with 500μl/well SRM.  Seven-day 
matured macrophages were trypsinized, resuspended in SRM at 4*10
5
 cells/ml and re-
plated on 0.4μm transwell inserts (Corning) in wells containing SMCs.  20μM BrdU was 
added to cocultures after 24hours.  At 48 hours SMC were fixed with 4% 
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paraformaldehyde, and immunohistochemically stained for BrdU incorporation.  BrdU 
index was calculated as the percent of BrdU-positive nuclei.   
 
Femoral Artery Injury: All animal procedures were approved by, and performed in 
accordance with the guidelines of the University of Colorado IACUC. Guide-wire 
denudation femoral artery injury was performed, as shown by us previously
137
, and as 
described in the Materials and Methods section of Chapter II.  
  
Flow Cytometry: Isolated injured, and contralateral control vessels, were digested to 
single cells by digestion at 37°C for 2hr in collagenase buffer (3.2mg/ml collagenase II, 
0.7mg/ml elastase (Worthington), 0.2mg/ml soybean trypsin inhibitor (Sigma) in Hank’s 
buffered saline solution (HBSS), pH7.5). Red blood cells were lysed for 2-5 min in RBC 
lysis buffer (0.15 M NH4Cl, 10 mM KHCO3, 0.1 mM Na2EDTA (pH 7.2)). Single cell 
suspensions were stained for CD11b, F4/80, Ly6g, CCR3, CCR7, and DAPI to stain for 
dead cells. Flow cytometry was performed on a Galios cytometer (Becton Dickenson) as 
demonstrated by our group previously
145
, and as described in the Materials and Methods 
section of Chapter II. 
 
Statistics: Data are expressed as means ± standard error. Student’s T-tests were used to 
compare data sets with two samples.  Data sets with more than two samples were 
analyzed by ANOVA followed by Tukey multiple comparisons post-tests.  Bonferroni 
multiple comparisons tests were used to compare select samples within a data set.  
Finally, Dunnett multiple comparisons tests were used to compare all samples to a single 
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control.  In instances, within a data set with more than two samples, when variances were 
different between groups (as determined by T-Test) serial T-tests were performed 
followed by Bonferroni correction to account for multiple comparisons. 
Results 
Phenotypic Modulation of Macrophages by Conditioned Media from SMCs.  We 
hypothesized that the signals driving macrophage phenotypic modulation are derived, at 
least in part, from medial SMCs.  We therefore developed an in vitro system to determine 
if maturation of bone marrow-derived monocytes in the presence of factors secreted by 
SMCs results in phenotypic modulation resembling lesion-associated macrophages.  Rat 
bone marrow cells (BMCs) were matured, as previously described
153
, with recombinant 
mouse M-CSF in the presence (sM) or absence (M0) of conditioned media (CM) 
obtained from rat aortic SMCs.  Aortic vascular smooth muscle cells isolated from the 
rat, and cultured ex vivo, have a proliferative index of about 24% when serum-restricted 
in 0.1% serum medium for 48 hours as they were for our conditioned medium collection 
procedure.  This proliferative index is in stark contrast to the SMC proliferation rate in 
vivo in an uninjured vessel, which has been documented by several groups as less than 
0.1% per day
156, 157
.  We previously showed that even out to 9 days in 0.1% serum media 
the proliferative index of cultured aortic SMC remains elevated above a truly quiescent in 
vivo level
158
.  Therefore, while serum-restricted to rule out confounding effects from 
serum-derived factors, SMCs in culture maintain a somewhat activated phenotype and 
model an activated SMC phenotype.  Bone marrow cells were exposed to CM from 




Figure 6: Maturation of macrophages in the presence of SMC conditioned 
media (CM) promotes an activated phenotype similar to macrophages from 
in vivo vascular lesions.   
A) Rat bone marrow cells (BMC) were matured with 20ng/ml macrophage-
colony stimulating factor (M-CSF) in the absence (M0) or presence of 20% SMC 
CM (sMϕ). Representative phase-contrast micrographs of M0 and sMϕ.  B) Rat 
bone marrow-derived cells (BMC) were matured with 20ng/ml M-CSF in the 
absence (M0) or presence of 20% SMC CM (Mϕ) on glass chamber slides.  Cells 
were assessed for CD68 expression by immunofluorescence.  SMC were assessed 
for CD68 as a negative control.  C&D) Total RNA was isolated and qPCR 
conducted for the indicated mRNAs.  Shown are mRNA copy number 
normalized to GAPDH. Means±SE; n=6 independent experiments. E) 
Conditioned media was collected from M0 and sMϕ at day 9, 48 hours after 
replacing media with SRM, concentrated, and assayed for IL-10, CCL5, and 
TNF-α protein levels by Luminex assay.  F) MMP9 expression was assessed in 
whole cell lysates from M0 and sMϕ by gelatin zymography. Shown are 
means±SE; n=7 independent experiments.  *P<0.05 versus M0. 
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exposure of BMCs to SMC-derived factors early in maturation resulted in a pronounced 
change in morphology.  These cells were more rounded with shorter processes whereas 
M0 cells were more elongated with 2 or more extended processes. The expression of the 
macrophage marker CD68 was assessed in these cells by immunofluorescence.  SM 
express CD68 (rat ED1) at similar levels as M0 macrophages, indicating these cells 
retained a macrophage fate (Figure 6B). QPCR analysis of the previously described in 
vivo 9-gene panel in sM, relative to M0 controls, closely recapitulated the signature 
found in macrophages isolated from injured vessels as compared to PBMC precursor 
monocytes (Figure 6C). Up- and down-regulation of CCL5, IL-6, IL-10, IL-12b, CCR3, 
CCR7, and MMP9 were concordant between this in vitro system and in vivo injury 
model.  Luminex multiplex bead assays were used to verify modulation of cytokines at 
the protein level.  Transcriptional regulation of Il-10, CCL5, and TNF-α correlated with 
protein production (Figure 6E) whereas IL-6 and IL-12p70 were undetectable by this 
method (not shown).  Gelatin zymography was used to assess catalytically active MMP9 
expression in these lysates.  Expression of MMP9 was decreased in sMϕ relative to 
control M0 macrophages (Figure 6F).  Expression of the M1/M2 markers iNOS and Arg 
I was assessed by qPCR in these cells.  Similar to macrophages recruited to injured 
vessels, sMϕ expressed high levels of iNOS, but unlike lesional macrophages, low levels 
of Arg I relative to M0 (Figure 6D).  We were unable to detect iNOS or Arg I protein by 
western blotting in these experiments (data not shown).  These data suggest that 
maturation of bone marrow-derived monocytes in the presence of factor(s) derived from 
SMC recapitulates many of the features of neointima-associated macrophages observed 
in vascular lesions in vivo.  This in vitro model system establishes a novel framework for 
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Figure 7: Physical characterization of SMC-derived factor(s) promoting 
macrophage phenotypic modulation.  
 A, left) Rat BMC were matured with 20ng/ml M-CSF in the absence (M0), presence 
of 20% SMC CM (CM), or presence of heat-treated SMC CM (Boiled). 
Representative phase-contrast micrographs. A, right) qPCR analysis of indicated 
mRNAs. Shown are means±SE; n=4 independent experiments. B) Conditioned media 
was collected at day 7, concentrated, and assayed for IL-10, CCL5, and TNF-α protein 
levels by Luminex assay. Shown are means±SE; n=3 independent experiments. C, 
left) Rat BMC were matured with 20ng/ml M-CSF in the absence (M0), presence of 
heat-treated SMC CM (Boiled ), or presence of protease and heat-treated SMC CM 
(Boiled, Trypsinized). Representative phase-contrast micrographs. C, right) qPCR 
analysis of indicated mRNAs. Shown are means±SE; n=3 independent experiments.  
D, left) Rat BMC were matured with 20ng/ml M-CSF in the absence (M0), presence 
of native or heat-treated SMC CM (CM and Boiled), or presence of native or heat-
treated SMC CM fractionated by size (<100kDa, >100kDa, respectively). 
Representative phase-contrast micrographs. D, right) qPCR analysis of indicated 
mRNAs. Shown are means±SE; n=3 independent experiments.  *P<0.05 versus M0; 




Figure 8: Exogenous TGF-β recapitulates effects of SMC CM on 
macrophage activation.   
A) Rat BMC were matured with 20ng/ml M-CSF in the absence (M0) or 
presence of 500pg/ml rh-TGF-β1 (tMϕ). Representative phase-contrast 
micrographs of M0 and tMϕ.  B) Total RNA was isolated and qPCR conducted 
for the indicated mRNAs.  Shown are mRNA copy number normalized to 
GAPDH. Means±SE; n=6 independent experiments.  C) Conditioned media was 
collected from M0 and tMϕ at day 9, 48 hours after replacing media with SRM, 
concentrated, and assayed for IL-10, CCL5, and TNF-α protein levels by 
Luminex assay. Shown are means±SE; n=3 independent experiments. D) Whole 
cell lysate (WCL) and concentrated conditioned medium (CM) were assayed for 
MMP9 expression by gelatine zymography.  E) Total RNA was isolated and 
qPCR conducted for iNOS and arginase I (Arg I).  Shown are mRNA copy 
number normalized to GAPDH. Means±SE; n=6 independent experiments. 
*P<0.05 versus M0. 
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studying macrophage maturation and function that is specifically relevant to injury-
induced neointima formation.  Further, this system establishes a novel in vitro platform 
for understanding intercellular cross talk between the SMCs and recruited macrophages. 
 
Characterization of the Factor(s) Produced by SMCs that Mediates sMϕ Induction.  To 
identify potential factor(s) secreted by SMCs responsible for macrophage phenotypic 
modulation, we employed several techniques to test physical properties of the factor(s). 
SMC CM was heat-treated in a boiling bath for 10min to denature heat-labile factors.  
The macrophage-modulating activity of SMC CM was enhanced by heat-treatment 
(Figure 7A).  Exposure of macrophages to heat-treated CM resulted in enhanced 
morphologic alteration of macrophages, enhanced up- or down-regulation of genes, and 
increased levels of IL-10, CCL5, and TNF-α protein (Figure 7B) compared to CM that 
had not been heated.  Trypsinization of CM completely abolished the macrophage-
modulating activity of the heat-treated SMC CM (Figure 7C), confirming that the 
factor(s) is a polypeptide.  Size fractionation was performed with 100kDa cut-off 
centrifugal filters and revealed that the macrophage-activating factor partitions to the 
>100kDa fraction in the native CM (Figure 7D).  To determine if heat-dependent 
activation of the factor(s) is due to dissociation of an inhibitor, or inhibitory complex, 
size exclusion studies were performed following heat-treatment.  These studies showed 
that the macrophage-modulating activity partitions to the <100kDa fraction following 
heat-treatment (Figure 7D). Together these data suggest that a peptide-based factor is 
secreted from SMCs in a large (>100kDa), less active complex and activity is enhanced 
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by heat-treatment through a mechanism resulting in decreased molecular weight of the 
active component.   
 
Exposure of Bone Marrow-Derived Cells to TGF- Leads to Induction of the sMϕ 
Phenotype.  Latent, complex-bound TGF-β is secreted into the extracellular space in the 
vasculature, and undergoes activation upon mechanical injury
125
.  Latent TGF-β is also 
known to be activated in vitro by heat and acidic conditions
113
.  Activation is associated 
with a change in molecular weight, similar to what we have observed with CM.  
Furthermore, blocking TGF-β signaling in in vivo vascular injury models has been shown 
to inhibit neointima formation
159-165
.  Since the macrophage modulating activity in SMC 
conditioned medium had characteristics consistent with TGF-β, we next tested the effect 
of recombinant human (rh) TGF-β on macrophage phenotype. Maturation of 
macrophages in the presence of rh-TGF-β1 recapitulated the morphologic modulation 
observed with SMC CM (Figure 8A) and recapitulated the expression signature of the 
previously described 9-gene qPCR panel observed in sM (Figure 8B).  Increased IL-10 
and CCL5 and decreased TNF-α protein levels were verified by Luminex assay (Figure 
8C). MMP9 expression was validated using gelatin zymography on either whole cell 
lysate (WCL) or macrophage conditioned medium (CM) (Figure 8D).  Similar to sMϕ, 
iNOS and Arg I expression was increased and decreased, respectively, in macrophages 
matured with rh-TGF-β (tMϕ) (Figure 8E).  Figure 9 shows a side-by-side comparison 
of gene expression changes in the 9-gene qPCR panel in macrophages matured with 
conditioned medium versus rh-TGF-β1.  Gene expression across this panel of markers 





SMC-derived TGF-β Promotes Macrophage Modulation Observed in In Vitro 
Maturation Studies. We sought to determine if the factor in SMC CM responsible for 
modulating macrophage phenotype was TGF-β.  Latent TGF-β1 was detectable in SMC 
CM at an average concentration of 350pg/ml (Figure 10A).  Bone marrow cells 
stimulated with SMC CM showed increased phosphorylation of SMAD2, which was 
detectable by 30 minutes, and remained elevated for at for least 90 minutes (Figure 10B).  
The level of stimulation was comparable to that observed with rh-TGF-1, indicating that 
canonical TGF-β signaling occurs in macrophages in response to SMC CM, although the 
kinetics were somewhat delayed. Delayed phosphorylation of SMAD2 suggested that 
macrophages activate SMC-derived latent TGF-β1. As shown in Figure 10B, activation 
Figure 9: Comparison of gene expression changes in CM versus rh-
TGF-β-matured macrophages. 
Rat BMC were matured with 20ng/ml M-CSF in the absence (M0) or 
presence of 20% SMC CM or 500pg/ml rh-TGF-β1 (tMϕ). Total RNA was 
isolated and qPCR conducted for the indicated mRNAs.  Shown are fold 
change in mRNA copy number, normalized to GAPDH, relative to M0.  
CM data originally presented in Figure 6C,D.  TGF-β data originally 























































of SMAD2 in response to SMC CM was completely inhibited by a specific TGF-β 
receptor 1 (TBR1) inhibitor, SB431542 (10μM).  
 To confirm that TGF-β is a critical factor in SMC CM responsible for inducing 
macrophage phenotypic modulation, we employed several complementary strategies.  
Pharmacological inhibition of TGF-β signaling with SB431542 resulted in blockade of 
the morphologic change induced by SMC CM (Figure 11A).  This inhibitor also 
abolished SMC CM-induced increases in gene expression of IL-6, CCL5, IL-10, IL-12a,  
Figure 10: TGF-β is present in SMC conditioned medium and 
engages canonical TGF-β signaling in macrophages in vitro.  
A) SMC CM was assayed for active and total TGF-β1 by ELISA.  
Statistical analysis was not possible because active TGF-β1 was not 
detectable. Shown are means±SE; n=3 independent experiments. B) 
Rat macrophages were stimulated for the indicated times with 
control media, SMC CM in the presence or absence of TBRI 
inhibitor (SB431542), or purified recombinant human (rh)-TGF-β. 
Representative western blot of for phospho-SMAD2 with β-tubulin 
loading control.  N=4 independent experiments.Figure 5:  
Macrophages recruited to the developing neointima express a 
distinct transcriptional signature.    
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Figure 11: TGF-β receptor inhibition prevents macrophage activation by SMC 
CM.   
Rat BMC were matured with 20ng/ml M-CSF in the absence (M0) or presence of 
20% SMC CM (sMϕ) and in the presence (+) or absence (-) of TRBI inhibitor 
SB431542. A) Representative phase-contrast micrographs. B-D) Total RNA was 
isolated and analyzed by qPCR for the indicated mRNAs. E) Rat BMC were 
matured with 20ng/ml M-CSF in the absence (M0) or presence of 20% SMC CM 
(sMϕ), and with or without the TRB1 inhibitor (SB431542). Conditioned media 
was collected, concentrated, and assayed for IL-10, CCL5, and TNF-α protein 
levels by Luminex assay. Shown are means±SE; n=3 independent experiments.  B-
D) Shown are mRNA copy number normalized to GAPDH. Means±SE; n=3 




IL-12b, CCR3, and CCR7, as well as reversed the decreases in TNF-α and MMP9 
expression (Figure 11B-C).  Finally the receptor inhibitor reversed the expression of 
macrophage phenotypic markers, decreasing expression of iNOS and increasing 
expression of Arg I (Figure 11D).  Inhibition of cytokine up/down regulation by TBR1 
inhibition was assessed by Luminex assay (Figure 11E).  To confirm these findings, a 
pan-specific anti-TGF-β neutralizing antibody was used to inhibit SMC CM-mediated 
TGF-β signaling in macrophages during maturation. Compared to vehicle control, 
neutralization of TGF-β resulted in blockade of the morphologic change (Figure 12A) 
and abolished altered gene expression of IL-6, CCL5, IL-10, IL-12a, IL-12b, CCR3, 
CCR7, TNF-α, MMP9, iNOS, and Arg I (Figure 12 B-D) induced by SMC CM.  These 
effects were specific for anti-TGF- and were not observed with antibodies against 
PDGF-BB or SDF-1; the selectivity of this effect due to TGF-β neutralizing antibody 
was determined by assaying the samples for CCL5 and MMP9 expression only by qPCR 
(Figure 12E-F).  
 TGF-β neutralizing antibody and TBR1 inhibition studies cannot rule out that an 
unknown factor produced by SMC triggers vesicle fusion, and TGF-β release from 
macrophages (as has been described elsewhere
166
), which then mediates these changes in 
an autocrine manner.  Therefore expression of TGF-β was silenced in SMCs using 
transient transfection of siRNA and conditioned medium collected from control or TGF-
β-silenced SMCs. TGF- was decreased by greater than 80% in cells receiving the TGF-
-specific siRNA compared to non-targeting control siRNA-treated SMCs (Figure 13A). 
Compared to maturation of macrophages in the presence of SMC CM from non-targeting 




Figure 12: TGF-β neutralization prevents macrophage activation by SMC CM.  
Rat BMC were matured with 20ng/ml M-CSF in the absence (-) (M0) or presence 
(+) of 20% SMC CM (sMϕ), and pan-TGF-β neutralizing antibody. A) 
Representative phase-contrast micrographs. B-D) Total RNA was isolated and 
analyzed by qPCR for the indicated mRNAs. E&F) Rat BMC were matured with 
20ng/ml M-CSF in the absence (M0) or presence of 20% SMC CM (sMϕ) and 
vehicle (-), pan-TGF-β neutralizing antibody (anti-TGF-β), PDGF-B neutralizing 
antibody (anti-PDGF-B), or SDF-1α neutralizing antibody (anti-SDF-1α). Total 
RNA was isolated and analyzed by qPCR CCL5 and MMP9 C-F) Shown are mRNA 
copy number normalized to GAPDH. Means±SE; n=3 independent experiments. 




showed a decrease in sMϕ morphologic modulation and a ~50% decrease in phenotypic 
modulation of CCL5 and MMP9 (Figure 13B-C). Taken together, these data suggest a 
critical role for SMC-derived TGF-β in the maturation of a phenotypically distinct 
macrophage population, which exhibits a hybrid M1/M2 activation state and may be 
specifically primed to contribute to SMC activation.  
 
Figure 13: Conditioned media from TGF-β-silenced SMC CM fails to promote 
macrophage phenotypic modulation.    
A) SMC were depleted for TGF-β1 by transient transfection with siRNAs.  
Conditioned media from untransfected, non-targeting siRNA-transfected (si-NT), 
and siRNA-mediated TGF-β1-silenced (si-TGF-β1) SMC were analyzed for TGF-
β1 expression by ELISA.  Shown are mean ±SE; n=3 independent experiments. B) 
Rat BMC were matured for 7 days with 20ng/ml M-CSF in the absence (M0), 
presence of non-targeting siRNA-transfected SMC CM (si-NT), or presence of 
TGF-β1 siRNA-transfected SMC CM (si-TGF-β1). Representative phase-contrast 
micrographs, and C) analysis of indicated mRNAs by qPCR. Shown are mRNA 
copy number normalized to GAPDH.  Shown are mean ±SE; n=3 independent 
experiments.  *P<0.05 versus M0; **P<0.05 versus si-NT. 
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Mouse and Rat In Vitro Matured Macrophages Exhibit Differential Responses to 
TGF-β. Since our initial in vivo studies were performed in a mouse model of arterial 
injury, we wanted to determine how mouse BMC-derived macrophages would behave 
when matured in the presence, versus absence, of purified TGF-β.  We therefore matured 
cryopreserved whole mouse bone marrow using the same experimental conditions as was 
used with rat bone marrow, as shown in Figure 8.  We found that mouse macrophages 
exhibited a similar morphologic modulation in response to 500pg/ml rh-TGF-β1 as did 
rat macrophages at day 7 of maturation (Figure 14A).  Interestingly, mouse BMCs only 
began to look like the rat macrophages, morphologically, after 6 to 7 days in culture.  
Prior to day six, the mouse BMC-derived macrophages exhibited a much more spindle-
like morphology, which was similar to PBMC-derived mouse macrophages at that time 
point (data not shown).  Assessment of qPCR phenotypic markers showed that several 
genes were regulated concordantly between mouse and rat tMϕs (Figure 14B: IL-6, 
TNF-α, iNOS, Arg I, and additionally CD206/mannose receptor).  However, several 
genes were regulated discordantly or were not modulated by maturation in the presence 
of TGF-β (Figure 14B: CCL5, IL-10, IL-12a, CCR3, CCR7, and MMP9).  These data 
suggest that mouse and rat bone marrow-derived macrophages may not represent 
equivalent cell populations when matured in vitro.  To try to determine if transcriptional 
repression of CCR3 and CCR7 was detectable at the protein level we performed flow 
cytometry analysis of in vitro matured mouse M0 and tMϕ macrophages and compared 
CCR3 and 7 expression in these cells with expression in macrophages present in injured 
and uninjured vessels.  We found that CCR3 expression in both in vivo macrophage 




Figure 14: Comparison of gene expression changes rat versus mouse 
macrophages matured in the presence of rh-TGF-β1.   
A) Rat and mouse bone marrow cells (BMC) were matured with 20ng/ml 
macrophage-colony stimulating factor (M-CSF) in the absence (M0) or presence 
of 500pg/ml rh-TGF-β1 (tMϕ). Representative phase-contrast micrographs of M0 
and sMϕ from both species.  B) Total RNA was isolated and qPCR conducted for 
the indicated mRNAs.  Shown are fold change in mRNA copy number, 
normalized to GAPDH, relative to M0. Means±SE; n=4 independent experiments 
*P<0.05 versus M0. Rat data originally presented in Figure 6, including 
statistical analysis. C) Mouse bone marrow cells (BMC) were matured with 
20ng/ml macrophage-colony stimulating factor (M-CSF) in the absence (M0) or 
presence of 500pg/ml rh-TGF-β1 (tMϕ).  Single cell suspensions were isolated 
from femoral arteries following 2-wks wire-induced injury (iRFA), and from 
pool uninjured vessels (aorta, carotid, and left femoral artery).  Cells were 




whereas ~30% M0 mouse macrophages expressed high levels of CCR3 and 70% 
expressed CCR3 levels similar to in vivo macrophages.  We did not perform this analysis 
with in vivo monocytes from peripheral blood. These data suggest that M0 in vitro mouse 
macrophages are a heterogenous population and may not fully represent a homogeneous 
control macrophage population.  With respect to CCR7 expression, we found that in both 
in vivo and in vitro cells, CCR7 was expressed at a low level, and injury or maturation 
with TGF-β was sufficient to reduce the percentage of CCR7 positive cells (Figure 14C 
bottom). This suggests that while we find discordant transcriptional regulation of some 
of our qPCR panel between the in vitro TGF-β-matured mouse macrophages and the in 
vivo lesional macrophages (when compared to either PBMC or uninjured vessel 
macrophage controls) the protein level expression - and percentage of cells expressing - 
some of these markers may be modulated in the same way by injury or maturation in the 
presence of TGF-β.  We are not able to perform this kind of protein-level assessment of 
cell surface markers (or heterogeneity analysis in control M0 macrophages) in the in vitro 
matured rat cells due to unavailability of reagents specific to rat cell surface proteins.   
 
Phenotypic Modulation of Macrophages by SMC-Derived TGF-β is p38 MAPK-
Dependent. To define mechanisms mediating the effects of SMC-derived factors on 
macrophage phenotype, we assessed the contribution of downstream signaling pathways 
using a pharmacologic strategy.  We assayed a panel of small molecule inhibitors of 
signaling pathways likely to be involved in altered maturation.  Macrophages were 
exposed to BAY 11-7082, an inhibitor of NF-B signaling; LY-294002, a PI-3K 
inhibitor; SB203580, a p38 MAP kinase inhibitor; PD-98059, a MEK-1/2 (MAP kinase 
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Figure 15: Macrophage phenotypic modulation by SMC-derived 
TGF-β is p38 MAPK-dependent. 
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Figure 15: Macrophage phenotypic modulation by SMC-derived TGF-β is p38 
MAPK-dependent. 
Rat BMC were matured with 20ng/ml M-CSF in the absence (M0) or presence of 
20% SMC CM (sMϕ). M0 and sMϕ were treated ± DMSO (Veh) or the following 
inhibitors: 0.1µM BAY-7082 (BAY), 1µM LY-294002 (LY), 10µM SB203580 (SB2), 
25µM PD-98059 (PD), or 25µM Sulindac Sulfide (SS) at the time of initial SMC 
CM addition. A) Representative phase-contrast micrographs of M0 vs sMϕ ± vehicle 
or drug at day 7. B &C) Total RNA was isolated and analyzed by qPCR for the 
mRNAs indicated.  Shown are mRNA copy number normalized to GAPDH. D) 
MMP9 expression, in whole cell lysates, was assessed by western blot and E) by 
gelatin zymography. Shown are mean ±SE; n=4 independent experiments. *P<0.05 
versus M0 vehicle control; **P<0.05 versus sMϕ, vehicle treated. 
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kinase) inhibitor; and Sulindac Sulfide, a cyclooxygenase inhibitor throughout the course 
of maturation with SMC CM. Drugs, or vehicle were added to Mϕ cultures immediately 
prior to addition of SMC conditioned medium.  Inhibition of p38 activity with SB203580 
was the only condition exerting an inhibitory effect on macrophage morphologic 
modulation by SMC CM (Figure 15A). In addition, p38 inhibition abrogated  
transcriptional changes induced in the previously described panel of genes (IL-6, CCL5, 
CCR3, CCR7, IL-10, IL-12a, IL-12b, TNF-α, MMP9, iNOS; no significant differences in 
Arg I) (Figure 15B-C). Rescue of repression of MMP9 by maturation in the presence of 
SMC CM was seen with SB203580 (Figure 15D-E).  Exposure to SB203580 also 
blocked the morphologic and transcriptional changes induced by recombinant TGF-β on 
CCL5 and MMP9 (Figure 16A-B) and inhibited up- and down-regulation of iNOS and 
Arg I, respectively, mediated by TGF-β (Figure 16C). These data suggest that the ability 
of SMC-derived factors to induce phenotypic modulation of macrophages is dependent 
on p38 MAPK signaling.  Interestingly, we did not observe altered levels of 
phosphorylation of p38 in response to either recombinant TGF-β or SMC conditioned 
medium in macrophages (Figure 17A).  This suggested to us that basal p38 kinase 
Macrophages Matured in the Presence of SMC-Derived TGF-β Exhibit Cross Talk 
with SMCs.  To begin to define how the phenotypic modulation of macrophages by 
SMC-derived TGF-β influences macrophage cross talk with SMCs, we performed in 
vitro coculture studies.  Following seven days of maturation, M0 cells or sM were 
placed in Boyden chamber inserts and cocultured with 48hr serum-restricted SMCs for 48 
hours. We observed an increase in cell proliferation, as assessed by SMC DNA synthesis 
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by BrdU incorporation assay, at 48 hours as compared to SMC alone or in coculture with 
M0 macrophages (Figure 18A).  We examined expression of several cytokines 
previously shown to be upregulated in activated SMC
137
.  Exposure of SMC to either M0 
or sM macrophages induced expression of MCP-1, KC, and SDF-1 in SMC after 48 
hours in coculture.   However, there was no significant difference in the degree of 
induction between M0 and sMϕ coculture conditions (Figure 18B).  We also assessed 
expression of the SM-contractile proteins smooth muscle myosin heavy chain (SM-
MHC), smooth muscle α-actin (SMA), calponin, and SM-22α (SM22) by western 
blotting in SMCs after 48 hours in coculture.  We did not find significant differences in 
SM-contractile protein expression in these SMCs in response to coculture (Figure 18C).  
Densitometry of blots from several independent experiments is shown in Figure 18D. 
Figure 16: Macrophage activation by TGF-β is p38 MAPK-dependent.   
Rat BMC were matured with 20ng/ml M-CSF in the absence (M0) or presence of 
500pg/ml TGF-β and with or without SB203580 (SB2). A) Representative phase-
contrast micrographs of M0 vs tMϕ (TGF-β1) ± SB203580. B & C) Total RNA 
was isolated and analyzed by qPCR for the indicated mRNAs. Shown are mRNA 
copy number normalized to GAPDH. Means±SE; B: n=4; C: n=3 independent 
experiments. *P<0.05 versus M0; **P<0.05 versus sMϕ, vehicle treated. 
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Figure 17: TGF-β does not induce p38 phosphorylation above baseline, 
and inhibition of p38 does not prevent Smad2/3 nuclear translocation.   
A) Time course analysis of  Mϕ stimulated with SMC CM in the presence or 
absence of the TBRI inhibitor SB431542, or with rh-TGF-1 was performed , 
by western blot, for phospho-p38 (p-p38), and total p38.  β-Actin was used as 
a loading control.  B) Mϕ were stimulated for 30min with 20% SMC 
conditioned medium (CM)  following 1hr prei-ncubation in  the  absence of 
drug, or in the presence of either 10μM p38 inhibitor SB203580 (SB2) or 




Figure 18: Coculture with sMϕ promotes SMC proliferation.  
A) Rat BMC were matured with 20ng/ml M-CSF in the absence or presence of 20% 
SMC CM. Macrophages were then re-plated in transwell inserts and cocultured with 
serum restricted SMC for 48 hours.  A) Cocultures received BrdU for the final 24 
hours of coculture. BrdU positive cells were quantified by counting BrdU immuno-
positive vs negative cells (BrdU Index). B) Rat BMC were matured and re-plated 
with serum restricted SMC for 48 hours. Total RNA was isolated from SMC and 
analyzed by qPCR for the indicated mRNAs. Shown are mRNA fold change in copy 
number, relative to SMC, normalized to GAPDH. C) Smooth muscle contractile 
proteins were also assessed after 48 hours in coculture, in SMC whole cell lysates.  
SM-αActin (SMA), SM-22α (SM22).  D) Densitometry analysis of smooth muscle 
contractile proteins assessed by western blot and in C.   “CC’d or +” = cocultured. 
Shown are means±SE; A&B :n=6, C&D: n=4 independent experiments. *P<0.05 vs 
untreated SMC.  
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Efforts to Identify sMϕ-Derived Factors Responsible for Inducing SMC Proliferation.  
We were interested in identifying what factors secreted preferentially by sMϕ versus M0 
macrophages might be responsible for increased SMC proliferation observed in coculture 
experiments.  We therefore isolated conditioned medium from M0 macrophages and sMϕ 
as described for Luminex assay.  We stimulated serum-restricted SMC with control, M0, 
or sMϕ conditioned medium for 10-90 minutes to assess what down-stream signaling 
pathways were engaged in SMC in response to these media.  We assessed 
phosphorylation of signal transducer and activator of transcription 3 (STAT3), AKT, and 
ERK.  Exposure of SMCs to CM from either M0 or sMϕ resulted in activation of both 
ERK and AKT signaling, as determined by expression of phospho-ERK and phospho-
AKT, however, we did not find any consistent differences in either the magnitude or the 
kinetics of activation (Figure 19A).  STAT3 activation was consistently slightly lower in 
response to sMϕ medium versus M0 medium (Figure 19A), suggesting that IL-6 is 
unlikely to be the sMϕ-derived factor responsible for inducing SMC proliferation.  Our 
lab previously showed that PDGF induces AKT and ERK activation in SMCs
168
 in 
addition to inducing proliferation
169
.  Because we observed increased proliferation in 
SMCs in response to coculture with sMϕ, we assessed if sMϕs were secreting more 
PDGF than M0 macrophages.  We assessed PDGF transcription in M0 versus sMϕ by 
qPCR (Figure 19B) and at the protein level by ELISA performed on macrophage 
conditioned medium collected, and concentrated, as for Luminex assay (Figure 19C).  
We found that PDGF mRNA and protein were repressed in sMϕ as compared to M0 
macrophages.  These data suggest that IL-6 and PDGF are not factors produced by sMϕ 
that are responsible for driving increased SMC proliferation in coculture in response to 
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Figure 19: Mϕ conditioned medium analysis and effects on SMC signaling 
pathway activation.  
A) Rat BMC were matured with 20ng/ml M-CSF in the absence (M0) or 
presence of 20% SMC CM (sMϕ). Conditioned media was collected from M0 
and sMϕ at day 9, 48 hours after replacing media with SRM.  SMCs were 
stimulated with control SRM, M0, or sMϕ CM for 10-90 minutes.  Whole cell 
lysates from SMCs were analyzed for phospho-STAT3 (pSTAT3), phospho-
AKT (pAKT), and phospho-ERK (pERK), by western blot.  βActin was used 
as a loading control.  B) Rat BMC were matured with 20ng/ml M-CSF in the 
absence (M0) or presence of 20% SMC CM (CM), boiled SMC CM (Boiled), 
or rh-TGF-β1 (rTGF-β).  Total RNA was isolated and analyzed by qPCR for 
PDGF-b mRNA.  Shown are mRNA copy number normalized to GAPDH .  C)  
Conditioned media was collected from M0 and sMϕ at day 9, 48 hours after 
replacing media with SRM, concentrated, and assayed for PDGF-b protein by 
ELISA. Shown are mean ±SE; n=3 independent experiments. *P<0.05 versus 
M0 vehicle control. 
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sMϕ. The factors mediating the effects of sMϕ on SMC proliferation remain to be 
determined.  
Discussion 
Conclusions:  We hypothesized that factors produced by SMCs were critical in 
promoting the injury-associated phenotype observed in macrophages isolated from 
vascular lesions in vivo (Chapter II).  Using an in vitro system we were able to 
demonstrate that changes in many genes in the signature seen in macrophages from 
injured vessels were recapitulated in bone marrow-derived macrophages exposed to 
factors from SMC (sM), compared to macrophages not exposed to these factors (M0).  
Using a number of strategies, we identified TGF-1 as the critical SMC-derived factor 
responsible for inducing this macrophage phenotype in in vitro macrophage maturation 
studies.  Table 3 summarizes the changes in gene expression observed in vivo  
(macrophages from injured vessels compared to PBMCs) compared to in vitro studies, 
and in the setting of inhibition of TGF- signaling in vitro.   
TGF-β has been implicated as a critical mediator of the neointimal hyperplastic 
response following vascular denudation injury (reviewed in Suwanabol et. al, 2011
111
).  
Mechanical injury results in the upregulation of TGF-β expression by medial SMC and 
the activation of latent matrix-bound TGF-β.  The restenotic response following vascular 
injury is enhanced with TGF-β infusion or over-expression while the response is 
suppressed when TGF-β is blocked or neutralized.  Additionally, downstream TGF-β 
signaling (Smad2/3) has been shown to be enhanced in injured vessels
111
.  However, 




(regardless of SMC developmental origin), by cooperating with SRF-myocardin 
complexes to induce smooth muscle contractile protein expression
115, 170
.  These data 
argue that the mechanism by which TGF-β promotes neointimal hyperplasia is not 
exclusively through a direct effect on medial SMCs, but rather through another cell 
population present in the developing neointima that then signals to SMCs in a pro-
proliferative manner.  Our data suggest that this involves phenotypic modulation of 
recruited monocyte/macrophages by SMC-derived TGF-β as well as bi-directional cross 
talk between these modulated macrophages and resident medial SMCs, indirectly 
Gene expression data from in vivo injury study (column 2; Fig. 1) compared with 
gene expression data from select in vitro macrophage maturation experiments.  
Column 3: Fig. 2, column 4: Fig. 3, column 5: Fig. 4, column 6: Supp. Fig. V. Data 
expressed as mean (Copy #/GAPDH relative (Rel.) to indicated condition) ± SEM. 
NA = not assessed. 




promoting SMC proliferation.  A study published in 2005 by Kobayashi et. al supports 
this idea. This group reconstituted lethally irradiated wild type mice with Smad3 
knockout or wild type bone marrow.  They found that, three weeks after vascular injury 
(photochemical), there was a reduction in neointimal hyperplasia in the animals that 




Limitations and Future Directions: In the studies presented in this chapter, studying uni-
directional signaling from one cell type to another proved to be a powerful approach that 
allowed us to identify TGF-β as a potent SMC-to-Mϕ signaling paradigm.  However, 
extrapolation of these results to the in vivo disease setting must be done with caution.  
There are several limitations of these studies that must be addressed further.  In follow-up 
studies we would like to examine if TGF-β is a critical mediator of macrophage 
phenotype in vivo, and if so, why do we see discordant regulation of macrophage genes in 
the in vivo setting as compared to the in vitro.  We are also interested to understand why 
there is discordance between the mouse and rat macrophages matured with TGF-β. While 
we feel that our macrophage maturation system is more physiologically relevant than 
stimulating mature macrophages, to assess phenotypic modulation in the context of 
vascular injury, it is unclear if macrophages matured from whole bone marrow in vitro 
truly represent the macrophages present in vascular lesions in vivo.  In addition to 
validating that macrophage TGF-β signaling is required for phenotypic modulation in 
lesional macrophages, we would also like to assess its overall role in progression of 
neointimal hyperplasia. We would like to determine how p38 MAP kinase is involved in 
TGF-β-dependent macrophage phenotypic modulation.  Finally, we would like to expand 
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our in vitro methodologies to include ways to assess: cross talk between SMCs and Mϕ 
that is not dependent on diffusible factors, to assess cross talk between Mϕ and fully 
quiescent versus fully activated SMCs, to assess cross talk between these SMCs and 
Mϕ in the presence of additional cell types that would be present in an in vivo lesion, 
such as fibroblasts and/or epithelial cells. 
We presented data in Chapter II that defined a distinct phenotype in Mϕ isolated 
from injured vessels, as compared to precursor monocytes. In this chapter, we describe a 
phenotypically modulated macrophage in response to maturation in the presence of SMC-
derived factors, as compared to in the absence of such factors.  The expression signatures 
we observed in the in vivo and in vitro settings were not completely concordant. 
Discordant gene expression between in vitro versus in vivo experiments could potentially 
be explained by the presence of other cell types, including increased numbers of dendritic 
cells in injured vessels versus circulating mononuclear cells in in vivo studies (Figure 
4B).  It is unlikely that TGF-β is the only factor present in vivo that influences 
macrophage phenotype, and macrophage heterogeneity may also result in discordant gene 
modulation between the in vivo and in vitro setting.  For example, resident arterial 
macrophages may be less sensitive to TGF-β signaling due to down-modulation of TGF-
β receptors in mature macrophages whereas infiltrating monocytes would be expected to 
be more susceptible to TGF-β signaling due to higher TBR expression
172, 173
.  Presence of 
both immature and mature monocyte/macrophages in the lesion may account for why 
TGF-β’s effect on macrophages in vivo may exhibit a less pronounced effect on genes 
like CCR3 and CCR7, and CCL5.  Additional autocrine and paracrine signaling 
mechanisms may be at play in the in vivo scenario that are absent in in vitro maturation 
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studies.  For example, it is possible that the induction of arginase I observed in vivo may 
be an effect of a paracrine signaling loop between infiltrating monocyte/macrophages and 
resident SMCs, or other cells present in the neointima.  Conversely, the enhanced gene 
modulation observed in in vitro studies may be the result of differentiation of whole bone 
marrow into a heterogenous population in the absence of a selective stimulus such as 
TGF-β.  Flow cytometry analysis of in vitro-matured mouse bone marrow-derived 
macrophages (Figure 14C) suggests that maturation in the presence of TGF-β may result 
in preferential survival or promotion of a homogenous population of macrophages. 
In these studies, we also observed discordance between mouse and rat 
macrophages matured in vitro when comparing M-CSF only-matured M0 macrophages 
and TGF-β-matured tMϕ.  We know that mouse M0 macrophages matured in vitro are 
heterogeneous with respect to CCR3 (Figure 12C) and F4/80 (data not shown) 
expression.  While it is possible that rat in vitro-matured macrophages may exhibit a 
similar heterogeneity we are unable to assess this by flow cytometry due to lack of 
reagents.  If control M0 macrophages matured in vitro from rat do not express the same 
level of heterogeneity as in the mouse, then that could account for some of the 
discrepancies we observed in TGF-β-dependent gene modulation in these two species.  
Finally, it is possible that mouse Mϕ require additional input from other SMC-derived 
factors in order to express the same phenotype as rat Mϕ; we might observe less 
discordance if we assessed maturation of mouse Mϕ in the presence of mouse SMC 
conditioned medium rather than purified TGF-β. 
Our strategy of characterizing the effect of a stimulus on macrophage phenotypic 
modulation as an immature precursor matures into a macrophage is, to our knowledge, 
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novel.  This method allowed us to identify SMC-derived TGF-β as a factor capable of 
modulating macrophage phenotype in a way that would be predicted to be pro-stenotic.  
It is known that as monocytes mature into tissue macrophages, their portfolio of surface 
receptor expression changes.  It is possible, therefore, that many studies that use fully 
mature bone marrow-derived macrophages as a model system to assess the effect of cell 
type x, or factor y, on macrophage phenotypic modulation may have missed a critical 
window when macrophages precursors might have been sensitive to cell type x-derived 
factors, or factor y.  Indeed, TGF-β receptors are known to be expressed on the surface of 
circulating monocytes, but are then repressed in mature tissue macrophages
174
. 
 The effect of TGF-β on immature circulating monocytes, which express both type 
I and type II receptors, is activating
172
.  For example, picomolar concentrations of TGF-β 
have been shown to induce TNF-α and IL-6 expression in human monocytes
173
.  
Interestingly, while we observed such an increase in TNF-α in vivo, TNF-α was 
reproducibly repressed in in vitro maturation in the presence of TGF-β.  It is possible that 
this discrepancy in observed TNF-α expression may be due to the kinetics of gene 
induction, and then subsequent repression by negative feedback mechanisms.  In our in 
vitro studies, we assessed mRNA and protein modulation of TNF-α at five and seven 
days, respectively, after TGF-β introduction.  Whereas published studies showing that 
TGF-β induced TNF-α upregulation in human monocytes assessed a 3 hour post-
stimulation time point
175
.  It is possible that the repressed TNF-α we observed in vitro 
may be an effect of late-phase negative feedback.  Whereas in vivo the increased TNF-α 
message we observed could be the result of marked upregulation in a subset of recently 
recruited monocytes, or possibly in a population of recently generated daughter cells 
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from adventitial hematopoetic progenitors 
176, 177
.  In contrast to the activating effect on 
monocytes, TGF-β is largely considered anti-activating for mature macrophages.  
However, most studies suggesting that TGF-β is a macrophage de-activating factor have 
been performed in the context of thioglycollate elicitation, lippolysaccharide, phorbol 
ester stimulation
89, 113, 132
. These studies therefore may not reflect the effect of TGF-β on 
macrophage phenotype in the absence of potent macrophage activating agents.   
In addition to ascertaining if our in vitro results hold across various populations of 
monocyte/macrophages, further studies will be required to ascertain if deficiency in TGF-
β signaling results in a net exacerbation or amelioration of neointimal hyperplasia in 
response to arterial injury.  Such studies could be performed in the setting of either 
systemic inhibition of TGF-β signaling, or in the setting of myeloid-specific TGF-β 
signaling deficiency. Systemic TGF- inhibition has previously been shown to reduce 
neointima formation in both the mouse and rat 
162, 163
.  While systemic inhibition of TGF-
 signaling in vivo is feasible, interpreting the results of such studies is problematic with 
respect to understanding macrophage-specific effects.  Recent work by Wan et. al.
163
 
demonstrated that systemic blockade of TGF- signaling, either using a TGF-β-specific 
neutralizing antibody or a pharmacological inhibitor of TBR1 reduced the recruitment of 
mesenchymal stem cells to the site of injury.  These authors also demonstrated that 
blocking TGF- signaling inhibited the increase in MCP-1 observed in response to 
injury, which would be expected to lead to an overall monocyte/macrophage recruitment 
defect.  Our future studies seek to define how TGF- promotes a phenotypic change in 
recruited macrophages, rather than to define how TGF-β influences monocyte 
recruitment or TGF-β-dependent paracrine effects of other cell types signaling to 
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macrophages.  We would therefore pursue the latter approach and genetically ablate 
TGF- signaling in myeloid cells. We are currently generating mice with targeted 
deletion of TBRII in myeloid lineage cells to address this question in an in vivo setting of 
vascular injury.  A myeloid-specific TBRII depletion study published in Cancer 
Discovery suggests that this approach is feasible and supports the idea that our in vivo 
gene expression signature may be largely TGF-β-dependent. Recent findings from Pang 
et. al.
134
 showed that myeloid-specific TBRII deficiency was sufficient to inhibit tumor 
metastasis, and to abrogate macrophage modulation (decreased iNOS, Arg I, IL-6, IL-10, 
and IL-12; and increased TNF-α, and MMP9).  In addition to suggesting that our in vivo 
expression signature is largely TGF-β-dependent, these data suggest that myeloid-specific 
inhibition of TGF-β signaling, upon macrophage recruitment to lesions, would be 
expected to significantly reduce neointimal hyperplasia following injury.  We propose to 
assess macrophage phenotype and neointima formation in the same model: LysM-Cre x 
TBRII floxed mice.  However, if myeloid specific TBRII knockout results in decreased 
monocyte recruitment to lesions, phenotypic analysis of lesional populations may not be 
possible or valid.  It may, therefore, be necessary to generate a TBRII conditional 
knockout that is specific for mature macrophages – such as CD68-Cre(±ER
T2
) x TBRII 
floxed - in order to avoid effects on TGF-β-dependent monocyte recruitment following 
injury. 
 Our results suggest that macrophage p38 MAP kinase signaling is critical for 
TGF-β-dependent phenotypic modulation.  Several human trials have exhibited a benefit 
of p38 MAP kinase inhibition in terms of repressing disease biomarkers and/or vascular 
inflammation
178, 179
. While, to our knowledge, human clinical trials have not exhibited a 
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net benefit of p38 inhibition on neointimal hyperplasia or primary atherosclerotic plaque 
development, several studies in pre-clinical models have shown such results.  Rabbit and 
rat vascular injury studies have shown reduction in NIH in response to systemic p38 
inhibition
180, 181
.  Our studies showed that pharmacological inhibition of p38 kinase 
activity blocked both the morphological change, and the changes in gene expression, 
induced in macrophages by SMC conditioned media or rh-TGF-β.  However, we have not 
been able to detect increases in active (phosphorylated) p38 in response to either stimulus 
(Figure 17A, and data not shown).  In fact, steady state levels of phospho-p38 in sM are 
not different from M0 macrophages at any of the time points examined.  It is possible that 
a transient activation of p38 occurs during the 5 day time course required for sM 
formation which we have failed to detect.  Alternatively, constitutive p38 activity in these 
cells may represent a necessary, but insufficient signal for sM formation. For instance, 
signaling by M-CSF may prime macrophages to respond to TGF- signaling, with both 
pathways collaborating to produce the sM phenotype. The requirement for basal p38 
activity in sM formation may partially explain the efficacy of p38 inhibitors in reducing 
endothelial denudation-induced stenosis
180, 181
.  There exists data to suggest that 
SB203580 may actually be inhibiting upstream kinase activity.  In studies from both Jung 
et. al. and de Nicola et. al.
182, 183
, SB203580 was able to prevent TGF-β induced p38 
phosphorylation.  The later study shows data to suggest that this is due to blockade of p38 
autophosphorylation, however it is possible that SB203580 may be preventing upstream 




 Our data indicate that sM can reciprocally signal back to SMC to promote some 
aspects of SMC activation.  SMC in coculture with sM had increased rates of 
proliferation compared to coculture with M0, suggesting production of a sM-specific 
soluble factor that stimulates SMC proliferation. We hypothesized that such a factor 
might be PDGF-BB; however, PDGF-BB expression was decreased in sM relative to 
M0.  Coculture of SMCs with macrophages also increased production of several pro-
inflammatory cytokines by SMCs.  However, a similar level of induction with either sM 
or M0 macrophages was observed.  Systematically examining quantitative levels of 
growth factors and cytokines produced by sMϕ versus M0 macrophages may explain the 
differential effect in SMC proliferation versus cytokine induction.  Additional 
experiments examining the dose response of target SMCs to condition media from these 
two macrophage populations may reveal difference in response at lower concentrations of 
conditioned medium.  Alternatively, M0 macrophages may acquire some features of the 
sM phenotype over time in coculture with SMC, masking differences between M0 and 
sM macrophages with respect to certain aspects of SMC phenotype.  Further studies will 
be required to understand what sM–specific factors are capable of inducing enhanced 
SMC proliferation, and if the factor(s) responsible for inducing differential rates of 
proliferation are the same as those inducing similar upregulation of pro-inflammatory 
cytokines.   
Our studies are limited in that they are restricted to assessing the contribution of 
soluble factors to the cross talk between SMCs and Mϕ. We are also interested to 
understand how sMϕ might influence SMC biology, versus M0 macrophages, in the 
setting of direct coculture, where we may be able to assess direct physical interactions.  
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We have shown that several cell surface chemokine receptors, and the scavenger receptor 
CD206, are modulated in response to maturation in the presence of TGF-β; it is possible 
that other cell surface molecules may be regulated differentially between M0 and sMϕ in 
such a way that they would induce differential levels of SM-gene modulation in a direct 
coculture scenario.  We would hypothesize that, unlike in the setting of indirect coculture 
where we did not observe repression of SM-genes, direct coculture with sMϕ would 
result in repression of SM-genes if, for example, macrophages express cell surface Notch 
ligands that engage downstream upregulation of HERP/HEY family members (which has 
been shown to result in repression of SM-genes by blocking SRF/myocardin association 
with CArG elements)
40
.  In order to perform these direct coculture assays we will need a 
way to re-isolate pure populations of SMCs and Mϕ after coculture.  This could be 
performed by FACS, but will require performing these assays with mouse-derived cells 
as flow cytometry reagents are not readily available for analysis of rat cells.  We will, 
therefore, have to first validate our previous findings in an all-mouse SMC/Mϕ culture 
system before proceeding to direct coculture studies.    
In future studies, we would also like to expand our analysis of the effects of SMC-
derived factors on Mϕ, to fully quiescent and fully activated SMCs.  Aortic vascular 
smooth muscle cells isolated from the rat, and cultured ex vivo, have a proliferative index 
of about 24% when serum-restricted in 0.1% serum medium for 48 hours as they were for 
our conditioned medium collection procedure (data not shown).  This proliferative index 
is in stark contrast to the proliferation rate of quiescent SMCs in vivo in an uninjured 
vessel, which has been documented by several groups to be less than 0.1% per day
157, 184
.  
We previously showed that even out to 9 days in 0.1% serum media the proliferative 
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index of cultured aortic SMCs remains significantly elevated above a truly quiescent in 
vivo level
158
.  Therefore, while serum-restricted to rule out confounding effects from 
serum-derived factors, SMCs in culture maintain a somewhat activated phenotype.  In 
contrast, a fully activated (PDGF-BB-stimulated, or PTEN-depleted (see Chapter IV for 
an introduction to PTEN-depletion as a model of SMC activation)) SMC exhibits 
approximately 5-fold higher proliferation than a cultured, serum-restricted, SMC
26, 137
. 
We have begun to assess the differences in cross talk between Mϕ and PTEN-depleted 
SMCs.  These data are presented in Chapter IV.  In future studies we would like to 
further assess cross talk between maximally activated SMCs, but also with SMCs driven 
into a more quiescent phenotype than what is possible under low serum conditions.  This 
may be accomplished by pre-treatment of SMCs with rapamycin; which has been 
established to induce SMC differentiation
185
.  Indeed, rapamycin (sirolimus)-coated 




Finally, in our in vitro studies, we have only assessed the cross talk that occurs 
between two of the several cell types present in the injured vessel.  We would like to 
develop novel in vitro/ex vivo culture methodologies to assess the contributions of 
additional cell types to the phenotypic modulation of Mϕ and SMCs.  It is possible that 
some of discordance we observe between our in vitro and in vivo results is due to signals 
derived from adventitial fibroblasts or endothelial cells etc. – or additional factors 
secreted from SMCs in response to signals from other cells present in the lesion.  Truly 
understanding the pathogenesis of this disease may ultimately require in vitro systems 
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that allow for high throughput experimentation, while closely recapitulating the in vivo 
milieu. 
In summary, this study is one of the first to successfully recapitulate an in vivo, 
neointimal lesion-like macrophage phenotype using an in vitro system.  Our results reveal 
a novel, physiologically relevant model system for studying macrophages that 
accumulate in the developing neointima.  Importantly, these studies suggest that SMC-
derived TGF-β1 may be a critical mediator of the macrophage vascular injury-specific 
polarization observed in vascular disease states such as atherosclerosis and restenosis.  
Further, our cross talk studies begin to address the apparent paradox in that active TGF-β 
acts as a pro-differentiation factor for SMC, yet in the setting of vascular injury the net 
result of TGF-β antagonism is reduced neointima formation
163, 165
.  Our results suggest 
that TGF-β signaling in maturing monocyte/macrophages results in an activated cell that 






EFFECT OF SMC-SPECIFIC PTEN DEPLETION ON MACROPHAGE 
RECRUITMENT AND PHENOTYPE IN VASCULAR INJURY 
 
Introduction 
Phosphatase and tensin homologue (PTEN) is a phospholipid phosphatase that is 
responsible for counteracting the effects of PI3K; it primarily dephosphorylates PIP3 to 
PIP2, which ultimately decreases AKT activation 
and cell proliferation.  Microarray
186
 and 
immunohistochemical staining studies (Weiser-
Evans, unpublished) have showed that PTEN is 
repressed in SMCs in human atherosclerotic 
lesions. Studies by Dr. Weiser-Evans’ lab 
demonstrated that balloon catheter-induced 
injury to rat carotid arteries results in 
phosphorylation, and thus deactivation, of PTEN 
selectively in SMCs (Figure 20)
187
.  Further, it 
was found that cultured neointimal SMCs, which 
exhibit serum-independent proliferation, express 
high levels of active AKT, mTOR, and p70S6K. 
This serum-independent proliferation was 
Figure 20. Balloon-mediated 
injury results in repression of 
PTEN in the rat.  
Rat carotid arteries were subjected 
to balloon catheter injury. Whole 
cell lysates from injured arteries 
were analyzed for phosphorylated 
and total PTEN; β-Actin = loading 
control.  Phosphorylated, inactive 
PTEN increased from 7-14 post-
injury (Studies done previously in 
the lab: Garl et. al. Circ Res. 2004.) 
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inhibited by PI3K or mTOR inhibition, or dominant negative AKT expression.  It was 
also demonstrated that this serum-independent growth phenotype could be recapitulated 
in vitro by morpholino-mediated loss of PTEN in serum-dependent primary SMCs
188
.  
Additional studies by Dr. Weiser-Evans’ group showed that serum-stimulated 
proliferation and AKT phosphorylation were significantly decreased in primary SMCs 
overexpressing a wild-type PTEN
187
.  These results were very interesting considering that 
genomic and somatic PTEN loss-of-function mutations or deletions are a common 
finding in various types of human cancers.  Additionally, PTEN has been found to be 
deregulated in tumors due to inappropriate subcellular localization or aberrant 
proteasomal degradation
189
.  It is possible that germline or de novo somatic mutations in 
PTEN that result in decreased 
activity could be a contributing 
risk factor for development of 
restenosis after angioplasty.  In 
order to further investigate the 
contribution of PTEN-
deactivation to restenotic 
neointima formation, our lab 
previously generated a smooth 
muscle cell–specific knockout 
mouse, using Cre recombinase 
under control of the SM22- 
promoter
147
.  As was predicted, 
Figure 21. SMC-specific depletion of PTEN 
results in SDF-1α upregulation.  
A) Serum of PTEN WT and SM-22α-Cre, SMC-
specific, PTEN knockout (KO) mice was analyzed 
by ELISA for SDF-1α chemokine levels.  SDF-1α 
was found to be increased in PTEN KO mice.  N=6 
B) WT (left panels) and PTEN KO (right panels) 
aortas were immunofluorescently stained for SDF-
1α (green) and SM-α-actin (red).  SMC-specific 
PTEN KO results in arterial medial hyperplasia and 
SDF-1α deposition (Studies done previously in the 
lab: Nemenoff et. al. Circ Res. 2008.). 
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AKT activation was increased in SMCs that were lacking PTEN.  Significant vascular 
remodeling including arterial medial hyperplasia, and increased deposition of the 
chemokine SDF-1 (Figure 21), was observed in these mice.  CXCR4, one of the 
cognate receptors for SDF-1, was found to co-express with SMA, suggesting the 
potential for autocrine SDF-1 signaling in SMCs in vivo.  In cultured SMCs from these 
mice, growth was induced by autocrine SDF-1 signaling, and conditioned media 




 Due to the fact that PTEN 
knockout driven by SM22--Cre caused 
these mice to survive only an average of 
21 days, wire injury studies in these 
animals were not possible.  A tamoxifen-
inducible PTEN knockout (PTEN iKO) 
mouse was therefore generated by 
crossing PTEN
fl/fl 
mice with transgenic 
mice expressing Cre recombinase fused to 
a mutant tamoxifen-responsive ligand-
binding domain of the estrogen receptor  









Figure 22.  SMC-specific depletion of 
PTEN results in increased BMC 
recruitment to lesions.  
WT (left panels) and PTEN iKO (right 
panels) mice were subjected to femoral 
wire-induced injury.  Mice were treated 
with control IgG or neutralizing anti-
SDF-1α for 3 weeks.  PTEN iKO mice 
exhibited increased neointima and 
macrophage recruitment to vascular 
lesions which is reversed by anti-SDF-1α 
antibody (Studies done previously in the 
lab: Nemenoff et. al. Arterioscler Thromb 
Vasc Biol. 2011) 
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induced injuries were performed on the right femoral arteries of these mice, as previously 
described
16
.  Both bone marrow transplantation with WT GFP bone marrow, and 
tamoxifen treatment for 5 days to induce PTEN knockout in SM-MHC-expressing SMCs 
were administered prior to injury.  These mice were transplanted with GFP bone marrow 
in order to determine if bone marrow-derived inflammatory and/or progenitor cells were 
contributing to neointima formation.  It was discovered that not only did PTEN iKO 
cause a marked increase in neointima formation at three weeks-post injury, but there was 
also a significant increase in the number of bone marrow-derived macrophages recruited 
to the lesion in the iKO animals.  This response to injury, in the setting of chronic PTEN 
depletion in SMCs, more closely recapitulates the severity of found in humans, as 
compared to wild type C57BL/6J mice in which form less severe lesions that regress over 
time
64, 192
.  Finally, it was determined that systemic administration of SDF-1 
neutralizing antibody reversed the effects of PTEN iKO on both neointima formation and 
macrophage recruitment (Figure 22)
137
.  We hypothesized, based on these data, that 
depletion of PTEN in SMCs results in altered cross talk between SMCs and recruited 
monocyte/macrophages that additively contributes to the pathogenesis of neointimal 
hyperplasia.  We therefore wanted to ascertain how chronic SMC-specific PTEN 
deficiency might alter macrophage recruitment or retention in lesions, as well as to 
understand how PTEN deficiency in SMCs might differentially modulate macrophage 




Materials and Methods 
Reagents: Flow cytometry antibodies:  F4/80-APC (AbD Serotec), CD11b-FITC, Ly6g-
PE-Cy7, Ly6c-PE, CD11c-APC-Cy7 (all BD Biosciences), and MHC-II-PerCP eFluor 
710 (eBiosciences).     
 
Femoral Artery Injury: All animal procedures were approved by, and performed in 
accordance with the guidelines of the University of Colorado IACUC. Guide-wire 
denudation femoral artery injury was performed, as shown by us previously (Figure 
2A)
137
, on right femoral arteries of male 20-28g PTEN iKO (smooth muscle-specific, 
tamoxifen-inducible PTEN knockout) or control (creERT only) mice at least one week 
following 5-day tamoxifen (0.033mg/kg, IP) treatment.  Guide-wire injures were 
performed as described in the Methods section of Chapter III. Injured femoral arteries 
were harvested on day 15 post-injury following euthanasia and flushing of the 
vasculature with heparinized PBS (80kU/L).  
  
Flow Cytometry: Isolated injured vessels, were digested to single cells by digestion at 
37°C for 2hr in collagenase buffer (3.2mg/ml collagenase II, 0.7mg/ml elastase 
(Worthington), 0.2mg/ml soybean trypsin inhibitor (Sigma) in Hank’s buffered saline 
solution (HBSS), pH7.5). Red blood cells were lysed for 2-5 min in RBC lysis buffer 
(0.15 M NH4Cl, 10 mM KHCO3, 0.1 mM Na2EDTA (pH 7.2)). Single cell suspensions 
were stained for CD11b, F4/80, Ly6g, Ly6c, MHC-II, CD11c, and DAPI to stain for dead 
cells. Flow cytometry was performed on a Galios cytometer (Becton Dickenson) as 
demonstrated by our group previously
145
, and as described above in the Methods section 
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of Chapter III. Autofluorescent counting beads (Spherotech) were added to cell 
suspensions in n=1 experiment to quantitate absolute numbers of macrophages in injured 
vessels in control versus PTEN iKO mice. Macrophage quantitation was calculated as: 
 
Volume analyzed = # of beads analyzed ÷ # of beads/50μl (from spec sheet) 
Mϕ/volume = # of Mϕ analyzed ÷ volume analyzed 
Mϕ in sample = Mϕ/volume x total volume 
Mϕ/mg tissue/vessel = Mϕ in sample ÷ tissue wet weight ÷ # vessels pooled in sample 
 
 
Cell Culture: Primary aortic SMCs were isolated from Sprague-Dawley rats as 
previously described
149
.  SMCs were used for experiments between passages 8 and 15.  
Rat SMCs were plated at 7*10
6
 cells/150 mm dish in MEM media supplemented with 
10% fetal bovine serum (FBS) and 1x penicillin/streptomycin (20 IU/ml penicillin, 
20ug/ml streptomycin).  PTEN deficient SMCs were generated by infecting cells with 
lentiviral particles carrying empty vector control or anti-PTEN shRNA constructs as 
previously described
137
.  PTEN knockdown was confirmed by western blotting.  Primary 
bone marrow-derived MΦ were isolated from C57BL6/j mice, as previously described
137
.  
Whole bone marrow was plated, directly following isolation from bones, for each 
experiment without passaging in the presence of 20ng/ml M-CSF (eBioscience). 
 
Macrophage Adhesion Assay: Macrophage adhesion assays were performed using a 
modified protocol as described elsewhere
97
.  Macrophages matured for seven days under 
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20ng/ml M-CSF were fluorescently labeled with 5ug/ml BCECF-AM (A.G. Scientific, 
Inc.) for 15min at 37˚C in HBSS.  Mϕ were then trypsinized for 5 minutes.  Mϕ were 
washed 1x with HBSS, centrifuged at 300g for 5 minutes to remove trypsin.  Cells were 
then resuspended to a concentration of ~10
6
 Mϕ/ml in SRM. One millileter of Mϕ 
suspension was then added per 35mm well of 24-hour serum-restricted control or PTEN-
depleted SMC monolayers (5*10
5
 SMCs plated per well).  Culture clusters were agitated 
every 5 minutes over the course of the experiment.  At 1, 5, 10, 20, 40, and 80 minutes 
after addition of Mϕ cell suspension non-adherent Mϕ were removed by aspiration, and 
washing gently once with HBSS.  After washing, adhered cells were maintained on SMC 
monolayers in SRM.   At the end of the time course, adhered fluorescent macrophages 
could be quantified by counting under a fluorescent microscope, or by lysing all cells and 
quantitating fluorescence on a fluorimeter. Lysis buffer used: 0.1% Triton X-100 in 0.1M 
Tris base.  
Results 
SMC-Specific Depletion of PTEN Results in Increased Macrophage Content in 
Vascular Lesions, and a Higher Percentage of Ly6c 
high
 Macrophages.  We previously 
observed that there were more macrophages present in vascular lesions in PTEN iKO 
animals versus controls by Mac-3 immunofluorsecent staining
137
. This prior observation 
was validated quantitatively by this student using flow cytrometry of control and PTEN 
iKO injured femoral arteries (Figure 23A).  We found that when normalized to wet 
weight of tissue (to normalize for differences in degree of overall neointimal mass) and 
number of vessels per condition, there was approximately a 5-fold increase in 
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macrophages/mg tissue/vessel in PTEN iKO versus control injured femorals.  We then 
wanted to understand if, in addition to increased macrophage recruitment/retention in 
vascular lesions in PTEN iKO lesions, if there might be a difference in macrophage 
phenotype or subset in the recruited cells.  Flow cytometry analysis revealed that there 




 macrophages present in 
lesions at this 15 day time point (Figure 23B-C).  We did not observe differences in 
expression in MHC-II or CD11c in the macrophages recruited to PTEN iKO lesions as 
compared to controls (data not shown). The increase in Ly6c
high
 macrophages present in 
Figure 23. Mϕ burden is increased in PTEN iKO lesions and a higher 
percentage of Mϕ express high levels of Ly6c.  
A) Quantitation of macrophages present in SMC-specific, inducible PTEN 
knockout (PTEN iKO) wire-induced lesions compared to wild type control (ctrl) 
lesions . Total number of macrophages normalized to mg of tissue and number of 
vessels pooled for analysis.  B) Representative histogram of Ly6c expression in 
macrophages isolated from control (green) and PTEN iKO (red) wire-induced 
lesions.  C) Quantitation of the ratio of Ly6c high-expressing cells (Ly6c Hi) to 
Ly6c low-expressing cells (Ly6c Lo).  Shown are means±SE.  A) n = 1; B-C) n=3 
independent experiments. *P<0.05 vs control injured vessels. 
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Figure 24. Mϕ adhesion to SMCs is increased in PTEN deficient SMCs.  
A) Western blot showing efficient knockdown of PTEN in lentivirus-transfected 
SMCs. B) Micrograph of fluorescently labeled macrophages adhered to vector 
control (Vector) or PTEN knockdown (PTEN KD2) SMC monolayers.  Time 
point shown = 40 minutes.  C) Quantitation of macrophage adhesion to control 
and PTEN knockdown SMC monolayers at 1, 5, 10, 20, 40, and 80 minutes by 
fluorescence (right) of  well lysate, or counting (left) of adhered  (fluorescent) 
cells.   Shown are means±SE. n=3 independent experiments. *P<0.05 vs control 
injured vessels.  
110 
 
lesions suggests an increased recruitment of inflammatory monocytes to iKO lesions at 




PTEN Depletion in Primary SMCs In Vitro Results in Increased Macrophage 
Adhesion.  We performed experiments, published in 2011, suggesting that increased 
adhesion of monocyte/macrophages to PTEN depleted SMCs might be an explanation for 
why monocyte-derived macrophage recruitment may be enhanced in in vivo lesions in 
PTEN iKO mice
137
.  In these studies we generated PTEN knockdown SMCs by lentiviral-
mediated introduction of shRNAs.  We found that several constructs were efficient in 
depleting SMCs of PTEN (PTEN KD SMC) as compared to vector-transfected SMCs 
(Figure 24A).  We then performed an in vitro adhesion time course assay to determine if 
(mouse) bone marrow-derived macrophages might adhere more readily to PTEN KD 
SMCs.  We found that by measuring the fluorescence intensity of fluorescently labeled 
macrophages to SMC monolayers – as well as by cell counts – macrophage adhesion to 
PTEN KD SMCs was significantly greater at later time points assayed (Figure 24B-C).   
Discussion 
Conclusions:  Given that PTEN is found to be repressed in SMCs in human 
atherosclerotic lesions, that our PTEN iKO model more closely recapitulates the human 
response to vascular injury versus wild type mice, and that we observed increased 
macrophage recruitment to PTEN iKO lesions, we therefore hypothesized that repression 
of PTEN in SMCs was responsible for differential monocyte/macrophage recruitment 
and/or phenotypic modulation in iKO lesions versus controls.  The data from our flow 
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cytometry experiments suggest that there is an increased macrophage burden in PTEN 
iKO lesions, at a 15-day time point.  The increase in Ly6c
high
-expressing macrophages 
suggests that these macrophages are likely derived from circulating inflammatory 
(Ly6c
high
) monocytes, or that there is an increase in inflammatory monocyte recruitment 
compared to patrolling monocyte recruitment in the setting of PTEN depletion.  Our in 
vitro adhesion data suggests that at least one aspect of this increased recruitment is likely 
due a greater capacity of PTEN KD SMCs to bind monocyte/macrophages versus control 
SMCs.   
 
Limitations and Future Directions:  Unpublished microarray data from our lab suggests 
that several adhesion molecules or matrix molecules (CD53, NCAM-1, versican) that 







, respectively) are upregulated in 
PTEN KD SMCs.  In future studies related to these findings we would like to validate 
that increased recruitment is indeed occurring at this time point, as opposed to local 
proliferation of macrophages expressing high levels of Ly6c.  We could assay this by 
performing adoptive transfer experiments of CD45.1 PBMCs into our CD45.2 control 
and iKO mice one day prior to flow cytometric analysis of lesional macrophage 
populations.  If recruitment is actively occurring in the iKO mice we would expect to see 
higher chimerism in lesions (relative to blood chimerism) in the iKOs versus the control 
mice.  We would then perform RNA-seq studies on FACS-isolated SMCs from inducible, 
conditional YFP expressing SMCs (Rosa-26 x SM-MHC creERT) from injured and 
uninjured vessels and compare expression signatures of these in vivo samples to our in 
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vitro PTEN KD SMCs. This analysis should identify a manageable number of molecules 
expressed by PTEN-depleted cells that may be responsible for the observed increase in 
macrophage adhesion to PTEN KD SMCs. We would then validate candidates in in vitro 
adhesion studies using transient transfection with siRNAs to deplete SMC-expressed 
adhesive molecules and macrophage-expressed cognate factors. 
It is possible that in addition to increased adhesion, other mechanisms could be 
contributing to increased numbers of macrophages in PTEN iKO lesions.  For example, 
we previously showed that PTEN repression in SMCs is sufficient to induce 
upregulation, and secretion, of factors that are chemotactic for monocyte/macrophages 
such as SDF-1α and MCP-1
149
. It is possible that the increased recruitment of monocytes 
to lesions could simply be due to more mobilization of hematopoetic precursors from the 
bone marrow and/or higher local accumulation in the circulation due to an enhanced 
chemotactic gradient; allowing for enhanced net monocyte adhesion.  We could assay 
monocyte content per volume in the peripheral blood by flow cytometric analysis of 
whole blood.  If recruitment proves not to be responsible for increased macrophage 
content in iKO lesions we would next assess if local proliferation of resident vascular 
macrophages is responsible for increased macrophage burden such as has been suggested 
in the ApoE
-/-
 murine model of atherosclerosis
65
.  Adoptive transfer of GFP+ PBMCs, in 
combination with a BrdU pulse, given one day prior to collecting vessels for 
immunostaining would allow us to ascertain what the relative contribution is to 
macrophage burden of proliferating resident macrophages (GFP-, BrdU+) versus 
recruited monocytes that are either proliferating or not (GFP+, BrdU+/-).  If local 
proliferation of tissue macrophages is a major contributor to lesional macrophage burden 
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our RNA-seq data should again allow us to identify candidate SMC-derived growth 
factors that may be responsible.  
As described in the Discussion section of Chapter III, we would ultimately like to 
move these studies forward to identify macrophage-derived factors that might be 
responsible for completing a feed-forward loop where SMCs modulate the phenotype of 
macrophages which then cross talk back to maintain SMCs in an activated state.  Since 
our PTEN iKO model of vascular injury more closely recapitulates human disease, we 
are hopeful that understanding PTEN-deficient SMC cross talk with macrophages, as 
compared to control SMC cross talk with macrophages, will lead us to identify novel 
paracrine signaling mechanisms at work between these two cell types that may be 
leveraged to ultimately develop anti-stenotic therapies that are more efficient and specific 






 SUMMARY AND FUTURE DIRECTIONS 
 
Summary  
 Arterial occlusion due to neointimal hyperplasia as seen in primary 
atherosclerosis, following arterial re-vascularization, and in the setting of graft or 
transplant arteriopathy, can result in death or significant morbidity.  Available therapies 
for the prevention of neointimal hyperplasia have advanced significantly in the past 10-15 
years.  However, there remains room for improvement, particularly with respect to 
identifying treatment strategies that may limit vascular smooth muscle cell proliferation 
and ECM production while encouraging re-endothelialization of regions of disrupted 
endothelial cell integrity.   
 We felt, at the time of initiating these studies, that while the data present in the 
literature convincingly suggested that macrophages contribute to the pathogenesis of 
neointimal hyperplasia, a paucity of data was available to suggest by what mechanisms 
macrophages drive the neointimal response to vascular injury. We were particularly 
interested to understand how vascular smooth muscle cells and macrophages cross talk in 
the injured vessel and how that cross talk influences both the differentiation state of the 
SMCs as well as the polarization state of the macrophages.  We hypothesized (Figure 25) 
that upon vascular denudation injury, monocytes are recruited to the lesion and undergo 
maturation and phenotypic modulation (or polarization) in response to factors secreted by 
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SMCs.  These phenotypically modulated macrophages are then able to signal back to the 
resident SMCs to either exacerbate or maintain their activation state.  This feed-forward 
signaling would be expected to ultimately result in worsened neointima formation in 
response to injury.  As described above, many studies in the vascular literature, 
particularly in atherosclerosis, have seized upon the idea that macrophages in the 
neointima express an M1 polarization.  Many published studies have thus used LPS/INF-
γ stimulation of macrophages in vitro to model an activated atherosclerotic or restenotic 
macrophage.  We felt that biasing our studies by assuming that LPS/IFN-γ stimulation is 
an accurate model of a restenotic macrophage would prevent us from understanding how 
Figure 25.  Project hypothesis and mechanistic model. 
Interactions of SMC with monocyte/macrophages (Mϕ) in vascular lesions result in 
phenotypic modulation of invading Mϕ. Modulated Mϕ (sMϕ) cross talk back to 




these two cell types modulate each other’s activation states in the setting of sterile 
inflammation.  We therefore did not preferentially activate our in vitro macrophages prior 
to stimulating them with SMC-derived factors.  We hypothesized further that in the 
setting of SMC-specific depletion of PTEN – a model that more closely recapitulates the 
human response to denudation injury, where lesion development in the C57BL/6J mouse 
is not as pronounced – that macrophage recruitment and/or phenotypic modulation would 
be increased or more skewed toward a pro-inflammatory phenotype as compared to in the 
wild type mouse.  
 In Chapter II of this dissertation we show that macrophages were found to be the 
predominant myeloid cell population present in injured vessels.  This quantitative 
analysis is an improvement over previous attempts to quantify these cells in vessels, as 
prior studies have primarily assessed lesional macrophages by immuno-staining in tissue 
sections
64, 137
.  We then assessed the phenotype of macrophages in injured vessels 
compared to macrophages from uninjured vessels, or to monocytes isolated from 
peripheral blood.  We found a distinct difference in macrophage phenotype in injured 
vessels as compared to monocytic precursors that suggested a hybrid activation state, 
and/or a heterogeneous population.  Additional replicates of these studies are needed to 
understand how expression of these genes in uninjured vessels relates to precursor 
monocytes and macrophages from injured vessels. However, these data suggest that there 
are maturation- (from monocyte to macrophage) specific patterns of gene regulation, as 
well as injury-specific patterns of gene regulation.  Together, these data suggest that upon 
recruitment to vascular lesions, and/or upon expansion of the resident macrophage 
population in the lesion, macrophages express a modulated phenotype relative to 
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macrophages in uninjured vessels or to precursor monocytes.  In future studies it would 
be informative to understand how macrophage phenotype, in the injured vessel as 
compared to both control populations, changes over time.  It is possible that some of the 
similarities we observed between gene regulation in macrophages from injured and 
uninjured vessels is due to lesional macrophages reverting to a more basal-like phenotype 
by 15 days.  Time course analysis may allow us to dissect out the maturation-dependent 
gene changes from the injury-dependent gene changes.  
 Based on the data presented in Chapter II, we hypothesized that recruited 
monocytes in the neointimal lesion undergo phenotypic modulation in response to factors 
derived from resident SMCs as they mature into macrophages.  We therefore set out to 
develop an in vitro assay that would allow us to assess uni-directional effects of SMC-
derived secreted factors on macrophage maturation from bone marrow-derived 
precursors. When we matured rat bone marrow cells in the presence of 20% conditioned 
medium from SMCs, we observed a marked morphologic change in the resulting 
macrophages.  This morphologic change was accompanied by a pronounced change in 
transcription of the panel of genes assessed in our in vivo injury studies.  The phenotype 
of the macrophages matured in vitro with SMC conditioned medium (sMϕ), relative to 
control macrophages, was very similar to the phenotype observed in macrophages from 
injured vessels compared to precursor monocytes as described in Chapter II.  Using a 
variety of strategies to assess the physical characteristics of the SMC-derived factor, we 
determined that SMC conditioned medium contained a heat stable peptide-based 
component of a large (greater than 100kDa) complex that included a heat labile inhibitory 
factor. This complex responded to heating by becoming more potent and decreasing in 
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size to less than 100kDa.  We also observed that the macrophage modulatory effects of 
this molecule were dependent on p38 kinase activity.  These data were consistent with 
TGF-β large latent complex.   
 We then observed that purified TGF-β was capable of inducing the same 
phenotypic modulation of macrophages that we observed with SMC conditioned 
medium.  Studies employing TGF-β neutralization, TGF-β receptor 1 inhibition, and 
TGF-β silencing in SMCs, illustrated that SMC-derived TGF-β was responsible for the 
phenotypic modulation observed in macrophages in vitro in response to maturation in the 
presence of SMC-derived conditioned medium.  We assayed the effect of mouse 
macrophage maturation in the presence of TGF-β (tMϕ) to assess if TGF-β would 
recapitulate the phenotypic modulation we observed in our in vivo studies, in the same 
species.  We found that while several genes were regulated similarly between tMϕ and 
macrophages isolated from injured vessels, there was discordance in several genes; more 
discordance, in fact, than between rat sMϕ/tMϕ and macrophages from injured vessels.  
This suggests to us that while TGF-β seems to be able to recapitulate the phenotype of 
macrophages in the injured vessel fairly well, perhaps in the mouse this phenotypic 
modulation requires cooperation between TGF-β and one or more additional factors.  In 
order to validate the importance of macrophage-specific TGF-β signaling on macrophage 
phenotype and overall neointima formation, we would like to perform injury studies in 
myeloid-specific (lysozyme-2 promoter-driven Cre x TBRII floxed) TGF-β signaling 
deficient mice, versus littermate Cre null controls. We anticipate (particularly in light of 
the findings by Pang et. al, showing that in the setting of cancer a similar Mϕ phenotype 
was observed and that it was abrogated by myeloid-specific TBRII knockout
134
) that if 
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macrophage recruitment to lesions is not significantly reduced by depleting TGF-β 
signaling in macrophages, then we should observe a similar abrogation in macrophage 
phenotype in injury relative to precursor monocytes.  We also expect that myeloid-
specific TBRII depletion will result in a net decrease in neointimal hyperplasia relative to 
controls. 
 We then expanded the use of this in vitro maturation model to study the effect of 
paracrine cross talk that occurs between SMCs and macrophages, with a focus on 
assessing feedback on SMCs. In vitro coculture of SMCs with sMϕ resulted in increased 
proliferation of SMCs which, interestingly, did not correlate with differential expression 
of pro-inflammatory cytokines or smooth muscle contractile protein repression as might 
be expected.  Subsequent attempts to determine if upregulation of PDGF-b in sMϕ might 
be responsible for increased SMC proliferation in coculture showed that this growth 
factor was actually repressed in sMϕ relative to M0 macrophages.  Attempts to isolate 
conditioned medium from sMϕ and M0 macrophages, and to subsequently identify 
signaling pathways induced in SMCs in response to these media did not provide 
consistent data to suggest what the sMϕ-derived factor might be that was responsible for 
inducing SMC proliferation.  Additional physical characterization studies, and 
optimization of macrophage conditioned medium collection, will be needed to determine 
the mechanism of this observation.  A difficulty in these studies is the extreme plasticity 
of macrophages.  Removal of SMC CM may result in reversion to a different phenotype 
more similar to M0 macrophages.  Thus novel strategies will need to be employed to 
stabilize the macrophage phenotype in coculture systems. 
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 As discussed above, we were also interested to know how repression of PTEN in 
SMCs, in the setting of injury, might influence macrophage phenotypic modulation and 
subsequent feedback to SMCs.  We were able to generate some preliminary data, to 
validate what had previously been observed in the lab by immunofluorescent staining of 
tissue sections, showing that macrophages are increased in lesions from mice depleted of 
PTEN specifically in SMCs versus in control mice.  Further, we observed an increase in 
Ly6c
high
 monocyte/macrophages present in the lesions at 15 days following injury in 
PTEN iKO mice.  This suggests to us that active recruitment of inflammatory monocytes 
to lesions in PTEN iKO mice is ongoing at this time point, while it seems to have abated 
in the control mice. Further studies will be required to characterize both monocyte 
recruitment and the phenotype of the macrophages present in PTEN iKO lesions over 
time as compared to macrophages in lesions from control animals.  Ultimately, we would 
like to isolate macrophages from PTEN iKO and control lesions, and perform ex vivo 
coculture studies with naïve mouse SMCs, to assess how the cross talk of PTEN iKO-
conditioned macrophages might result in differential activation of SMCs.   
 If our in vitro data related to TGF-β-dependent modulation of macrophages can be 
validated in vivo, then these data suggest that pharmacologic blockade of TGF-β 
signaling or downstream (as of yet unidentified) Mϕ-to-SMC signaling may lead to better 






In the Summary section of this chapter, I have outlined the immediate follow up 
studies that we would like to perform to expand upon our findings and asses their 
relevance in an in vivo model of disease.  Here I would like to expand upon those studies 
and discuss how these data may direct studies to develop more targeted therapies for 
preventing neointimal hyperplasia.  
The studies presented in Chapter II: Quantitation of Myeloid Cell Populations, 
and Characterization of Macrophage Phenotype in a Murine Model of Resentosis, could 
be more informative if we could expand those studies to look at macrophage phenotypic 
modulation in the injured vessel over time.  It is possible, in addition to the fact that these 
populations may be more heterogeneous than we can detect by our limited flow 
cytometry panel, that a more TGF-β-dependent phenotype might be observed earlier 
following injury.  The discordance we see between some of the markers when comparing 
in vivo samples at 15 days and in vitro samples at 7 days may be due to the in vivo cells 
losing their TGF-β-dependent phenotype over time, or conversely they may not yet be 
maximally activated by TGF-β.  In our in vitro studies, changes in this panel of genes 
were modulated maximally at 5 days after exposure to SMC CM (data not shown), as 
compared to 3 and 4 days.  We did not assess later or earlier time points.  Recruitment of 
monocytes to lesions begins within a short period of time upon vascular injury
113
.  These 
monocytes would begin maturation in the presence of TGF-β immediately upon 
recruitment if they are capable of activating latent TGF-β. (Activation of latent TGF-β 
was shown to be maximal following injury from 3-14 days
163
.)  If TGF-β-dependent 
macrophage phenotypic modulation is then expected to be maximal at 5 days post-injury, 
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we may be analyzing these cells as they are reverting back to a less activated state.  
Alternatively, if TGF-β-induced macrophage phenotypic modulation only accounts for a 
significant enough percentage of myeloid cells in the lesion starting at day 15, when 
macrophage content is maximal, the optimum time to assess phenotype might be closer to 
20 days after injury.  Time course analysis will be required, prior to assessing the 
dependency of lesional macrophage phenotype and neointima formation on myeloid 
TGF-β signaling, in order avoid generating falsely negative results.   
We would also like to characterize the transcriptome of the macrophages present 
in lesions, both from wild type animals as well as from PTEN iKO animals, in order to 
define the phenotypes of these cells in an unbiased manner.  Based on our panel of  only 
11 genes, we might conclude that macrophages from injured and uninjured vessels are 
not phenotypically different.  We might find the same result if we were to compare the 
phenotype of macrophages isolated from PTEN iKO lesions versus wild type lesions.  
However making such assertions based on such a limited panel of markers may be 
unwise.  Proteomic analysis may allow us to more confidently describe macrophages 
derived from vascular lesions as different from various control populations. Proteomic 
analysis may also allow us to develop better methods for isolating inflammatory 
populations from non-inflammatory populations, even within the injured vessel, by 
identifying reliable cell surface markers.  We hypothesize that there is some level of 
heterogeneity present in monocytes or macrophages derived from vessels or peripheral 
blood, and a critical next step in moving forward with these studies will be to understand 
what the contribution of various subpopulations of these cells is to neointima 
development.  In addition to assessing the heterogeneity of macrophage populations in 
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vivo, and their phenotypic modulation over time, it will also be important to assess the 
contribution of the other cell populations present in the injured vessel to macrophage 
modulation, to SMC phenotype, and to SMC-macrophage cross talk. 
 Due to the fact that TGF-β’s effect on SMCs is largely described as being anti-
proliferative and pro-differentiating we hypothesize that inhibiting TGF-β signaling may 
not be a viable therapeutic strategy.  Even if a TGF-β receptor inhibitor compound could 
be delivered locally, such as on a coated stent, inhibition of TGF-β signaling in local 
SMCs may result in net exacerbation of neointimal hyperplasia.  Inhibition of TGF-
β signaling in endothelial cells at the margins of the denuded area would be predicted to 
both encourage endothelial cell survival and re-endothelialization of the vessel if the 
TGF-β receptor 1 isoform ALK1 predominates; whereas the opposite effect would be 
anticipated if the ALK5 isoform predominates
196
.  Careful dose-response studies would 
have to be performed to determine what the net effect of TGF-β receptor inhibition is 
with respect to neointimal hyperplasia.  A potentially more viable strategy for identifying 
a targetable mechanism might be to determine what macrophage-derived factors are 
responsible for feed-forward activation of resident SMCs.  The transcriptome analysis 
described above, potentially in combination with proteomic data generated from 
macrophage conditioned medium characterization from in vitro experiments, should 
provide insight into what macrophage-derived mediators signal to SMCs.  Ideally this 
analysis would yield candidates that might exert opposing effects on SMCs and 
endothelial cells.  Such a factor might promote activation of SMCs but induce apoptosis 
or repress proliferation of endothelial cells.  Inhibition of such a factor, or its signaling, 
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would then result in repression of SMC proliferation and hopefully encourage endothelial 
cell proliferation and migration.  
 Normal function of the artery involves both the integrity of its complex structural 
organization as well as proper dynamic cross talk between its composite cells and cells in 
the circulation.  Angioplasty and stenting attempts to maintain proper vessel 
macrostructure, while drugs eluted from stents modulate the behavior of the composite 
cells.  Dual anti-platelet treatment’s goal is to modulate the thrombotic response of 
platelets in the circulation to the damaged artery and the stent itself.  Unfortunately, the 
combination of these strategies has yet to completely prevent the occurrence of post-
intervention restenosis.  It is possible that therapies for preventing restenosis could be 
improved by targeting inflammation and intercellular cross talk rather than, or in addition 
to, targeting cellular proliferation as most current drug-eluting-stents do.  The optimal 
strategy for preventing restenosis is likely to require a thorough understanding of cross 
talk between more than just two of the major cell populations present in the developing 
neointima. Our studies have begun to elucidate how intercellular cross talk between 
SMCs and macrophages in the lesion occurs.  These studies may provide a framework for 
how we can go about understanding interactions between other cell populations in the 
future.  Effective treatment for restenosis will entail development of combinatorial 
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 EARLY COCULTURE STUDIES 
 
Introduction  
This appendix includes a discussion of the data I generated during the first year of 
work in Dr. Nemenoff’s laboratory.  This data was determined to not be publishable due 
to the presence mycoplasma contamination in our primary vascular smooth muscle cell 
cultures.  I have included this section because it may be instructive for future students 
who may work towards understanding the cross talk that occurs between innate immune 
cells and other cells present in diseased tissue.  Additionally, there are several methods 
and experimental strategies that may prove useful for the lab and/or future students.  
Hopefully these methods will be less likely to be lost or forgotten if they are presented 
herein.   
The introductory material for this data is the same as that presented in Chapter I 
and the introduction of Chapter III.  In brief, multiple studies in the literature suggest that 
the recruitment of monocytes to regions of vascular injury, the subsequent maturation of 
those monocytes into macrophages, the retention of those cells in the lesion, and cross 
talk with resident arterial SMCs function to exacerbate SMC activation and disease 
progression.  We initially hypothesized that soluble mediators produced by either or both 
of these cell types would initiate bi-directional activation of both cell types, and that this 
reciprocal activation would be expected to result in exacerbation of disease.  We set out, 
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therefore, to characterize if and how the phenotype of these two cell types would be 
modulated if they were allowed to exchange soluble signals in in vitro culture. Our 
subsequent objectives were to understand if coculture results in bi-directional activation, 
then which cell type is responsible for initiation.  Further, we were then interested in 
identifying the mechanism of how the initiating cell type signals to the responding cell, 
and reciprocally how the responding cell signals back to the initiating cell to result in its 
activation. 
The data presented in this section are not necessarily statistically significant, 
because experimentation was terminated when it was determined that these data did not 
address the research questions we set out to answer.  I have discussed these data as 
though they were found to be statistically significant in order to explore what conclusions 
they support and what additional hypotheses derive from them.   
Methods and Materials 
Reagents: Antibodies: iNOS (BD Biosciences), arginase I, anti-rabbit-AP and anti-
mouse-HRP and p65 (Santa Cruz Biotechnologies), IκBα, phospho-STAT3, phospho-
AKT, phospho-ERK, and total ERK (Cell Signaling Technologies), Versican (V0/V1 
neo) and β-actin (Sigma), cyclophilin B (Abcam).  SiRNAs: non-targeting, si-cyclophilin 
B-Cy3, si- rat TLR2 (Thermo Scientific), si- rat p65 (Santa Cruz Biotechnologies). 
Promoter reporter plasmids: NF-κB-luciferase (triplet consensus NF-ΚB response 
elements upstream of a luciferase gene in a pGL3-basic vector (Promega) a generous gift 






Cell Culture: Primary aortic SMCs were isolated from Sprague-Dawley rats as 
previously described
149
.  SMCs were used for experiments between passages 8 and 15.    
Preparation of SMC conditioned medium: Rat SMCs were plated at 7*10
6
 cells/150 mm 
dish in MEM media supplemented with 10% fetal bovine serum (FBS) and 1x 
penicillin/streptomycin (20 IU/ml penicillin, 20ug/ml streptomycin). Twenty four hours 
after plating, cells were serum restricted in 0.1% serum media (reduced serum media; 
SRM) for 24 hours, then new SRM was refreshed and allowed to condition for a further 
24 hours.  This conditioned medium was cleared by centrifugation at 500g for 10min, and 
stored at -80˚C until use.  Primary bone marrow-derived Mϕ were isolated from Sprague-
Dawley rats, as previously described
137
.  Whole bone marrow was frozen as described
154
, 
and thawed for each experiment without passaging in the presence of 20ng/ml M-CSF 
(eBioscience). 
 
In-Direct Coculture: Bone marrow-derived macrophages were matured under 20ng/ml 
M-CSF for seven days.  While Mϕ were being matured in transwell inserts, SMCs were 
plated at 2.5*105 cells per 35mm dish (6-well culture clusters).  Twenty four hours after 
plating SMCs they were washed and media replaced with SRM for 24hrs to growth 
restrict the cells.  At day 7 of Mϕ maturation, Mϕ-containing transwells were added to 
culture clusters containing serum-restricted SMCs for 24 to 48hrs.  Mϕ and SMC lysates 
were collected at 24hrs for mRNA analysis, and 48hrs for protein analysis. Pre-
conditioned media isolation:  following 24hr coculture, transwells were removed to new 
culture dishes and fresh SRM added to pre-cocultured (pre-conditioned) Mϕs and SMCs.  
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After an additional 24hrs pre-conditioned Mϕ and SMC conditioned medium (Mϕ* and 
SMC*, respectively) was collected and prepared for future use as described  
 
Real Time qPCR: cDNA was prepared from total RNA isolates (1ug/rxn) using the 
iScript cDNA Synthesis kit from Bio-Rad.   Real time qPCR then performed using the 
Power Sybr Green supermix from Applied Biosystems as shown previously
147-149
.  
Reactions were carried out on an iCycler (Bio-Rad).  Cycling parameters were: 5min at 
95˚C; 15sec at 95˚C, 30sec at the annealing temperature optimized for each primer pair, 




: See Table 4. 
Table 4: Appendix A qPCR primers. 
β-Actin Forward: agg gtg tga tgg tgg gta tgg 
Reverse: aat gcc gtg ttc aat ggg g 
TNF-α Forward: ctc ttc tgt cta ctg aac ttc ggg 
Reverse: gagaagatgatctgagtgtgaggg 
IL-6 Forward: aac tcc atc tgc cct tca gga aca 
Reverse: aag gca gtg gct gtc aac aac atc 
IL-10 Forward: gca gga ctt taa ggg tta ctt ggg 
Reverse: ctt gat ttc tgg gcc atg gtt ctc 
Il-12a Forward: ggt gat gaa cta tct gag ctc ctc c 
Reverse: ttc cta cag gag ctg aag gtc aac 
iNOS Forward: tgt gac aca cag cgc tac aac atc 
Reverse: aca gcc cgg tct ttc cag a 
Arginase 1 Forward: gga tgc tca cac tga cat caa cac 




Table 4 continued. 
MCP-1 (CCL2) Forward: tgc tgt ctc agc cag atg cag tta 
Reverse: tac agc ttc ttt ggg aca cct gct 
KC (Cxcl1) Forward: cta aaa ggt gtc ccc aag taa c 
Reverse: att gta tag tgt tgt cag aag cc 
SDF1 (CCL12) Forward: ttt gag agc cat gtc gcc ag 
Reverse: tgt tgt tgc ttt tca gcc ttg c 
Cxcl1/KC Forward: cta aaa ggt gtc ccc aag taa c 
Reverse: att gta tag tgt tgt cag aag cc 
Cx3cl1/Fractalkine Forward: aat ccc agt gac ctt gct cat cca 
Reverse: cac gct tct caa act tgc cac cat 
SM-αActin Forward: cca gcc agt cgc cat cag 
Reverase: agg atc atc acc agc aaa gc 
SM-22α Forward: aac gct act ctc ctt cca 
Reverse: gct cct cat cat act tct tct c 
Calponin Forward: cac caa tca tac aca agt tca g 
Reverse: ctt ctc agg ctc aaa tct cc 
SM-MHC Forward: gta ttg aac tga ttg agc ggc 
Reverse: tga gca cag ctt ctc cac aaa 
Versican (All isoforms) Forward: caa cga aga gta gag gaa gag cag 
Reverse: gtg agc aca gtc att ccc tct aag 
Cyclophilin B Forward: acg tgg ttt tgg caa agt 
Reverse: ctt ggt gtt ctc cac ctt cc 
TLR2 Forward: ggg agc tag gta aag tag aaa cgg 
Reverse: ctt tct cca gga ggg aat aca cag 
Mycoplasmal 16s rRNA Forward: act cct acg gga ggc agc agt a 





Western Blotting: Whole cell lysates were prepared using protein lysis buffer (50mM β-
glycerophosphate [pH 7.2], 100μM sodium vanadate, 2mM magnesium chloride, 1mM 
EGTA, 0.5% Triton X-100, 1mM DTT, and protease inhibitor cocktail [1:100 Sigma, 
P8340]) and cleared by centrifugation.  Samples were normalized by protein 
concentration and SDS-PAGE was performed as described previously
155
.  One volume of 
conditioned medium was concentrated by addition of 1/6
th
 volume each trichloroacetic 
acid and deoxycholic acid, incubating over night at 4°C, and centrifuging at 10,000g for 
10 minutes at 4°C. Precipitated protein pellets were resuspended in 30µl 1x Laemmli 
Buffer and neutralized by addition of 3µl 2mM Tris-base prior to electrophoresis. 
Electrophoresed proteins were transferred to polyvinylidene difluoride membranes, and 
blocked with 5% bovine serum albumin or non-fat dry milk in tris-buffered saline. 
Membranes were probed with primary antibodies, and subsequently with horseradish 
peroxidase or alkaline phosphatase-conjugated secondary antibodies.  Antibody binding 
was visualized with either enhanced chemiluminescence substrate (Perkin Elmer) or 




Immunofluorescent Staining:  Bone marrow derived macrophages were matured on 
glass chamber slides for 7 days prior to stimulation with SMC CM for 0, 10, 30 or 60 
minutes.  Cells were fixed in 4% PFA, permeabilized with MeOH, and incubated with 
anti-p65 primary antibody overnight at 4˚C. P65 antigen:antibody complexes were 
visualized using Alexa Fluor-488 conjugated secondary antibodies (Life Technologies). 
Coverslips were mounted with VectaShield medium (Vector Laboratories) containing 
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DAPI to detect all cell nuclei and cells imaged using an Olympus fluorescent microscope 




Transient Transfection of Primary Mϕ with siRNA: Was performed as described 
elsewhere
198
, with several modifications.  Frozen bone marrow cells were thawed and 
plated as described under Cell Culture at 2x10
6
 nucleated cells per 35mm culture dish.  
At day 4 of in vitro maturation, cells were transfected with siRNA:  50nM siRNA 
oligonucleotide, resuspended to 20μM in siRNA buffer (Thermo Scientific), was added to 
20μM OptiMEM media (Gibco).  Six μL of Lipofectamine 2000 (Life Technologies) was 
added per 200μL of suspended siRNA.  Liposomes were allowed to incubate for 
20minutes at room temperature.  Day 4 Mϕ were washed 2x with HBSS in order to 
remove penicillin/streptomycin (pen/strep).  Liposomes were resuspended to a final 
volume of 2ml with pen/strep-free DMEM medium with 10% FBS and 20ng/ml M-CSF.  
Mϕ were transfected with siRNA-loaded liposomes for 24hrs.  After 24hrs (day 5), 
liposomes were removed and media was replaced with liposome-free pen/strep-free 
DMEM with 10% FBS and 20ng/ml M-CSF.  Mϕ were used for experiments 72hrs after 
transfection, or day 7 after initial plating.  
 
NF-κB Response Element Luciferase Assay: Promoter assays were performed as 
described by Kaplan-Albuquerque et. al 
168
.  Briefly, day 6 Mϕ were transfected with 4μg 
CMV β-galactosidase plasmid and 4μg NF-κB-consensus sequence luciferase reporter 
plasmid as described under Transient Transfection of Primary Mϕ with siRNA, but using 
Lipofectamine (Life Technologies) as a transfection reagent, for 4hrs.  After 4hrs 
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liposome media was removed and replaced with control medium or experimental SMC 
conditioned medium.  After 24hours, Mϕs were lysed in reporter lysis buffer (Promega), 
and assayed for luciferase activity upon addition of luciferin substrate (Promega) using a 





SMC Proliferation Assay:  SMC proliferation was assessed as previously described
137, 147
 
in response to stimulation with Mϕ (non-targeting or si-TLR2 transfected Mϕ, with or 
without prior coculture with SMCs) conditioned medium.  Briefly, SMCs were plated in 
24-well plates at a density of 3*10
4
 cells/well, allowed to attach and spread overnight, 
and media replaced with 500μl/well SRM.  After 48 hours of serum restriction SMCs 
were stimulated with 20% control medium, conditioned medium  from naïve si-NT or si-
TLR2 transfected macrophages (si-NT or si-TLR2 Mϕ CM), or conditioned medium 
from si-NT or si-TLR2 transfected SMC pre-conditioned macrophages (si-NT or si-TLR2 
Mϕ* CM).  20μM BrdU was added to SMC cultures after 24hours of CM stimulation.  
After 48 hours of stimulation, SMC were fixed with 4% paraformaldehyde, and 
immunohistochemically stained for BrdU incorporation.  BrdU index was calculated as 
the percent of BrdU-positive nuclei.   
 
Real Time PCR Assay for Mycoplasma Contamination: Previously isolated cDNA 
samples from primary SMC and Mϕ cultures were assessed for the presence of 
mycoplasma by performing qPCR reactions with primers specific for mycoplasma 16s 
rRNA as described elsewhere
201
.  Briefly, 0.5μl of cDNA isolated SMCs or Mϕs 
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following coculture experiments (from 20μ iScript reaction) were added to PCR reaction 
mixtures containing: 1x PCR buffer (Life Technologies), 10mM dNTP mix (Life 
Technologies), 50mM MgCl2,10μg/ml BSA, 500pmol of sense primer (GPO-1), 500pmol 
of antisense primer (MGSO), and 1U of Taq DNA polymerase (Life Technologies).  
Cycling parameters: 40 cycles of 94°C for 1min, 55°C for 1min, 72°C for 2min.   
 
Statistics: Data are expressed as means ± standard error. Student’s T-tests were used to 
compare data sets with two samples.  Data sets with more than two samples were 
analyzed by ANOVA. Bonferroni multiple comparisons tests were used to compare select 
samples within a data set.  In instances, within a data set with more than two samples, 
when variances were different between groups (as determined by T-Test) serial T-tests 
were performed followed by Bonferroni correction to account for multiple comparisons.   
Results 
SMC-Mϕ Coculture Results in Reciprocal Activation of Both Cells. We hypothesized 
that upon vascular injury, infiltrating monocytes/macrophages interact with resident 
vascular smooth muscle cells in the damaged artery and these cells cross talk to modulate 
one another’s phenotype and function.  We initially set out to test this hypothesis in vitro 
by coculturing rat bone marrow-derived macrophages (day 7-matured) with rat SMCs.  
We found that when we cocultured these two cells together for 24 hours we saw robust 
activation of both cell types.  Cocultured SMCs transcriptionally upregulated several pro-
inflammatory cytokines: SDF-1α, MCP-1, Cxcl1 (KC), Cx3cl1 (fractalkine), and IL-6 
(Figure 26A).  Correspondingly, cocultured SMCs transcriptionally repressed the SM- 
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genes SM-αActin, SM-22α, and Calponin.  SM-myosin heavy chain was not significantly 
repressed, but the error in these data was extremely large, perhaps suggesting a technical 
problem in the qPCR method for assessing expression of this gene.  We also observed  
increased expression of iNOS in these SMCs, which has been shown to occur in SMCs in 
response to stimulation with IL-1β
202
.  We also observed increase phosphorylation of the 
pro-proliferative kinases AKT and ERK (Figure 26B).  Further, we observed increased 
Figure 26:  SMC are activated by in-direct CC with Mϕ.  
A) Rat BMC were matured for 7 days under 20ng/ml M-CSF and then cocultured 
in-directly with serum restricted SMC for 24 hours (SMC + Mϕ). Total RNA was 
isolated from SMC and analyzed by qPCR for the indicated mRNAs. Shown are 
mRNA fold change in copy number, relative to SMC cultured alone (SMC), 
normalized to β-Actin. Shown are means±SE; n=3. *P<0.05 vs untreated SMC. B) 
Whole cell lysate was collected from SMCs 48hr after culture alone or in coculture 
with Mϕ. Lysates were anlalyzed by western blotting for iNOS, phospho-AKT 
(pAKT), phospho-ERK (pERK), total ERK, and β-Actin as a loading control. C) 
As in panel A, mRNA was analyzed following coculture for versican. D) Equal 
volumes of concentrated conditioned medium from SMCs cultured alone, the 
assembled coculture (SMCs + Macs), and macrophages cultured alone were blotted 
for versican. Shown are means±SE. n=3 independent experiments. *P<0.05 vs 
SMCs cultured alone.  
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expression, by both qPCR as well as by western blotting of TCA/DOC concentrated 
conditioned medium, of the pro-stenotic matrix proteoglycan versican (Figure 26C-D).  
This molecule was previously shown, by the Weiser-Evans lab, to be upregulated 
following vascular injury in the rat
203
, and has been suggested to be a macrophage 
activating ligand that functions by serving as an endogenous ligand for TLR2
152
.   
 This activation was, as stated previously, bi-directional.  Following coculture with 
SMCs, Mϕ became activated as well.  Transcriptionally, Mϕ cocultured with SMCs 
upregulated pro-inflammatory genes such as TNF-α, IL-1β, and IL-6.  They also 
modulated expression of IL-10, Il-12a, iNOS, and Arg I in a classically activated/M1 
fashion:  increased iNOS, IL-10, and Arg I, with repression of IL-12a (Figure 27A).  The 
ratio of Il-12a: IL-10, a metric used to characterize M1/M2 polarization in mouse 
macrophages
74
, decreased significantly following coculture (Figure 27B). In the mouse 
an LPS/IFN-γ-induced M1 phenotype is characterized as increased expression of iNOS 
and IL-12a, with repression of IL-10 and Arg I.  In this system M1 macrophages express 
a higher IL-12:IL-10 ratio compared to M0 macrophages
141
.  However, we observed that 
in rat bone marrow-derived macropahges, LPS/IFN-γ stimulation resulted in regulation of 
these genes as described in our coculture experiments (Figure 27D-E) rather than the 
pattern of regulation observed in mouse BMDMs.  In addition to transcriptional changes, 
we observed induction of iNOS and phosphorylation of AKT and ERK in Mϕ in response 
to SMC coculture (Figure 27C).   
 These data suggested that bi-directional cross talk between these two cell types, 
mediated by soluble factors, was capable of inducing robust pro-inflammatory activation 
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of both cells.  We therefore wanted to determine which cell type was basally secreting a 
factor, or factors, that might be able to initiate this bi-directional cross talk.   
 
Reciprocal Activation of Mϕ and SMC in Coculture is Dependent on an SMC-Derived 
Factor(s). In order to identify which cell type was responsible for basally producing a 
Figure 27:  Mϕ are activated by in-direct CC with SMC.   
A) Rat BMC were matured for 7 days under 20ng/ml M-CSF and then cocultured 
in-directly with serum restricted SMC for 24 hours (Mϕ + SMC). Total RNA was 
isolated from Mϕ and analyzed by qPCR for the indicated mRNAs. Shown are 
mRNA fold change in copy number, relative to SMC cultured alone (SMC), 
normalized to β-Actin. Shown are means±SE; B) Coculture of Mϕ with SMCs 
results in a ~10 fold decrease in IL-12/IL-10 mRNA ratio in Mϕ. C) Western 
blotting at 48hr shows upregulation of iNOS, arginase I (Arg I), and increased 
phosphorylation of ERK (pERK).   D) Macrophages matured for 7 days with 
20ng/ml M-CSF were stimulated LPS/IFN- (M1), IL-4 (M2), or no stimulus (M0).  
Western blotting of whole cell lysates for iNOS and arginase I (Arg I), or E) 
analysis of total RNA for IL-12:IL-10 by qPCR.  A-C) Shown are means±SE. n=3 




factor to initiate the intercellular cross talk observed in indirect coculture, we prepared 
conditioned medium from both cell types prior to coculture (Mϕ or SMC), or from the 
cocultured cells following separation (Mϕ* or SMC*).  We stimulated new cultures of 
Mϕ or SMC with those conditioned media for 24-48hrs.  We found that induction of 
SDF-1α, MCP-1 and IL-6 in SMCs was not induced by conditioned medium from Mϕ, 
but these genes were induced by Mϕ* CM (Figure 28A). Similarly, SM-αActin, SM-22α, 
and calponin expression was not affected in response to Mϕ conditioned medium but 
these contractile apparatus genes were repressed in response to Mϕ* conditioned medium 
(Figure 28B).  We then compared signaling pathway engagement in SMCs in response to 
Mϕ and Mϕ* conditioned media (CM) stimulation. We found that STAT3 activation and 
IκBα degradation were markedly increased in SMCs in response to Mϕ* CM as 
compared to Mϕ CM.  Similarly we observed slight increases in AKT and ERK 
activation in response to Mϕ* CM as compared to Mϕ CM (Figure 28C).  These data 
indicate that production of SMC activating factors by Mϕ is dependent on the 
macrophages first having been exposed to SMCs.   
We performed the reciprocal experiments on macrophages stimulated with 
conditioned medium from SMCs or SMC*s.  We found that SMC and SMC* conditioned 
medium induced a similar degree of pro-inflammatory gene upregulation in Mϕ (Figure 
29A).  Further, SMC conditioned medium repressed the IL12:IL-10 ratio with similar 
efficiently as did conditioned medium from SMC* (Figure 29B). Since SMC conditioned 
medium was capable of inducing the classically NF-κB-regulated genes TNF-α, IL-6, and 
IL-1β in Mϕ, we sought to determine if modulation of these genes correlated with NF-κB 




Figure 28: SMC-preconditioned macrophage (Mϕ*) CM stimulates 
SMC activation, while naïve Mϕ CM does not.   
Rat BMC were matured for 7 days under 20ng/ml M-CSF and then cultured 
alone (Mϕ) or cocultured in-directly with serum restricted SMC for 24 
hours (Mϕ*). Cocultured cells were then separated and new low serum 
medium (SRM) was added to cells and conditioned medium was collected 
24hours later.  SMCs were then stimulated for 24 hrs, or 5-60 minutes, with 
control SRM, Mϕ CM, or Mϕ* CM.  A) Total RNA was isolated from 
SMCs and analyzed by qPCR for the indicated mRNAs.  Shown are mRNA 
copy number normalized to β-Actin. B) SMCs were stimulated from 5-60 
minutes with Mϕ CM or Mϕ* CM.  Whole cell lysates were then analyzed 
for phospho-STAT3 (pSTAT3), phospho-AKT (pAKT), IκBα, and phospho-
p65 (p-p65).  β-Actin was used as a loading control.  Shown are means±SE. 





Figure 29: Naïve SMC CM stimulates Mϕ activation; naïve SMC CM 
activates NF-κB in Mϕ.   
A) Serum restricted SMC were cultured alone (SMC) or in in-direct 
coculture with Mϕ for 24 hours (SMC*). Cocultured cells were then 
separated and new low serum medium (SRM) was added to cells and 
conditioned medium was collected 24hours later.  Mϕ were then stimulated 
for 24hrs, or 5-40 minutes, with control SRM, SMC CM, or SMC* CM.  A) 
Total RNA was isolated from Mϕ and analyzed by qPCR for the indicated 
mRNAs.  Shown are mRNA copy number normalized to β-Actin. B) Mϕ 
were stimulated from 5-40 minutes with SMC CM or SMC* CM.  Whole 
cell lysates were then analyzed for IκBα. β-Actin was used as a loading 
control.  Shown are means±SE. n=3 independent experiments. *P<0.05 
versus SRM; **P<0.05 versus SMC CM. D) Mϕ matured for 7 days on glass 
chamber slides with 20ng/ml M-CSF were stimulated with naive SMC CM 
for 10min (10min).  Cells were stained by in-direct immunofluorescence for 
p65. E) Mϕ were transfected with β-galactosidase (β-gal) and NF-κB 
response element-luciferase plasmids and stimulated for 72hrs with SRM, 
SRM with 20ng/ml M-CSF, or naïve SMC CM.  Shown are luciferase units 
normalized to β-galactosidase activity. N=1. 
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degradation, by western blot, in response to control medium or SMC conditioned 
medium.  We found that SMC conditioned medium induced IκBα degradation in Mϕ at 
10-40min following stimulation, whereas control medium did not (Figure 29C).  We also    
assessed p65 nuclear localization by immunofluorescent staining and NF-κB 
transcriptional activity, by luciferase assay, in response to SMC conditioned medium.  
We found that SMC conditioned medium, as compared to control, induced p65 nuclear 
translocation within 10 minutes (Figure 29D), and it also increase NF-κB-dependent 
transcription (Figure 29E). This suggested to us that an SMC-derived factor was present 
in naïve SMC conditioned medium that was responsible for inducing NF-κB activation in 
Mϕ, which correlated with activation as assessed by pro-inflammatory cytokine 
upregulation.  We assessed if NF-κB signaling in Mϕ was required for the phenotypic 
modulation observed in response to SMC conditioned medium, and if TLR2 activation 
was responsible for said NF-κB activation. 
 
NF-κB Activation and Cytokine Upregulation in Response to SMC conditioned 
Medium is TLR2-Dependent.  Kim et. al published in 2009 that soluble versican, 
secreted by lung carcinoma cells, was capable of inducing a Mϕ phenotype characterized 
by TNF-α, IL-1β, and IL-6, that was dependent on TLR2 expression in Mϕ
152
.  Because 
our SMCs produced versican at baseline (Figure 26D), and because we saw the same Mϕ 
phenotype in response to SMC conditioned medium that Kim et. al. did, and NF-κB 
activation, we set out to determine if TLR2 signaling was required for the phenotype 
induced by SMC conditioned medium.   
161 
 
Figure 30: Transient transfection of Mϕ with siRNAs.  
Primary rat Mϕ were transfected with siRNAs (non-targeting (NT), Cy3-
conjugated anti-Cyclophilin B (CypB), anti-p65 (sip65), or anti-TLR2 (si-TLR2)) 
as described in the Materials and Methods section of this chapter.  A) Phase-
contrast micrographs, with fluorescence overlay, of macrophages transfected with 
non-targeting or fluorescently labeled Cyclophiliin B siRNA.  B) Whole cell 
lysates from NT or si-CypB transfected macrophages were assessed for CypB 
protein by western blotting 96hrs after transfection.  C) Whole cell lysates from NT 
or si-p65 transfected macrophages were assessed for p65 protein by western 
blotting 72hrs and 96hrs after transfection. D) 48hrs after transfection of 
macrophages with NT or TLR2 siRNA total RNA was isolated and assessed for 
TLR2 mRNA.  Shown is mRNA copy number, normalized to β-Actin, relative to 
NT control. Shown are means±SE. n=2. 
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 In order to perform these assays, we needed to establish a method to deplete Mϕ 
selectively for TLR2.  After optimizing modifications of a previously published 
method
198
, we were able to show robust uptake of Cy-3-labeled siRNA (anti-cyclophilin 
B) into primary bone marrow-derived Mϕ 24 hours after transfection (Figure 30A), and 
corresponding depletion of cyclophilin B at 96 hours after transfection (Figure 30B).  
Using this method we were also able to efficiently deplete p65 or TRL2 in rat Mϕ 
(Figure 30C-D).   
 We then assessed the ability of SMC conditioned medium to induce NF-κB 
activation in Mϕ in the presence or absence of TLR2 expression.  We found that TLR2 
depleted Mϕ no longer exhibited p65 nuclear import in response to SMC conditioned 
medium (Figure 31A).  Neither did TLR2 depleted Mϕ exhibit IκBα degradation in 
response to SMC conditioned medium (Figure 31B).  We observed a slight reduction in 
NF-κB transcriptional activity, by promoter-luciferase assay, in TLR2 knockdown Mϕ as 
compared to a complete inhibition in p65 depleted Mϕ (Figure 31C).  We also assessed 
the effect of TLR2 depletion on downstream cytokine induction.  We found that in 
response to SMC conditioned medium, TRL2 depletion blunted TNF-α, IL-6, and IL-12 
upregulation.  IL-1β upregulation in response to conditioned medium was not reduced 
(Figure 31D); upregulation of IL-1β in response to SMC conditioned medium could be 
due to a different factor that does not signaling through TLR2 and is therefore not 
effected by TLR2 depletion. Taken together, these data suggested to us that TLR2-
dependent signaling was responsible for NF-κB activation and cytokine transcriptional 
upregulation observed in Mϕ in response to SMC conditioned medium.  We therefore 
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assessed if SMC pre-conditioned, TLR2-depeleted, Mϕ conditioned medium would lose 
the ability to induce SMC activation.   
 
Ability of SMC-Preconditioned Mϕ (Mϕ*) to Activate SMCs is TLR2-Dependent.  In 
order to determine if TLR2-depleted Mϕ cannot be phenotypcially modulated by SMCs 
Figure 31: Activation of NF-κB in Mϕ, by SMC CM, is TLR2-dependent. 
TLR2 silencing results in decreased production of pro-inflammatory 
cytokines by Mϕ in response to SMC CM.   
Primary rat Mϕ were transfected with siRNAs (non-targeting (si-NT), anti-p65 
(sip65), or anti-TLR2 (si-TLR2)) A) Si-NT and si-TLR2-transfected Mϕ, plated on 
glass chamber slides, were stimulated with SMC CM for 10-60min.  Cells were 
then detected for p65 by in-direct immunofluorescence.  B) Untransfected Mϕ 
were stimulated with SMC CM or purified TNF-α for 5-30/60min.  Si-TLR2-
transfected Mϕ were stimulated with SMC CM for 10-60min.  Whole cell lysates 
were analyzed for IκBα degradation by western blot. C) Si-NT and si-TLR2-
transfected Mϕ were transfected with β-galactosidase and NF-κB response 
element-luciferase plasmids and stimulated with SRM or SMC CM for 72hrs. 
Shown are luciferase units normalized to β-galactosidase activity. N=1.  D) Si-NT 
and si-TLR2-transfected Mϕ were stimulated with SRM or SMC CM for 24hrs.  
Total RNA was isolated from Mϕ and analyzed by qPCR for the indicated mRNAs.  
Shown are mRNA copy number normalized to β-Actin. N=1.  
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in coculture, and subsequently secrete SMC-activating factors, we cocultured non-
targeting siRNA-transfected Mϕ (si-NT) and TRL2-depleted Mϕ (si-TLR2) with SMCs.  
We then removed the SMCs from the macrophages and collected conditioned medium 
from these pre-conditioned Mϕ*.  We also collected conditioned medium from si-NT and 
si-TLR2 macrophages that had not been cocultured with SMCs.  When we stimulated 
SMCs with conditioned medium from naïve si-NT or si-TRL2 macrophages for 24 hours 
we did not see much modulation of SDF-1α, MCP-1, or SM-α Actin gene modulation.  
We did however, see increased SDF-1α and MCP-1, and decreased SM-α Actin 
expression in response to si-NT Mϕ* conditioned medium.  This effect was lost in 
response to si-TLR2 Mϕ* conditioned medium; and SM-αActin expression increased 
(Figure 32A).  We also assessed the effect of these media on SMC proliferation.  We 
found that 48 hour stimulation with si-NT Mϕ* conditioned medium resulted in a 40% 
increase in SMC proliferation compared to conditioned medium from si-NT macrophages 
that had not been exposed to SMCs in coculture, as assessed by BrdU incorporation.  
Whereas si-TLR2 Mϕ* conditioned medium did not induce an increase in proliferation 
compared to si-TLR2 macrophages that had not been exposed to SMCs (Figure 32B).  
These data suggested that a significant component of the ability of SMC-preconditioned 
macrophages to cross talk back to naïve SMCs was due to TLR2-dependent activation of 
macrophages by an SMC-derived factor.  We then set out to assess what SMC-derived 
factor was acting as an endogenous ligand for TLR2 capable of activating NF-κB 




The Mϕ-Activating Factor Present in SMC Cultures is Not SMC-Derived. Due to the 
results published by Kim et. al
152
 suggesting that versican can act as an endogenous 
ligand of TLR2, we hypothesized that SMC-derived versican was responsible for the 
macrophage activation that we observed.  We were beginning to develop methods to 
deplete versican in SMCs, when we ceased to be able to replicate SMC conditioned 
medium-dependent NF-κB activation in macrophages.  While trying to replicate this data 
with isolation after isolation of primary SMCs, we searched the literature for other ideas 
Figure 32: Si-TLR2 SMC-activated Mϕ* lose the ability to induce SMC 
activation versus control SMC-activated Mϕ*.  
Si-NT and si-TLR2-transfected Mϕ were cultured alone (Mϕ) or cocultured in-
directly with serum restricted SMC for 24 hours (Mϕ*). Cocultured cells were then 
separated and new low serum medium (SRM) was added to cells and conditioned 
medium was collected 24hours later.  SMCs were then stimulated for 24hrs, or 5-60 
minutes, with control SRM, Mϕ CM, or Mϕ* CM.  A) Total RNA was isolated from 
SMCs and analyzed by qPCR for the indicated mRNAs.  Shown are mRNA copy 
number normalized to β-Actin. B) Serum restricted SMCs were cultured in the 
presence of SRM, Mϕ CM from si-NT or si-TLR2-transfected Mϕ, or Mϕ* CM 
from si-NT or si-TLR2-transfected Mϕ*. 20μM BrdU was added after 24hrs of 
stimulation and after 48hrs of stimulation SMCs were analyzed for BrdU 
immunoreactivity.  Shown are % BrdU positive SMCs relative to all cells.  
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about candidate molecules that might act as endogenous activators of toll-like receptors.  
In conducting this literature search, it became clear that the concept of existence of 
endogenous ligands for TLRs is a controversial one.  For example, some investigators 
feel that none of the studies presented in the literature sufficiently control for the presence 
(whether detectible by limulus amebocyte lysate assay or not due to association with 
LPS-binding proteins) of LPS in culture reagents
204, 205
.  Other investigators feel 
comfortable accepting the evidence that both damage-associated molecular patterns and 
other endogenous TLR ligands do exist and are critical regulators of innate immunity
206
. 
Figure 33: Effect of SMC conditioned medium on Mϕ phenotype is due to 
mycoplasma contamination of SMC cultures.   
CDNAs isolated from Mϕ, pre- (Suspect Mϕ) and post-coculture with SMCs 
(Mϕ after CC+ SMC) and SMCs (Suspect SMC) from experiments shown in 
Figures 22 and 23, as well as SMCs from which conditioned medium did not 
activate NF-κB in Mϕ (Un-contaminated SMC), were analyzed for 
amplification of the sequence of the mycoplasmal 16s rRNA. A no template 
control was included as a negative control. 
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We hypothesized that the simplest explanation is likely the correct one.  We therefore 
sought to determine if the SMC-derived factor that was capable of inducing such robust 
activation in our macrophages could be a contaminant.   
 Because we were no longer able to generate conditioned medium that activated 
NF-κB in Mϕ we felt that it was unlikely that any potential contaminant was present in 
live cultures, but that it had be present in earlier cultures.  Cell wall components, such as 
would be present in cultures contaminated with Gram-negative bacteria, such as LPS, 
would activate NF-κB in a TLR4 rather than TLR2-dependent manner.  However, 
mycoplasma lipoproteins are known activators of TLR2 signaling
204
.  We therefore 
employed a previously published method for assessing the presence of mycoplasmal 16s 
rRNA in cDNAs prepared from cocultured SMCs and macrophages
201
.  Using this 
method we discovered that, like no template control, SMCs whose conditioned medium 
was not capable of inducing NF-κB activation in Mϕ (Un-contaminated SMC) and pre-
coculture macrophages (Suspect Mϕ) did not amplify positive for mycoplasma 
contamination.  However, SMCs from the coculture experiments described in Figure 
26A-D did amplify positive for mycoplasmal contamination.  Additionally, macrophages 
from the same experiments, while not contaminated initially, became contaminated in 
response to coculture with contaminated SMCs (Mϕ after CC+ SMC) (Figure 33).  This 
indicated to us that the ability of SMCs, in these early experiments, to induce robust 
macrophage activation was the result of mycoplasma-derived pathogen-associated 
molecular patterns activating TLR2 on the cultured macrophages.  This discovery, 
unfortunately meant that the data described in this appendix was unsuitable for 
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publication as it did not address our research objective which was to understand the 
molecular cross talk the occurs between macrophages and SMCs.   
Discussion 
The data presented here, in Figures 26-33, were initially quite promising.  
Coculture, or conditioned media stimulation, of macrophages with SMC resulted in a 
classically activated/M1 phenotype that, as described in Chapter I, would be predicted to 
be pro-stenotic in the setting of vascular injury.  We also observed that upon pre-
conditioning with SMCs, macrophages gained the ability to induce a pro-inflammatory, 
dedifferentiated phenotype, and increased proliferation, in cross talk studies with SMCs.  
We determined that the effect of the SMC-derived factor(s) on macrophage phenotypic 
modulation, and subsequent cross talk with SMCs, was dependent on macrophage TLR2.  
All that remained, we hoped at the time, was to validate that soluble versican was the 
SMC-derived factor influencing macrophage phenotype, and to validate that IL-6 was the 
Mϕ*-derived factor responsible for Mϕ-to SMC cross talk via STAT3 signaling.    
 Unfortunately, the discovery that the factor responsible for modulating 
macrophage phenotype was mycoplamsa, or mycoplasma-derived, meant that we had not 
made any progress after all in addressing the hypothesis that SMCs and macrophages 
cross talk to modulate one another’s phenotype in the pathogenesis of neointimal 
hyperplasia.  Many groups, due to observations from the atherosclerosis literature that 
lesional macrophages may express an M1-like phenotype, have used LPS/IFN-γ 
stimulation to model lesional macrophages. We feel that using what amounts to a model 
of bacterial infection-induced macrophage phenotype is not relevant to studying disease 
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processes that develop in a largely sterile setting.  We feel that modeling macrophage 
phenotype with LPS is of particularly little utility if we want to understand the – mostly 
likely fairly subtle - effects of a smooth muscle cell on macrophage phenotype.   
 We feel that the data presented in the main chapters of this dissertation, in the 
absence of potent macrophage polarizing agents, may be more physiologically relevant to 
sterile inflammation-driven disease than pre-polarizing macrophages with LPS (advertent 
or inadvertently) prior to performing cross talk assays. We hope that any future students 
who take on similar projects in the lab can learn from this information to preemptively 
identify any such confounders in their reagents or cells.  This data illustrates how 
attaining statistical significance does not necessarily prove physiologic relevance of an in 







CCTSI TL1 PRE-DOCTORAL PROGAM CLINICAL EXPERIENCE 
 
 In the second year of my graduate training I was accepted into the Colorado 
Clinical and Translational Sciences Institute (CCTSI) TL1 pre-doctoral training program.  
This training program entailed a seminar series designed to inform the pre-doctoral 
trainees about the logistics and ethical considerations of designing clinical trials, as well 
as about considerations relevant to working with patients from cultural backgrounds 
different from ourselves. The program also involved monthly meetings where trainees 
had to opportunity to learn about, and discuss, current and cutting-edge clinical-
translational research.  As part of the certificate program, I completed electives in 
immunology and epidemiology. The program also included “summer reading,” and book 
club-like discussions, of non-fiction or fictional works relevant to clinical-translational 
science.  The books read during my participation in the program included The Immortal 
Life of Henrietta Lacks
207





. I also participated in the national TL1 meeting, held in St. 
Louis, MO, in 2011.  I presented a poster at this meeting that described the then current 
progress on my thesis research project.  During my first year as a pre-doctoral fellow in 
the program, I received funding to participate in a clinical experience in addition to my 
thesis research.   
 My clinical experience for the TL1 program focused on the link between 
endothelial dysfunction and cardiovascular disease, and what patients with diabetes, a 
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condition where endothelial dysfunction is common, go through in order to manage their 
disease.  I spent several clinical sessions shadowing my clinical mentor Dr. Jane Reusch, 
at the Veteran’s Affairs Hospital in Denver.  Over the course of these clinics I observed 
Dr. Reusch discuss with her patients how best to regulate their blood sugar, in order 
minimize damage to the peripheral vasculature and nerves.   
The vast majority of patients I observed in these clinics presented with type 1 
diabetes (reviewed in Melmed, 2011
210
).  This form of diabetes is characterized by 
autoimmune destruction of pancreatic beta cells that normal produce insulin, the hormone 
responsible for inducing uptake of glucose from the blood by skeletal muscle and adipose 
tissue.  These patients respond to insulin, but as they cannot produce it, they must 
regulate their blood sugar through administration of exogenous insulin.  If not sufficiently 
regulated, elevated blood glucose results in an inability of the vascular endothelium to 
generate nitric oxide.  This, in turn, results in negative remodeling of the peripheral 
vasculature due to prolonged SMC contraction, and decreased blood flow.  Decreased 
blood flow can result in damage to peripheral nerves leading to symptoms such as 
gastroparesis, or decreased movement of food through the digestive tract and associated 
discomfort.  Decreased blood flow can also result in an angiogenic response in the retina, 
or proliferative retinopathy, which can impair visual acuity.  Amputation of under-
perfused extremities is another complication typically associated with diabetes, due to 
infection of wounds that go unnoticed because of damage to peripheral nerves. 
In order to sufficiently regulate blood sugar, the patients I observed were required 
to take extensive notes on diet, exercise, and insulin administration.  Keeping these notes 
allowed them, and Dr. Reusch, to identify when and how they were under or over-dosing 
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their insulin.  These visits really impressed upon me how incredibly difficult and time 
consuming it is for these patients to accurately calculate the required dose of insulin 
relative to what they are consuming and how active they are.  I would have thought, 
before participating in this clinical experience, that due to consequences as serious as 
amputation and blindness, that most patients would be extremely diligent about their 
treatment.  It became clear to me, however, that managing diabetes while meeting other 
everyday responsibilities is nearly impossible for most people.   
In addition to the many type I diabetics that I observed in Dr. Reusch’s clinic, I 
also observed a few type 2 diabetic patients.  In type 2 diabetes (reviewed in Melmed, 
2011
210
) the pancreatic beta cells often produce a lower than normal amount of insulin, 
and the skeletal muscle and adipose tissue are resistant to the action of insulin.  While the 
type 1 diabetic patients were often very rather thin, the type 2 patients were frequently 
significantly overweight.  Obesity is a prominent risk factor for type 2 diabetes, in 
addition to consumption of large amounts of sugar, often from soft drinks.  One of the 
major therapies prescribed to these patients, by Dr. Reusch, was physical activity.  Patient 
compliance with respect to this treatment was consistently poor.   
It was this observation that lead Dr. Reusch, and her colleagues Dr. Irene Schauer 
and Dr. Judith Regensteiner, to design a study to try to understand if elevated free fatty 
acids in the blood was sufficient to induce cardiac dysfunction and impaired exercise 
capacity in healthy subjects.  Elevation of free fatty acid in the blood was used as a 
stimulus because it is known to induce insulin resistance
211
.  Patients with type 2 diabetes 
exhibit decreased oxygen consumption and oxygen uptake when they begin exercise
212-
214
.  The principle investigators were interested to determine if free fatty acid infusion 
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would repress the ability of endothelial cells to induce vasodilation, making diabetic 
patients more uncomfortable during physical activity than healthy controls, thus possibly 
helping to explain why these patients have such difficulty complying with prescribed 
physical activity.  Endothelial function was assessed non-invasively by brachial artery 
diameter (BAD) measurement
215, 216
.  Briefly, in this assay, endothelium-dependent flow-
mediated vasodilation is assessed by high-resolution ultrasonography of the brachial 
artery upon release of a pneumatic tourniquet.  Vessel diameter is measured using FMD 
Studio software (Quipu) 1 minute, and 10 minutes after tourniquet deflation.  Flow-
mediated dilation is calculated as the ratio of a baseline reading to the 1min post-dilation 
reading.  I participated in several meetings between Dr. Schauer and ultrasound 
technicians at the Clinical Translational Research Center at the Anschutz Medical 
Campus.  The object of these meetings was primarily to troubleshoot transfer of the 
ultrasound records from the ultrasound machine to a computer equipped with the FMD 
Studio software.  The rest of my time spent on this project involved actual analysis of 
flow-mediated dilation data.  Unfortunately, I was not able to spend enough time working 
with these data, while my clinical experience was funded, to make any conclusions about 
the effect of lipid infusion on endothelial function.  To my knowledge these studies are 
ongoing.  Observing this study, and gaining exposure to the process of developing a 
clinical research protocol, gave me an appreciation for the technically challenging and 
ethical aspects of performing research in the clinical setting.    
The experience I gained by participating in the CCTSI TL1 pre-doctoral training 
program has given me a much better understanding of what is involved in translating 
basic pre-clinical research into a clinical setting.  I have learned a great deal about how 
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necessary it is to construct appropriate collaborations in order to perform meaningful 
clinical studies.  I also gained an appreciation for how very different working with a 
patient population is from working in pre-clinical models; and the epidemiology course 
that I took as a requirement for this program showed me the importance of accounting for  
confounders and attrition when working with patient data.  I would highly recommend 
this experience to anyone who is interested in learning from clinical studies where basic 
science can make the largest contribution to understanding the pathogenesis of disease, 
and in translating basic discoveries into clinical practice.  
 
